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Resumo 
As doenças cardiovasculares (DCV) compreendem as principais doenças do coração e do 
sistema circulatório que fornecem o coração, o cérebro e os tecidos periféricos. As DCV são 
o principal grupo das doenças não transmissíveis (DNT), tendo causado 17,9 milhões de 
mortes em todo o mundo em 2015, número que aumentou globalmente em 12,5% desde 
2005, com quase 80% dessas mortes ocorrendo em países de baixa e média renda. A sua 
ocorrência e mortalidade, perda de independência e produtividade, deterioração da 
qualidade de vida e custos sociais e económicos são razões imperiosas para preocupação. 
 
Os fatores de risco para as DCV são partilhados com a maioria das DNT e são devidos à 
exposição a fatores de risco comportamentais: consumo de tabaco e álcool, dieta 
inadequada e inatividade física. Estes comportamentos influenciam o metabolismo e podem 
resultar em fatores de risco intermediários (metabólicos): obesidade, hipertensão arterial, 
diabetes e hipercolesterolemia. Há também fatores de risco de DCV que não podem ser 
controlados, como a idade, sexo, antecedentes familiares e etnia, e outros ligados a 
condições socioeconômicas ou o fenómeno da urbanização. 
 
As DCV e os factores de risco associados têm sido negligenciadas na África Subsariana, 
mas têm aumentado com o envelhecimento e crescimento das populações. Tal como outros 
países da região, Angola não tem um sistema nacional de vigilância das DNT e apresenta 
um contexto social em rápida mutação. Com esta tese pretendemos contribuir para uma 
melhor compreensão da epidemiologia dos factores de risco das DCV em Angola, através 
do estudo de uma comunidade angolana adulta (15 a 64 anos) da zona de abrangência do 
Centro de Investigação em Saúde de Angola. 
 
Para atingir esse objetivo, criamos e implementamos um protocolo de estudo e uma 
estratégia de acompanhamento para abordar a vigilância dos fatores de risco para as DCV 
(Artigo I) - o CardioBengo. A partir de uma investigação anterior, realizámos um estudo de 
acompanhamento da mesma população, para avaliar pela primeira vez a incidência de 
hipertensão arterial (Artigo II).  
 
A partir dos dados extraídos do CardioBengo, foram realizados quatro análises (Artigos III a 
VI) referentes à caracterização da hipertensão arterial, diabetes, hipercolesterolemia, 
tabagismo e índice de massa corporal. Também analisou-se o conhecimento prévio, o 
tratamento e o controlo da hipertensão arterial, diabetes e hipercolesterolemia e avaliou-se o 
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agrupamento desses fatores de risco, comprovando dados adicionais para o planeamento 
de futuras intervenções.  
 
Os próximos parágrafos descrevem o objetivo específico perseguido em cada análise, bem 
como a metodologia adotada e os principais resultados. 
 
Estimar a incidência de hipertensão nos últimos dois anos e a associação com 
características sociodemográficas, antropométricas e comportamentais (Artigo II) 
A partir de um estudo anterior realizado em 2011, 303 indivíduos em risco de hipertensão 
foram avaliados após 2 anos, seguindo a abordagem da Organização Mundial da Saúde 
STEPwise. A incidência cumulativa e o risco relativo foram calculados e o método de 
Cochran-Matel-Haenszel foi utilizado para calcular o risco relativo ajustado para a idade. A 
incidência cumulativa de 2 anos de hipertensão foi de 12,2%, semelhante em mulheres 
(12,2%) e homens (12,3%), significativamente maior nos indivíduos com mais de 40 anos 
(21,3% versus 8,1%) e de áreas rurais (25,0% versus 10,3% nas áreas urbanas). 
Consumidores regulares de álcool e indivíduos obesos ou com excesso de peso 
apresentaram risco significativamente maior de desenvolver hipertensão (2,5 e 2,3%, 
respetivamente). Entre os novos casos, existe uma baixa frequência de conhecimento prévio 
(37,8%) e tratamento (21,4%), sem qualquer caso controlado. 
 
Quantificar a prevalência, o conhecimento prévio, o tratamento e o controlo da 
hipertensão, diabetes e hipercolesterolemia e a associação com características 
sociodemográficas, antropométricas e comportamentais (Artigo III) 
Constituindo a linha de base do CardioBengo, 2.354 indivíduos com idades entre os 15 e os 
64 anos foram avaliados quanto às características comportamentais, sociodemográficas e 
físicas. Foi aplicada um ajuste pós-estratificação para a obtenção das prevalências. Os odds 
ratios ajustados para cada variável relacionada às condições, foram calculados usando 
modelos de regressão logística. Em geral, a prevalência de hipertensão foi de 18,0%, da 
diabetes 9,2% e da hipercolesterolemia 4,0%. Entre os hipertensos, o nível de conhecimento 
prévio foi de 48,5%, 15,8% estavam em tratamento e 9,1% tinham a sua pressão arterial 
controlada. Apenas 10,8% estavam cientes de que tinham diabetes, 4,5% estavam em 
tratamento e 2,7% controlados. O nível de conhecimento prévio para a hipercolesterolemia 
foi de 4,2%, com 1,4% dos indivíduos em tratamento e 1,4% controlados. A prevalência de 
diabetes foi maior nos homens, e a hipertensão e a hipercolesterolemia em mulheres, com 
níveis de conhecimento prévio mais elevados entre indivíduos idosos e maiores níveis de 
educação. A obesidade e o tabagismo relacionaram-se com as três condições, sendo a 
prevalência de diabetes e hipercolesterolemia maior nas áreas urbanas. 
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Descrever o consumo de tabaco e a sua relação com as características 
sociodemográficas e determinar o nível de dependência de nicotina (Artigo IV) 
A informação sobre a frequência e os determinantes do consumo de tabaco em Angola não 
está sistematizada. Analisando os resultados do CardioBengo, quanto ao tipo de consumo 
de tabaco e sua quantificação diária, estimamos a prevalência de tabagismo e valores 
médios de dependência de nicotina por gênero e variáveis sociodemográficas. Utilizámos a 
Abordagem Stepwise da Organização Mundial de Saúde e o Teste de Dependência de 
Nicotina de Fagerström para avaliar a dependência de nicotina. A prevalência de tabagismo 
diário foi de 6,1%, significativamente maior nos homens (10,0% versus 2,6%), e a de ex-
fumadores foi de 7,5%, também maior nos homens. Apenas 0,2% relataram consumo de 
tabaco de mascar. Um terço dos fumadores relataram ter começado a fumar diariamente 
antes dos 18 anos. Os níveis de dependência de nicotina foram classificados como muito 
baixos ou baixos em 84% dos fumadores. A prevalência diária de tabagismo aumentou com 
a idade; foi também maior nas áreas rurais, nos indivíduos sem escolaridade, menores 
rendimentos e consumo de álcool. 
 
Quantificar a prevalência de categorias de índice de massa corporal e avaliar a sua 
relação com características sociodemográficas (Artigo V) 
Não existem dados nacionais de prevalência de obesidade para Angola, mas as tendências 
regionais apontam para um aumento. Dos 2.357 indivíduos com idade entre os 15 e os 64 
anos do CardioBengo, foram recolhidas medidas antropométricas e dados 
sociodemográficos. As mulheres apresentaram uma prevalência significativamente maior de 
obesidade (10,5% versus 2,8%), mas a frequência da categoria abaixo do peso foi 
semelhante aos homens (10,2% versus 12,4%). O excesso de peso e a obesidade 
aumentaram com a idade, sendo o abaixo de peso a categoria mais prevalente na faixa 
etária dos 15 aos 24 anos, em ambos os sexos (18,5% nas mulheres e 18,4% nos homens). 
A obesidade foi mais prevalente entre os indivíduos que vivem com companheiro (em 
relação conjugal), diminuiu com a escolaridade (nas mulheres), mas foi maior nas áreas 
rurais e para aqueles com renda familiar mensal acima dos 150 dólares, em ambos os sexos. 
 
Estimativa da distribuição da população por categorias de risco cardiovascular e 
elegibilidade para tratamento farmacológico (Artigo VI) 
Nesta análise, estimamos o risco a 10 anos de um evento cardiovascular em 468 indivíduos 
com idades entre os 40 e os 64 anos que não estivessem a fazer terapia medicamentosa. 
Calculámos também a proporção de participantes elegíveis para tratamento farmacológico 
de acordo com valores clínicos isolados e o risco cardiovascular total. A maioria dos 
participantes foi classificada como tendo um risco cardiovascular baixo (<10%) a 10 anos 
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(87,6%), com apenas 4,5% apresentando um risco cardiovascular elevado (≥ 20%). Se 
considerarmos o critério único para a hipertensão arterial, 48,7% da população deve ser 
considerada para o tratamento com anti-hipertensivos, mas se aplicarmos a previsão de 
risco, esse número diminuirá para metade, para 22%, sem alterações no uso de 
hipoglicemiantes (19,0% em ambas as situações) e 3,8% para o uso de Estatinas. 
 
Esta tese ajudou a criar uma linha de base estável para avaliar as DCV e os fatores de risco 
associados, que pode alimentar uma definição mais clara da política de saúde de Angola 
para as DCV e as DNT em geral. As principais conclusões são: 
• O risco de hipertensão é alto nesta população, e mesmo com uma perda significativa 
de indivíduos no seguimento, este estudo gera a primeira evidência de que a 
hipertensão está a aumentar com o envelhecimento da população, estando 
associado à obesidade. 
• A atual prevalência de hipertensão e diabetes também é maior, existindo também 
hipercolesterolemia. A prevalência da Diabetes e hipercolesterolemia foi maior entre 
os moradores urbanos, onde a prevalência da obesidade também foi maior. A 
urbanização está a marcar o aumento dos fatores de risco associados à dieta, 
especialmente entre as mulheres. 
• Os baixos níveis observados de conhecimento prévio, tratamento e controlo de todas 
as condições indicam um alto fardo de condições não diagnosticadas e não 
controladas, colocando ênfase adicional na necessidade de intervenção nos 
cuidados de saúde primários. 
• Esta população angolana apresenta uma baixa prevalência de tabagismo, com um 
baixo número de cigarros fumados diariamente e baixos níveis de dependência de 
nicotina, apesar dos baixos preços e fácil acesso aos cigarros fabricados. A 
implementação de intervenções restritivas mais fortes pode interromper e reverter a 
tendência observada na região africana do aumento do tabagismo. 
• A prevalência de encontro de obesidade e baixo peso foi semelhante entre as 
mulheres, refletindo um estado de transição nutricional. Como em outras 
comunidades africanas, as mulheres apresentam uma maior prevalência de excesso 
de peso e obesidade, coexistindo valores semelhantes de baixo peso. Isto salienta a 
necessidade de programas de promoção e intervenções específicas para as 
mulheres, que lidem com a acumulação de fatores de risco. 
• Existe uma necessidade urgente de tratamento farmacológico dos distúrbios 
cardiovasculares nesta população, integrada com medidas não farmacológicas. Isso 
pode ser feito usando a metodologia de previsão de risco, que melhora globalmente 
a eficácia das intervenções e reduz custos. 
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Abstract 
Cardiovascular diseases (CVDs) comprise the major disorders of the heart and the arterial 
circulation supplying the heart, brain and peripheral tissues. In 2015, CVDs were the leading 
causes of non-communicable disease (NCD) deaths with 17.9 million deaths worldwide, a 
number that has increased globally by 12.5% since 2005. Almost 80% of these deaths 
occurred in low and middle-income countries. The common occurrence of CVDs and 
associated mortality, loss of independence and productivity, impaired quality of life and social 
and economic costs are compelling reasons for public health concern.   
 
Risk factors for CVDs are shared with the majority of NCDs and are due to the exposure to 
behavioural risk factors: tobacco and alcohol consumption, unhealthy diet, and physical 
inactivity. These unhealthy behaviours influence metabolic pathways and ultimately result in 
intermediate (metabolic) risk factors: obesity, raised blood pressure (hypertension), sugar 
(diabetes) and lipids (dyslipidaemia). There are also some major CVD risk factors that cannot 
be controlled, like age, sex, genomics and ethnic differences, and others tied to 
socioeconomic conditions like education, urbanisation and economic power.  
 
Cardiovascular diseases and associated risk factors in Sub-Saharan Africa have been 
negligible but are rising with the ageing and growing populations. Like other countries in the 
region, Angola has no national surveillance system for NCDs and presents a fast-changing 
social context. This thesis, aimed to contribute to a better understanding of the epidemiology 
of CVD risk factors in Angola, through the study of an adult Angolan community (15 to 64 
years old) in the catchment area of the Centro de Investigação em Saúde de Angola.   
 
To accomplish this purpose, we created and implemented a study protocol to create a 
baseline and an expected follow-up strategy to address the surveillance of risk factors (Paper 
I): the CardioBengo. From previous work, a follow-up survey was conducted to assess, for 
the first time, the incidence rate of hypertension in the same population (Paper II). From the 
data extracted from the CardioBengo baseline, four studies (Papers III to VI) were performed 
regarding the characterization of hypertension, diabetes, hypercholesterolemia, tobacco 
consumption and body mass index categories in this population. We also aimed to analyse 
the awareness, treatment and control of hypertension, diabetes and hypercholesterolemia 
and to assess the clustering of these risk factors, proving additional data for the planning of 
future interventions. The next paragraphs describe the specific objective pursued in each 
analysis, as well as the methodology adopted and the main results. 
 
 6 | Abstract 
 
Estimate the incidence of hypertension in the last two years and the association with 
socio-demographic, anthropometric and behavioural characteristics (Paper II) 
From a previous community-based study conducted in 2011, 303 individuals at risk for 
hypertension were evaluated after two years, following the World Health Organization (WHO) 
STEPwise approach to Surveillance procedures. Cumulative incidence and relative risk were 
calculated, and the Cochran-Matel-Haenszel method was used to compute sex-age-adjusted 
relative risk. The two-year cumulative incidence of hypertension was 12.2% and was similar 
in women (12.2%) and men (12.3%) but significantly higher in those over 40 years (21.3% 
versus 8.1%) and living in rural areas (25.0% versus 10.3% in urban areas). Regular alcohol 
drinkers and overweight or obese individuals presented a significantly higher risk of 
developing hypertension (2.5 and 2.3, respectively). Among incident cases, there was a low 
frequency of awareness (37.8%) and treatment (21.4%) without any controlled case.  
 
Quantify the prevalence, awareness, treatment and control of hypertension, diabetes 
and hypercholesterolemia and the association with socio-demographic, 
anthropometric and behavioural characteristics (Paper III) 
Constituting the baseline of the CardioBengo, 2,354 individuals between 15 and 64 years old 
were assessed for behavioural, socio-demographic and physical characteristics. Post-
stratification survey weights were applied to obtain prevalence levels. Adjusted odds ratios 
for each variable related to conditions were calculated using logistic regression models. 
Overall, the prevalence of hypertension was 18.0%, of diabetes 9.2%, and of 
hypercholesterolaemia 4.0%. Among hypertensive individuals, the awareness level was 
48.5%: 15.8% were on treatment, and 9.1% had their blood pressure controlled. Only 10.8% 
were aware they had diabetes: 4.5% were on treatment, and 2.7% were controlled. The 
awareness level for hypercholesterolaemia was 4.2%, with 1.4% of individuals on treatment 
and 1.4% controlled. The prevalence of diabetes was higher in men, and hypertension and 
hypercholesterolaemia higher in women, with awareness levels higher among older and 
educated individuals. Obesity and smoking were related to all three conditions, and the 
prevalence of diabetes and hypercholesterolaemia was higher in urban areas. 
 
Describe the tobacco consumption and its relation to socio-demographic 
characteristics, and determine the nicotine level of dependence (Paper IV) 
Information on the frequency and determinants of tobacco use in Angola are not 
systematised. By analysing the results from the CardioBengo baseline, regarding the type of 
tobacco consumption and its daily quantification, we estimated the prevalence of tobacco 
use and nicotine dependence mean values by gender and socio-demographic variables. We 
used the WHO STEPwise Approach to Chronic Disease Risk Factor Surveillance, and the 
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Fagerström Test for Nicotine Dependence to assess nicotine dependence. The prevalence of 
daily smoking was 6.1%, significantly higher in men than in women (10.0% versus 2.6%). 
Regarding ex-smokers, the prevalence was 7.5% (also greater in men). Only 0.2% reported 
smokeless (chewing) tobacco. One-third of every smoker reported having started smoking 
daily before the age of 18. The nicotine dependence levels were classified as ‘very low’ or 
‘low’ in 84.0% of the smokers. Daily smoking prevalence increased with age and was higher 
in rural areas and in individuals with no formal education, lower incomes, and alcohol 
consumption. 
 
Quantify the prevalence of body mass index categories and evaluate its relation to 
socio-demographic characteristics (Paper V) 
No national prevalence data for obesity exists for Angola, but the regional trends point to a 
rise. Anthropometric measurements and socio-demographic data were collected from 2,357 
participants, aged 15 to 64 years, of the CardioBengo baseline. Women presented a 
significantly higher prevalence of obesity than men (10.5% versus 2.8%), but women’s the 
underweight frequency was similar to males (10.2% versus 12.4%). Overweight and obesity 
increased with age, with underweight being more prevalent in the 15-to-24-year age group in 
both sexes (18.5% in females and 18.4% in males). Obesity was more prevalent among 
individuals living with a companion (in a marital relationship), decreased with education (in 
females), but was higher in rural areas, and for those with a family monthly income above 
150 US dollars in both sexes. 
 
Estimate the distribution of the population by cardiovascular risk categories and its 
eligibility for pharmacological treatment (Paper VI) 
In this analysis, we estimated the 10-year risk of a fatal or nonfatal major cardiovascular 
event (World Health Organization/International Society of Hypertension risk prediction charts) 
for 468 individuals aged 40 to 64 years not using drug therapy. We computed the proportion 
of untreated participants eligible for pharmacological treatment according to clinical values 
alone and total cardiovascular risk. Most of the participants were classified as having a low 
(< 10%) 10-year cardiovascular risk (87.6%), with only 4.5% having at least a high (≥ 20%) 
cardiovascular risk. If we consider the single criterion for hypertension, 48.7% of the 
population should be considered for treatment with antihypertensive drugs, but if we apply 
the risk prediction chart, this number reduces to 22.0%, without any changes for the use of 
hypoglycaemic drugs (19.0% in both situations) and 3.8% for the use of lipid-lowering drugs 
following the risk prediction chart. 
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This thesis helps to create a stable baseline to further evaluate CVDs and associated risk 
factors (socioeconomic, behavioural and metabolic) that can contribute to a clearer definition 
of Angola health policy for CVDs and NCDs in general. The major conclusions of this thesis 
are as follows: 
• The hypertension risk is high in this population, and even with a significant loss of 
individuals in the follow-up, this study generates the first evidence that hypertension 
is rising with the ageing of the population and associated with obesity. 
• The current prevalence of hypertension and diabetes is also higher, with 
hypercholesterolaemia also existing. Diabetes and hypercholesterolaemia were 
higher among urban dwellers, where obesity was also higher. Urbanisation marks the 
rise of diet-associated risk factors, especially among women.  
• The observed low levels of awareness, treatment and control of all conditions indicate 
a high burden of undiagnosed and uncontrolled conditions, increasing the need for 
primary care intervention. 
• This Angolan population presents a low smoking prevalence, with a low number of 
daily smoked cigarettes and low levels of nicotine dependency, despite the low prices 
and easy access to manufactured cigarettes. The implementation of stronger 
interventions at the beginning of the expected rise in smoking prevalence may halt 
and revert the tendency observed in the African region. 
• The encountered prevalence of obesity and underweight was similar among women, 
reflecting a nutrition transition state. Like in other African communities, women 
present a higher prevalence of overweight and obesity, but the values of underweight 
were similar among sexes. This highlights the need for special health promotion and 
interventions designed to deal with the accumulation of risk factors for different 
disease groups in females. 
• There is an urgent need for pharmacological treatment of cardiovascular disorders, 
integrated with non-pharmacological measures, in this population. This can be 
accomplished using risk prediction charts, which globally improve the efficacy of the 
interventions and reduce costs. 
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1. Introduction 
Non-communicable diseases (NCDs), which include cardiovascular disease, cancer, 
diabetes, chronic respiratory disease and mental health conditions, are the leading cause of 
death worldwide. These diseases are responsible for almost 70% (38 million) of the world’s 
deaths in 20121 and 39.8 million deaths in 2015.2 This group of conditions, also known as 
chronic diseases, are non-transmissible between individuals, usually of long duration and 
slow progression, affect all ages and all regions, and often associated with older age groups 
and high-income countries. 
 
Evidence shows that almost three-quarters of all NCD deaths occur in low- and middle-
income countries (LMICs), and 16 million death attributed to NCDs occur before the age of 
70, with 82% of these deaths occurring in LMICs,1,3 making this disease group one of the 
major developing challenges in the near future as targeted by the World Health Organisation 
(WHO) “Global NCD Action Plan”4 and included in the Sustainable Development Goals.5 
 
Although globally life expectancy and age-standardised death rates are improving, mainly 
due to the reduction of deaths caused by infectious diseases, the burden created by CVDs, 
diabetes and cancer temper this trend, mainly among LMICs.2 People in these countries are 
living well enough to develop these conditions but might not have access to the right 
treatment to avoid the rise of mortality due to NCDs.  
 
Factors like the ageing of populations, rapid urbanisation and the globalisation of unhealthy 
lifestyles can drive the increase of NCDs in LMICs.1,3 These processes are part of the theory 
of epidemiologic transition that links the change in patterns of health and disease with their 
demographic, economic and sociologic determinants and consequences.6 In the transition 
across epidemiological stages, the leading causes of death and disability shift from nutritional 
deficiencies and infectious diseases in less developed countries to NCDs in more develop 
countries, putting some LMICs between transition periods, facing a double burden of 
diseases: communicable and non-communicable. 
 
1.1. Cardiovascular diseases 
Cardiovascular diseases comprise the major disorders of the heart and the arterial circulation 
supplying the heart, brain and peripheral tissues. Following the International Statistical 
Classification of Diseases and Related Health Problems (ICD 10), CVDs are mainly 
classified as Diseases of the Circulatory System (I00 to I99).7 These ten conditions are 
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ischemic (or coronary) heart disease, cerebrovascular disease (e.g. stroke), hypertension 
and peripheral vascular disease (mainly due to atherosclerosis)8,9, as well as rheumatic heart 
disease, cardiomyopathy, cardiac arrhythmia, congenital heart disease, deep vein 
thrombosis and pulmonary embolism.  
 
1.1.1. Atherosclerosis and clinical presentation of cardiovascular diseases 
Atherosclerosis is a complex pathological process, with the accumulation of fatty material 
and cholesterol inside the lumen of medium- and large-sized blood vessels. These deposits 
(plaques) cause the inner surface of the blood vessels to become irregular and the lumen to 
become narrow, making it harder for blood to flow through. The development of 
atherosclerotic plaque (atherogenesis) begins early in life and progresses over many years 
(usually decades) throughout the life span. The atherosclerotic plaque, whether fully matured 
or in intermediate stages of development, precipitate blood clot formation (thrombosis) with a 
sudden interruption of blood flow. A variety of outcomes may follow, depending on the 
location, severity and duration of the interruption.8,9 
 
Ischemic (or coronary) heart disease is caused by the narrowing and obstruction of one or 
more blood vessels supplying the myocardium, and which may culminate in myocardial 
infarction (commonly known as heart attack). It is likely there is considerable variability in the 
process from patient to patient before a myocardial infarction (MI), but the common scenario 
involves rupture of an atherosclerotic plaque followed by platelet aggregation and possibly 
thrombotic occlusion in the right or left anterior descending or in the left circumflex artery. 
The result of such a process is significant necrosis of the myocardium, which can quickly 
progress to arrhythmia and sudden cardiac death.9 
 
Cerebrovascular disease is caused by acute disruption of the blood supply to the brain due 
to either blockage (ischemic stroke) or rupture of a blood vessel (haemorrhagic stroke). As 
with ischemic heart disease, strokes are usually caused by atherosclerotic plaque either 
developing in place or dislodged from a larger (upstream) artery. Plaque rupture, platelet 
aggregation, and thrombotic occlusion may all be involved.9 
 
Hypertensive heart disease occurs when the heart continually pumps against high resistance 
in the peripheral circulatory system. Resistance to blood flow in the peripheral arteriolar 
system increases with the constriction of blood vessels (vasoconstriction). As the peripheral 
resistance to blood flow increases, the heart (particularly the left ventricle) must work harder 
to maintain cardiac output. This sequence leads to left ventricle hypertrophy and dilatation 
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and may cause the pooling of blood in the left ventricular chamber (left-sided congestive 
heart failure). If there is long-standing high blood pressure in the lungs (pulmonary 
hypertension), the right ventricle may undergo hypertrophy leading to right-sided congestive 
heart failure (cor pulmonale).9 Peripheral artery disease is caused by obstruction of the 
arteries (usually by atherosclerotic plaque) supplying the arms and legs. This condition is 
often a forerunner of ischemic heart disease due to atherosclerosis.9 
 
1.1.2. Burden of cardiovascular diseases 
Cardiovascular diseases were the leading causes of NCD deaths in 2015 with 17.9 million 
deaths worldwide, a number that has increased globally by 12.5% since 2005. Almost 80% of 
these deaths occurrs in LMICs.2 Only two CVDs, MI and stroke, accounted for 85.1% of all 
deaths due to CVDs that year2 and were the leading causes of disability-adjusted life years 
(DALYs) worldwide in 2015.10 Their common occurrence and associated mortality, loss of 
independence and productivity, impaired quality of life and social and economic costs are 
compelling reasons for public health concern.9  
 
Since 1990, there has been a global shift towards NCDs and CVDs as leading causes of 
death. CVD deaths are rising in LMICs (Africa, Asia and South America) and stagnating or 
even decreasing in high-income regions (North America, Europe and Oceania) (Figure 1) in 
different points of the epidemiologic transition.  
 
Figure 1. Cardiovascular Diseases annual variation rate (%) 
Both sexes, all ages, 1990 to 2015, deaths per 100,000 
 
Source: Institute for Health Metrics and Evaluation, University of Washington, 2017. 
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The international patterns of CVDs can be divided into four distinct stages:11,12  
i. Excess rheumatic heart disease and other inflammatory conditions in children and 
young adults (Sub-Saharan Africa, rural India and South America),  
ii. Excess hypertensive heart disease in young and middle-aged adults (China and urban 
Asia), 
iii. Rapidly increasing rate of MI and strokes, obesity and diabetes (urban India and Latin 
America), 
iv. Decline of CVDs among adults (North America, Western Europe and Oceania).  
 
A fifth stage was proposed for countries where social upheaval or war collapses the existing 
social and health structures of a region, leading to a resurgence of conditions seen in the first 
two stages, while third- and fourth-stage diseases persist (e.g., Russia).11,12 This stratification 
was designed in 2001, and after 15 years, some regions have moved to the “upper” stages of 
the epidemiologic transition, with countries from Sub-Saharan Africa (SSA) distributed in 
phases 1 to 3.11 A recent analysis that considers the ageing and growth of the population, 
puts central SSA in phase 2 (of 6) with increasing CVD deaths due mostly to population 
growth.13 
 
The prevalence configuration of the CVD is distinctly different in SSA than in the rest of the 
world, where an unprecedented decline in mortality and the corresponding increase in the 
expectation of life at birth are shifting the epidemiological landscape of the region. Large 
economic and social changes are occurring in many countries due to the postcolonial era, 
the end of civil wars and natural resource discovery. Some are beneficial to the population’s 
health (economic growth and increasing access to health interventions), whereas others are 
associated with growing exposure to risk factors that lead to increased morbidity and 
mortality.14 
 
Adult mortality as a public health issue in SSA remains neglected, with CVDs (and NCDs in 
general) coexisting with the conditions related to underdevelopment, such as malaria, 
malnutrition and tuberculosis. Infectious and inflammatory causes for CVDs are relatively 
more frequent, and atherosclerosis less, but this is not necessarily permanent when 
urbanisation and population ageing are ongoing.15 
 
These countries face a double burden as they struggle to cope with NCDs and infectious 
diseases associated with a lack of socio-economic development.14 This predicament is likely 
to worsen (Figure 2) because the majority of their populations are less than 35 years of age, 
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and the determinants and risk factors for CVDs are prevalent and increasing within this age 
group.16 
 
Figure 2. Estimated percentage change in premature cardiovascular mortality, from 2013 to 2025, if 
risk factors continue their current trend 
 
Source: Roth et al. Estimates of Global and Regional Premature Cardiovascular Mortality in 2025.16 
 
The percentage of deaths by cardiovascular diseases for SSA, in 2015, was 11.2,17 
occupying the third place for mortality causes, whereas in 2010, this figure was 8.8%,15 and 
in 1990, it was the fourth cause of death at 7.5%.17 MI, together with strokes, were 
responsible for 10.8% of deaths among females and 8.6% in males in 2015 in the entire SSA 
region.17 This represents an increase in mortality of 38.0% for strokes and 52.1% for MI in 
both sexes, since 1990,17 revealing the rising trend of CVDs in SSA.  
 
The estimates made for Angola follow the same pattern: strokes are responsible for 5.35% 
and MI for 4.65% of all deaths in 2015, making these the fourth and sixth causes of mortality 
in Angola, respectively.17 For the age group above 50, strokes and MI are the first and 
second causes of death in Angola.17  
 
In the area studied in this thesis, the Dande Health and Demographic Surveillance System 
(Dande-HDSS) Verbal Autopsy System reported that among the 407 reported deaths in 
individuals older than 15 years, from 2009 to 2012, 59 (14.5%) were due to circulatory 
system diseases, the leading cause of death attributable to a specific disease in this 
population for this period.18 
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1.2. Cardiovascular disease risk factors 
Atherosclerosis is the underlying disease process in the blood vessels that causes the vast 
majority of CVDs. Factors that promote atherogenesis are known as risk factors, a term used 
for the first time in 1961, as a result of the Framingham Heart Study, a large longitudinal 
investigation that started in 1948 in Massachusetts, United States.19 This ground-breaking 
epidemiological study of CVDs18 was instrumental in the original identification of many factors 
associated with an increased risk of CVDs.19,20 
 
Risk factors for CVDs (as a result of atherosclerosis) are shared with the majority of NCDs 
and are due to exposure to behavioural risk factors: tobacco and alcohol consumption, 
unhealthy diet and physical inactivity. These unhealthy behaviours influence metabolic 
pathways and ultimately result in intermediate (metabolic) risk factors: obesity, raised blood 
pressure (hypertension), sugar (diabetes) and lipids (dyslipidaemia).1,8  
 
Common approaches that address behavioural and metabolic risk factors, which often 
coexist in the same person and act synergistically to increase the individual’s total risk, are 
effective for prevention of CVDs and NCDs in general.21 However, there are also some major 
CVD risk factors that cannot be controlled, like age, sex, genomics and ethnic differences, 
and others tied to socioeconomic conditions, like education, urbanisation and economic 
power.  
 
1.2.1. Non-modifiable risk factors 
The usual focus in cardiovascular epidemiology is the modifiable risk factors derived from 
unhealthy behaviours and the drivers of these behaviours, such as education level, 
urbanisation and economic status. However, the attributable burden of age, sex, genomics 
and ethnic differences must be taken into consideration to best understand patterns of 
modifiable risk factors, especially in populations where knowledge of this topic does not exist. 
 
1.2.1.1. Age 
The Framingham Study indicated an independent effect of age on CVD incidence, taking all 
the major risk factors into account.19 The cardiovascular system is strongly affected by 
ageing, with clinical manifestations of atherosclerosis increasing with age.22 Most of the 
health burden from risk factors for CVDs occurs at older adult ages,23 with shifts in population 
age structures accounting for more than 23% of increased global mortality due to MI and 
strokes.2  
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There is a predominance of CVD deaths in older ages in developed countries, but for 
developing countries, CVD deaths are more prominent among younger individuals.23,24 The 
onset of CVDs in these countries is 10 to 15 years earlier than that of developed countries,25  
and DALYs account for this difference by giving a higher weight to deaths at younger ages.23 
In SSA, adults are more likely to die from a non-CVD cause compared with the rest of the 
world, and the region has the lowest years of life lost due to CVDs: the mean age of death by 
CVD in SSA is 65 years old, the lowest in the world.15 
 
In addition to the intrinsic outcome in the structural and functional changes in the heart and 
vessels, it may be that ageing is also a reflection of the length of exposure to the burden of 
modifiable risk factors.22 In cardiovascular epidemiology, the effect of age is often removed to 
isolate these factors. However, health-system planning also requires an understanding of the 
full burden of disease and the effect of ageing. The use of age-specific prevalence can assist 
in this analysis.13  
 
1.2.1.2. Sex 
The most common cause of death in women, as in men, is CVDs, but the percentage of 
global deaths is higher: 34.1% for women and 30.5% in men in 2015.17 Men are generally at 
greater risk for CVDs than premenopausal women at similar ages. After menopause, 
however, blood pressure increases in women to levels even higher than in men.26  
 
The female life expectancy is greater than the male, and women who develop CVDs tend to 
be elderly, which creates specific management issues because older women are likely to 
suffer from comorbidities, such as diabetes and hypertension, important risk factors.27 This 
conjunction of factors can explain the worse outcomes for CVDs in women.  
 
Rarely CVD is presented as a women’s health problem, namely in developing countries, 
where health interventions are frequently concentrated on maternal and reproductive health. 
The impact of a CVD in females is direct when they experience the illness themselves (with 
higher levels of morbidity and mortality), but also indirect when their socio-economic 
circumstances are affected by death or disability among family members.24 
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1.2.1.3. Family history 
The majority of early cardiovascular events in a population occur in families with a positive 
family history of CVD and can sometimes be the crucial and single most important risk factor 
in predisposing an individual to early disease.28 A large proportion of MI or strokes occurring 
at a young age could be attributable to inherited or familial predisposition.29 Sudden cardiac 
death in youth is defined as death prior to 40 years old from an identified or suspected 
cardiac cause, usually heritable cardiomyopathies, primary electrophysiologic disorders, 
congenital heart disease or early coronary artery disease.30 
 
A family history paired with an examination of relatives may lead to a more precise diagnosis 
and the identification of multiple individuals at risk, helping to guide preventive efforts. A 
family history of CVD is defined as having a male first-degree relative experiencing the first 
manifestation of CVD under the age of 45 or a female first-degree relative under the age of 
55.28,29 
 
Also, part of the genetic heritage is familial hypercholesterolemia, an autosomal dominant 
condition associated with high levels of total and low-density lipoprotein (LDL) cholesterol. 
The individual inherits a defective LDL cholesterol receptor gene from one or both parents. At 
least 50% of males and 30% of females with familial hypercholesterolemia who do not 
receive effective treatment will experience a coronary event before the age of 50.31  
 
1.2.1.4. Ethnicity 
Ethnicity is a categorisation of individuals who share similarities, such as common ancestral, 
language, social, cultural or national experiences. The use in public health of this 
categorisation occurs because people identified as members of particular ethnic groups often 
differ in disease rates or risk factor distributions from other groups. Group membership 
defined by ethnicity may indicate genetic, cultural, socioeconomic or other differences, and 
interpretation of related differences in health and disease may require deep investigation.9 
 
The ethnic composition of populations is also implied in differences in the CVD burden and 
outcomes, attributable to biological, cultural, healthcare and social issues. The understanding 
of ethnic differences in health is beneficial to minorities, and it contributes to decreasing 
health inequalities in a broad sense.32 An increased stroke rate is noted for Blacks, some 
Hispanic Americans, Chinese and Japanese populations, and increased CVD deaths are 
noted for South Asians and American Blacks in comparison with Whites.33 
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Cardiovascular disease rates among Blacks in Africa are relatively low when compared with 
the rates in most western countries, like the prevalence of most conventional risk factors. 
Exception are made for hypertension, which is higher among Blacks than other groups within 
Africa and the world.33 Hypertension among Blacks occurs at a younger age and often 
involves more severe blood pressure levels than among Whites. This is due to a complex 
interaction between environmental responses to diet and stress and a potential 
genetic/physiological difference in sodium/potassium excretion, which together with obesity 
(especially among women) may be part of the explanation. Black patients with hypertension 
are particularly vulnerable to strokes and hypertensive kidney disease. They are three to five 
times as likely as Whites to have renal complications and end-stage kidney disease.34 
 
1.2.2. Modifiable risk factors 
More recent and larger population studies of cardiovascular risk factors, like the MONICA 
project and the INTERHEART study,25,35 focused on modifiable risk factors. In this section, 
we will focus on hypertension, diabetes, hypercholesterolemia, tobacco use and overweight 
and obesity. Raised blood pressure, glucose and cholesterol, and overweight and obesity are 
directly linked to unhealthy diets as further discussed. 
 
Regarding attributable deaths worldwide, the leading CVD risk factor in 2004 was raised 
blood pressure, followed by tobacco use, raised blood glucose, overweight and obesity, and 
high blood cholesterol.23 In Table 1, different attributable results to each modifiable risk factor 
are listed from the world and African population of the INTERHEART study.25,36 
 
Table 1. Compared attributable results for each risk factor, globally and in Africa, in both sexes 
 Attributable deaths
 
World, 200423 
PAR* 
World, 1999-200325 
PAR* 
Africa, 1999-200336 
Raised blood pressure 12.8% 23.4 29.6 
Raised blood glucose 5.8% 12.3 16.7 
Raised blood cholesterol 4.5% - - 
Tobacco smoking 8.7% 36.4 38.9 
Overweight and obesity 4.8% - - 
   * PAR - population attributable risk 
 
Updating these values to 2015, raised blood pressure is also one of the principal risks for 
both sexes, contributing to 9.2% of DALYs for men and 7.8% for women. Smoking was the 
second-leading risk factor for men in 2015, contributing to 9.6% of DALYs and a large 
proportion of male disease burden from CVDs. In 2015, raised blood glucose was associated 
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with 6.0% of DALYs for men and 5.6% for women. Both raised blood glucose and overweight 
and obesity have increased by more than 20% since 1990.37  
 
The evolution of the five risk factors, the object of this thesis, can be observed in Figure 3. All 
five have been rising since 1990 and, in 2015, were among the seven leading risk factors for 
DALYs, globally, in both sexes.37  
 
Figure 3. Leading global risk factors for DALYs for both sexes combined, 1990, 2005 and 2015, with 
percentage change in number of DALYs, and all-age and age-standardised rates 
 
Source: GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk 
assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of 
risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.37 
 
Specifically, among the African population participating in the INTERHEART study, five risk 
factors (smoking, diabetes, hypertension, abdominal obesity and an elevated apolipoprotein 
B to apolipoprotein A-1 ratio) accounted for 89.2% of the population attributable risk for the 
first myocardial infarction.36 The same study suggested that uncontrolled major risk factors 
have a larger impact on the burden of CVDs in Africa than elsewhere in the world.  
 
If the current trends persist, the risk of dying from NCDs will increase in the African region. 
However, this rising risk could be reversed by reaching the proposed targets for six risk 
factors (tobacco use, alcohol use, salt intake, obesity, increased blood pressure and glucose 
levels) out of the nine global targets proposed by the WHO Global NCD Action Plan.4,38  
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1.2.2.1. Hypertension 
Blood pressure is created by the force of blood pushing against the inner walls of blood 
vessels. Measured in millimetres of mercury (mmHg), this force is recorded as systolic blood 
pressure and diastolic blood pressure. Systolic blood pressure is the highest pressure in 
blood vessels and happens when the heart contracts; diastolic blood pressure is the lowest 
pressure in blood vessels and occurs in between heartbeats when the heart muscle relaxes. 
The higher the pressure in blood vessels, the harder the heart has to work.39 Most 
hypertensive individuals do not present any symptoms but sometimes have headaches, 
shortness of breath, dizziness, chest pain, heart palpitations and nose bleeds.39 
 
Raised blood pressure (hypertension) is defined as a systolic blood pressure of 140 mmHg 
or higher, a diastolic blood pressure of 90 mmHg or higher, or both. The systolic blood 
pressure is the basis for diagnosis in most patients.34,39 About 95% of adults with raised 
blood pressure have primary hypertension, with the remain 5% classified as secondary 
hypertension, mainly driven by chronic kidney disease.  
 
The causes of primary hypertension are not known, although its connection with ageing, 
genetics and unhealthy lifestyles (sedentary life, tobacco and alcohol consumption) and diet 
(obesity, salt intake and cholesterol) is well known.34,39 Multiple clinical trials provide 
evidence that lowering blood pressure decreases the risk of future cardiovascular events, 
stroke and end-stage renal disease.40  
 
The goal of treating hypertension is to reduce blood pressure to levels below the numbers 
used for making the diagnosis and deal with all other identified risk factors for CVDs: lipid 
disorders, diabetes, obesity and smoking. Furthermore, hypertension management implies 
significant lifestyle changes.1,4,21,34,39 
 
Hypertension was the most important risk factor globally in 2015 (Figure 3), with 211.8 million 
DALYs37 as the most important cause of CVDs.1,4,37,39 Since 1975, mean blood pressure has 
decreased in high-income countries and increased in low-income countries in South Asia and 
SSA.41 The number of adults with hypertension increased from 594 million in 1975 to 1.13 
billion in 2015, largely in LMICs.41 
 
In 2010, approximately 75% of people with hypertension were living in LMICs where 
hypertension prevalence was higher (31.5%) than in high-income countries (28.5%).42 The 
African Region presented the highest estimated prevalence of hypertension (30%) in all 
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adults across WHO regions in 20141 and, in 2010, the highest prevalence in women 
(36.3%).42 The global age-standardized prevalence of hypertension was 25.9% in adults 20 
years or older in 2000, with an increase of 5.2% over ten years. Although this prevalence 
decreased by 2.6% in high-income countries, in LMICs it increased 7.7% (Figure 4).42 
 
Figure 4. Worldwide age- and sex-standardized prevalence of country-specific hypertension 
in 2000 and 2010 in individuals ≥20 years 
 
Source: Adapted from Mills et al. Circulation, 2016.42 
 
Also at the level of hypertension awareness, treatment and control disparities occur between 
high-income countries and LMICs. High-income countries had almost double the proportions 
of awareness (67.0% versus 37.9%) and treatment (55.6% versus 29.0%) and four times the 
proportion of control among patients with hypertension (28.4% versus 7.7%) in comparison 
with LMICs in 2010.42 
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1.2.2.2. Diabetes 
Diabetes mellitus is a chronic disease that arises when the pancreas fails to produce enough 
insulin (type 1 diabetes) or when the body cannot effectively make use of the insulin 
produced (type 2 diabetes). Failure of insulin secretion, action or both leads to raised blood 
glucose and other metabolic changes, which if uncontrolled, can cause retinopathy, 
nephropathy, neuropathy and CVDs.43-45  
 
Other types of diabetes (e.g.,. gestational diabetes) and lesser degrees of abnormal glucose 
levels (impaired glucose tolerance and impaired fasting glycaemia) are not described in this 
thesis. When the clustering of type 2 diabetes with several other CVD risk factors, such as 
obesity, dyslipidaemia, hypertension, insulin resistance and microalbuminuria occurs, a 
condition named metabolic syndrome is developed.44,45 
 
Diabetes is typically diagnosed by a glycated haemoglobin (HbA1c) level of 6.5% or greater, 
fasting glucose of 126 mg/dL (7 mmol/L) or above, or a glucose level of at least 200 mg/dL 
(11.1 mmol/L) from the non-fasting state or after a two-hour post-load glucose challenge 
test.46 The pharmacological treatment of such condition requires insulin for type 1 and oral 
hypoglycaemic agents for type 2. 
 
Although for type 1 diabetes there are no prevention measurements, with the majority of the 
cases occurring in children and adolescents, modifiable factors exist to prevent type 2 
diabetes: weight management, healthy diet, physical activity and smoking cessation.43 Also 
ethnicity, family history of diabetes and previous gestational diabetes combined with older 
age are risk factors for type 2 diabetes.43-45  
 
In 2015, there were 1.5 million deaths worldwide directly caused by diabetes, which was the 
seventh cause of death among both sexes,17 with the total deaths from high blood glucose 
rising to 5.2 million in the same year.17 Diabetes is an important risk factor for CVDs and 
other diseases; adults with diabetes have a two or three times higher rate of CVDs than 
adults without diabetes.21,43-45,47-48  
 
Since 1980, the number of people with diabetes has steadily risen. Worldwide, the number of 
individuals rose from 108 to 422 million (four times higher). Forty percent of this increase is 
estimated to result from population growth and ageing, 28% from a rise in age-specific 
prevalence, and 32% from the interaction of these factors.49 Thus, the global prevalence of 
diabetes has grown from 4.7% in 1980 to 8.5% in 2014, during which time prevalence has 
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increased, or at best remained unchanged, in every country. Over the past decade, diabetes 
prevalence has risen faster in LMICs than in high-income countries.49 
 
In 2015, 8.8% of adults (20 to 79 years old) were estimated to have diabetes, and 75% of 
these adults lived in LMICs.47 If the current trend persists, by 2040, this number will increase 
to 642 million people, a prevalence of 10.4%.47 The SSA region will rise from the present 
prevalence of 3.2% to 3.7% in 2040, doubling the number of people with diabetes (from 14.2 
to 34.2 million). SSA also has the highest proportion of undiagnosed diabetes (66.7%). 47  
 
As urbanisation increases and populations age, type 2 diabetes will pose an ever-growing 
threat, as current trends in the last decades prove.50-53 In 2015, around 320 thousand deaths 
in SSA could be attributed to diabetes, with 79.0% of those deaths occurring in people under 
the age of 60, the highest proportion of any region. Diabetes-attributable mortality was 1.7 
times greater in women than in men (Figure 5).47 
 
Figure 5. Mortality due to diabetes, Sub-Saharan Africa, 2015 
 
Source: International Diabetes Federation. Diabetes Atlas. 201545 
 
1.2.2.3. Hypercholesterolemia 
Hypercholesterolemia (also called dyslipidemia) is a condition characterised by high levels of 
total cholesterol in the blood. Total cholesterol comprises four components, classified by their 
density: very low-density lipoprotein; low-density lipoprotein (LDL); intermediate density 
lipoprotein, and high-density lipoprotein (HDL).54  
 
All lipoproteins carry cholesterol, but elevated levels of lipoproteins other than HDL, 
particularly LDL, are associated with an increased risk of atherosclerosis and coronary heart 
disease.55 In contrast, higher levels of HDL cholesterol are beneficial, as HDL carries 
cholesterol away from the arteries back to the liver for excretion.56 Elevated levels of total 
and LDL cholesterol, as well as low HDL cholesterol, are widely documented as risk factors 
for CVDs.55,57,58 The female sex hormone oestrogen tends to raise HDL cholesterol levels, 
which may help explain why premenopausal women are relatively protected from developing 
coronary heart disease.56,58 
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Treatment with lipid-lowering drugs (particularly statins) enables an effective reduction in LDL, 
and therefore total cholesterol levels, with resulting reductions in CVD incidence, deaths and 
overall mortality.21,59 Cholesterol reduction is beneficial in both primary and secondary 
prevention of MI and strokes and is currently recommended for all people with histories of 
these conditions, as well as those with a ten-year CVD risk of 20% or more.21,60  
 
Hypercholesterolemia is conservatively defined as a level of 240 mg/dL or more of total 
cholesterol in the blood.21,61 Some guidelines point to a value of total cholesterol less than 
190 mg/dL; however, there is no evidence of an ideal target level of cholesterol. The current 
guideline is to maintain the lowest possible levels of cholesterolemia, particularly in patients 
with the highest total risk of cardiovascular events, in which the greatest benefit from statin 
therapy can be obtained.21,61    
 
In 2015, high total cholesterol was responsible for 7.1% of deaths worldwide in both sexes, 
while in SSA, it was only connected with 1.7% of deaths.17 This low value could be caused 
by the difficulties in determining values of blood cholesterol in African communities because 
of the high cost of laboratory tests.  
 
For example, from 30 surveys conducted between 2004 and 2012, following the WHO 
stepwise approach to chronic disease risk factor surveillance (STEPS) in SSA, only 14 
reported values of prevalence for hypercholesterolemia. These results varied from 2.1% in 
Mozambique to 26.0% in Tanzania.62 The mean value of total cholesterol presents a high 
heterogeneity across Africa (Figure 6). Despite the difficulties, a value of 4.08 mmol/L for 
men and 4.27 mmol/L for women, the lowest value worldwide, was determined for the serum 
total cholesterol in 2008 in SSA.63  
 
Figure 6. Estimated Mean Total Cholesterol (mmol/L), both sexes, age ≥15 years, 2010 
 
Source: Adapted from Silwa et al. Circulation, 2016. 64 
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The percentage of people with raised blood cholesterol who are effectively treated remains 
small worldwide, and many of those affected are unaware of their condition.61 This problem 
raises the concern for the SSA region, where the general population is not alerted to NCDs.  
 
1.2.2.4. Tobacco 
Smoking is the most common way tobacco is consumed worldwide.65 Cigarette smoke 
contains more than 7000 chemicals, including nicotine (which creates dependence), reactive 
oxygen and nitrogen species, carbon monoxide, nitric oxides, cadmium, polycyclic 
hydrocarbons, and other metals and oxidants. Some of these chemicals are well established 
as toxic and carcinogenic.65  
 
Even in low consumption levels or passive smoking, smoking is one of the strongest lifestyle 
behaviours associated with the risk of CVDs.21,22,25 Smoking damages the endothelium lining 
of the blood vessels, increases cholesterol plaques and clotting, raises LDL levels and 
lowers HDL, and promotes coronary artery spasm. Nicotine accelerates the heart rate and 
raises blood pressure.66 Women smokers have a higher risk of MI than male smokers. 
 
There is strong evidence that proves the beneficial effect of smoking cessation on coronary 
heart disease mortality. However, the magnitude of the effect and the time required to 
achieve beneficial results are unclear.21,22 The benefits of no longer smoking to health are 
clear, but the most effective strategy to encourage cessation is not clearly established.21,66 
 
Tobacco presently accounts for 7 million deaths annually,17 projected to increase to 8 million 
by 2030.1 Between 1980 and 2012, global estimates showed a decreasing trend of smoking 
in both sexes: 967 million smokers lived in 187 countries in 2012. Despite this decrease in 
prevalence, the total number of smokers is expected to increase as the population grows.66 It 
is estimated that close to 80% of the people who smoke tobacco in the world are from 
LMICs.67  
 
In 2015, tobacco smoke was responsible for 3.8% of deaths in SSA (the seventh cause of 
mortality in both sexes), with a rise in the number of attributable deaths from 240 thousand in 
1990 to 300 thousand in 2015.17 Generally in SSA, the prevalence of smoking among women 
is much lower than among men,68 with a vast heterogeneity between country estimates.62,68 
Figure 7 illustrates this heterogeneity and reveals considerable missing national data, 
including Angola.  
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Figure 7. Age-standardized prevalence estimate for smoking (%), both sexes, age ≥15 years, 2006 
 
Source: Adapted from Silwa et al. Circulation, 2016. 64 
 
1.2.2.5. Overweight and obesity 
Overweight and obesity are defined as abnormal or excessive fat accumulation.1,69 The body 
mass index (BMI), a person’s weight (in kilogrammes) divided by the square of their height 
(in metres), is a crude population measurement used to define people’s “weight category”. A 
person with a BMI of 25 kg/m2 or more is considered overweight, and one with a BMI of 30 
kg/m2 or more is obese.69 
 
Overweight and obesity are major problems for global public health because they are 
strongly related to raised blood pressure, type 2 diabetes and hypercholesterolemia, all know 
cardiovascular risk factors. A weight-reducing diet, combined with exercise, produces 
significant weight loss, reduces cholesterol and improves control of blood pressure and 
diabetes.1,21,22,69,70 
 
Between 1980 and 2013 the proportion of adults with overweight and obesity increased 
worldwide, from 28.8% to 36.9% in men and from 29.8% to 38.0% in women. This 
phenomenon was observed in all regions of the world.71 This global occurrence is related to 
poorer populations moving up in the income scale, shifting from traditional diets to western 
diets and moving from subsisting to overeating, transforming obesity in the past decades into 
a pandemic across developing countries.72 
 
However, underweight (BMI less them 18 kg/m2) remains an important social and health 
threat in the poorest parts of the world. Associated with increased risk of morbidity and 
mortality,70-73 underweight is only slowly decreasing in Africa.74 This paradox of obesity rates 
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rising and underweight persisting is referred as ‘nutrition transition’ and sometimes can occur 
within the same household.75 
 
Historically under-nutrition has received more attention in SSA than over-nutrition; thus, 
nationally representative studies of obesity in SSA are scarce. The available studies, 
however, suggest that obesity rates vary widely from country to country,70,71,74 as evidenced 
in Figure 8. 
 
Figure 8. Prevalence of obesity (%), both sexes, age ≥15 years, 2005 
 
Source: Adapted from Silwa et al. Circulation, 2016. 64 
 
In 2015, a high BMI was the tenth leading factor of death in SSA with 3.3% in both sexes, 
rising from the 14th risk factor in 1990.17 This rise in obesity was not followed by proper 
treatment or prevention measures, creating a higher prevalence of obesity across SSA in 
urban areas, among the poorest individuals, less educated people and females.76,77 
Urbanisation, sedentary lifestyles and nutritional changes towards westernised diet, high in 
sugar and fats, are leading to an increased obesity prevalence that coexists with the burden 
of communicable diseases.11-15 
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1.2.3. Socioeconomic risk factors 
The drivers of the behaviours that cause the rise in prevalence of some modifiable risk 
factors are connected with individuals’ socioeconomic conditions, like education level, area of 
residence (i.e., rural or urban settings) and economic power. These conditions gain particular 
interest in LMICs since they set a different context than that of high-income countries, where 
the majority of CVD research is conducted. 
 
Individuals of low socioeconomic status generally experience a higher burden of risk factors. 
However, the direction of the association between socioeconomic status and behavioural risk 
factors may have changed in the last decades. Unhealthy behaviours were more frequent in 
high socioeconomic groups at the beginning of the 20th century, but the burden later shifted 
towards the disadvantaged socioeconomic groups in high-income countries,78 breaking the 
paradigm that CVD is a “disease of affluence” in high-income societies or a “western disease” 
when comparing world regions.79 
 
The situation is less clear in LMICs due to the scarcity of data. A recent systematic review 
and the World Health Survey identified that individuals of low socioeconomic status in LMICs 
were more likely to use tobacco and alcohol and to have less healthy diets, whereas 
individuals of high socioeconomic status tended to be more physically inactive.80,81 
 
1.2.3.1. Education 
Education has been used as a measurable marker of the relationship between 
socioeconomic status and adverse health effects and has been reported as an important 
predictor of CVDs.36,82,83  
 
Usually in high-income countries, relative risk increases progressively from patients in the 
most educated class to those in the less educated,82 but this is not necessarily true in LMICs. 
In a study conducted in 44 countries, a higher education level was not protective against 
cardiovascular events in LMICs, particularly in women.83 In a systematic review that 
assessed the association between socioeconomic status and obesity in LMICs, individuals 
with higher educational attainment were more likely to be obese.84  
 
In the INTERHEART Africa study, among the Black population, those who had less than 
eight years of schooling, as opposed to those with higher educations, showed an increased 
risk of acute myocardial infarction. The direction of association was the opposite for the 
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European and other African groups. In these groups, those with tertiary education had a 
significantly lower risk.36  
 
These differences between results from high-income and LMICs highlights the need for 
further studies that consider the socio-demographic patterning of risk factors, allowing a 
better characterisation of the social distribution of health and for planning prevention 
programs. 
 
1.2.3.2. Urbanisation 
The world has become more urban in the last century. Today, more than half of the world’s 
population lives in cities, compared to 10% in 1900 and 30% in 1950.85 Africa still remains 
mostly rural, with 40% of its respective populations living in urban areas. The rate of 
urbanisation in Africa is expected to be faster than the other regions and is projected to 
become 56% urban by 2050.85 Countries where most of the population is rural are seeing 
urbanisation progress quickly, with a constant passage of young people from the rural areas 
seeking education and work in urban areas. 
 
In many LMICs, new urban areas develop so quickly that health and education 
infrastructures do not have time to develop,85,86 worsening the effects of urban food and built 
environments, as well as the new technologies that accompany city living that lead to poorer 
diets (increased intake of energy-dense foods and high-calorie sugary meals and drinks), 
more sedentary lifestyles and less energy-demanding jobs.11,86,87  
 
The effects of urbanisation on CVDs is well established in published literature.87 The 
modifiable risk factors for CVDs (e.g., smoking, hypertension, and obesity) may be 
exacerbated by city living and its decreased availability of safe, green space for exercise and 
recreation, increased pressures from mass marketing and the availability of cheap but 
unhealthy food options.87 A study from South Africa suggests that future MI risk may be 
higher amongst affluent Black South Africans as exposure to urban dietary trends occurs. 
The “westernisation” of the traditional diet increases the dietary intake of fat and animal 
protein, leading to increases in LDL cholesterol levels of men and women.88 
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1.2.3.3. Income level 
Income level is one component in an individual’s socioeconomic status. The country’s 
economic development, measured by the Gross Domestic Product (GDP) per capita, is also 
used as predictor of CVD risk factors.79 In a cross-national analysis of 85 countries, a 
concave and nonlinear association between GDP per capita, mean BMI and serum 
cholesterol, with higher risk factor levels at intermediate (versus low) GDP levels and 
comparable to slightly lower risk factor levels at high (versus intermediate) GDP levels, was 
found.79 
 
Regarding cross-country associations of income inequality with CVDs and risk factors, 
income inequality is likely to have an effect on cardiovascular risk factors. Higher income 
inequality was related to higher mean SBP in both sexes, and positive associations were 
observed between higher income inequality and mean BMI, obesity prevalence and MI 
mortality rates.89 
 
The influence of an individual’s income level depends on the national GDP. Although income 
level and weight have a positive association in low-income countries, they have a negative 
association in high-income countries.83,90 These relationships and their causes need to be 
tested in larger and more diverse national studies in LMICs, especially in Africa where the 
cultural aspects and the shifting demography are important roles in the contextualisation of 
health and wealth relations.  
 
1.3. Health policies for cardiovascular disease prevention 
As discussed earlier, CVDs and associated risk factors and their prevention, management 
and control are major global health issues, involving public officers, clinical researchers, 
epidemiologists and patients. Being part of the larger group of NCDs, CVDs share the same 
risk factors and interventions. 
 
Significant health gains in cardiovascular health can be made through public health and 
treatment interventions that have an impact on large segments of the population. Much of 
these approaches were used in high-income countries, but the challenge of adapting the 
knowledge acquired to halt and reduce the burden of CVDs in LMICs remains. 
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1.3.1. Health promotion and system approach 
For successful prevention, control and cessation of the CVD epidemic, changes are needed 
in health policies, legislation and taxation. All of these also require public understanding, 
support and demand, allied to an international strategy of knowledge and solution sharing. 
Thus, global health initiatives were created in the last decade, with a strong involvement of 
governments, health professionals, researchers and patient associations.   
 
The most cost-effective methods for reducing CVD incidence involve population-wide efforts 
to reduce modifiable risk factors through multiple economic and educational policies and 
programs, like: 
• food labelling for nutritional content;  
• educational programs to promote decreased consumption of fats, sugars, sodium and 
alcohol; 
• tobacco use targeting and penalization;  
• and campaigns advocating regular physical activity for weight reduction and control.4 
 
The first international convention related specifically to CVDs is the WHO Framework 
Convention on Tobacco Control that began in 2005.91 Currently, with 180 countries, this 
global agreement provides the basis to implement and manage tobacco control on a 
worldwide scale, using the MPOWER measures to assist and monitor evolution. In 2015, 
more than half the countries had implemented at least one MPOWER measure at the highest 
level of achievement.91 Despite the fact that raising tobacco taxes to more than 75% of the 
retail price is among the most efficient and cost-effective tobacco control interventions, only a 
few countries have increased tobacco taxes to the best practice level.91 
 
Following the Political Declaration on NCDs adopted by the United Nations General 
Assembly in 2011, the WHO developed a global monitoring framework to enable global 
tracking of progress in globally preventing and controlling the four major NCDs (CVDs, 
cancer, chronic lung diseases and diabetes) and their key risk factors.1,3,4  
 
This framework took the form of the WHO Global action plan for prevention and control of 
NCD 2013–2020 (known as the Global NCD Action Plan).4 Nine global targets and 25 
indicators where defined, highlighting the importance of prioritizing country action to reduce 
harmful use of alcohol, insufficient physical activity, salt/sodium intake, tobacco use and 
hypertension; halt the rise of obesity and diabetes; and improve coverage of treatment for 
prevention of MI and strokes and access to basic technologies and medicines.4 
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These voluntary global targets are aimed to fight global mortality from NCDs, accelerating 
action against the leading risk factors and strengthening national health system responses. 
The mortality target, a 25% reduction in premature mortality from NCDs by 2025, was 
adopted by the World Health Assembly in 2012.1,3,4 Some concerns have been raised by 
researchers, if the correct trend persists, that no WHO region will meet this goal.2,38  
 
Before this framework and global strategy, the WHO developed a surveillance and 
epidemiological system that allowed countries with poor resources to find evidence on NCDs 
adapted to their needs and available resources. The WHO-STEPS focuses on obtaining core 
data on the traditional risk factors that underlie the NCD burden. This system was designed 
to be flexible, allowing each country to obtain data on the core variables and risk factors and 
to expand to optional modules based on state interest, need and resources. The use of the 
same standardised questions and protocols enables appropriate comparisons across 
countries.92  
 
There are currently two STEPS surveillance systems, the STEPwise approach to risk factor 
Surveillance and the STEPwise approach to Stroke Surveillance. The three key steps of the 
survey tool are the collection of basic demographic, behavioural and lifestyle factors; physical 
measurements, such as height, weight and blood pressure; and biochemical assessments, 
including fasting blood glucose and blood cholesterol.92 
 
Even with these knowledge structures and policy frameworks, the improvements in 
prevention and treatment that led to decreases in CVDs in many high-income countries do 
not occur in many other parts of the world where the burden is greatest. For that, the WHO 
create technical packages to strengthen NCD management, which complement WHO 
strategies, and packages for population-based primary prevention of CVD, including tobacco 
control and salt reduction.93  
 
One recent tool, launched in 2016, is the technical package HEARTS.94 Aimed to prevent 
CVDs by ensuring equitable access to continuous, standardised high-quality care for people 
at high risk, HEARTS provides a set of effective, practical interventions for strengthening the 
management of risk factors for CVDs in primary health care.94 This package covers six key 
elements: healthy lifestyle, evidence-based treatment protocols, access to essential 
medicines and technology, risk-based management, team care and task-sharing, and 
systems for monitoring. 
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1.3.2. Cardiovascular risk prediction and individual approach 
Although public approaches have an important role in the fight against CVDs, the final 
solution to this problem resides in the individual capacity and will to change unhealthy 
behaviours (primary prevention) and enlist in the proper treatments to reduce the needed risk 
factors or recurrence of CVDs (secondary prevention). For this, governments need to secure 
the proper health education for individuals, as well as increase the availability of drugs and 
medical facilities: the two major issues in developing countries. 
 
Risk factors often cluster together, and the number of risk factors and their co-occurrence are 
directly related to the incidence of CVDs.22 To understand an individual’s risk of CVD, it is 
important to realise an individual’s ‘global risk’ of developing the condition.4,21,22 Usually, this 
involves the determination of the ten-year risk of developing a CVD.  
 
The WHO and the International Society of Hypertension (ISH) created a risk prediction 
chart21 that can be applied in different regions and settings. This approach is more cost 
effective than other approaches that only make treatment decisions based on individual risk-
factor thresholds (e.g., hypertension, hypercholesterolemia).22,93  
 
This risk prediction methodology aligns with the more ‘holist’ approaches, which integrate 
non-pharmaceutical lifestyle modifications into the use of medicines, like aspirin, blood 
pressure modification, statin medication for hypercholesterolemia and specific medications to 
regulate blood glucose. Also, some intensive techniques are employed in patients with CVDs, 
such as coronary stenting and coronary artery bypass grafting for ischemic heart disease 
and thrombolytics for cerebrovascular disease. 
 
One suggested approach to individual care is the ABCDE, a straightforward and organised 
guide for consistent, comprehensive management of cardiovascular risk in daily clinical 
practice.95 This suggestion from the American College of Cardiology integrates lifestyle 
interventions with drug therapy and consists of an assessment of risk and antiplatelet therapy, 
blood pressure management, cholesterol management, cigarette/tobacco cessation, diet and 
weight management, diabetes prevention and treatment, and exercise.95 
 
Even if some of the proposed methodologies cannot be easily applied due to the steady 
supply of drugs, changes to personal lifestyle can be encouraged, with good results in the 
decrease of the global cardiovascular risk.  
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1.4. Cardiovascular diseases in Africa: from epidemiology to intervention 
The epidemiological study of CVD is a common practice among high-income societies. First 
started in the 1950s and based on observational prospective studies with steady cohorts and 
follow ups over decades, this study has progressed in recent years to interventional 
studies.96 This natural evolution is due to the need to assess whether the presence of risk 
factors not only predict clinical outcomes, but also whether their control and reduction causes 
a decline in the risk. However, CVD research in SSA has been negligible, with the majority of 
published studies conducted at hospital services, not in the general population.97,98 
 
In continental Africa, particularly in SSA, the majority of countries are classified as low- or 
middle-income, sharing with other regions of the world the same lack of health and research 
infrastructures that allow knowledge of and intervention into the real burden of CVD. With the 
adoption of the World Health Organisation’s “Global Action Plan for the Prevention and 
Control of non-communicable diseases, 2013-2020”, global awareness for this problem is 
rising.4 One of the pillars of this global plan is the need for a national dimension of risk 
factors for CVDs (and other NCDs) reporting on a regular basis.3,4  
 
The distribution of CVDs and their risk factors is heterogeneous across SSA but high in some 
settings, creating a heavy burden on the already weakened infrastructures of the region. 
Because of the lack of vital statistics systems, larger epidemiologic studies with a variety of 
designs (cross-sectional, longitudinal and interventional) can assist in the analyses of trends 
and the definition of patterns. This can provide a better understanding of such diseases and 
inform health-care policy to mitigate the CVD burden.97 
 
Cardiovascular diseases in SSA can no longer be ignored or left behind the communicable 
diseases in the research and health intervention agenda, but must be integrated with 
them.98,99,100 Without setting these areas aside, there is an opportunity to use structures that 
are already in place to maximize resources. The international community should consider 
expanding the mandate of current programs to include outcome-oriented measures for 
improving general health and lifestyles.100 For example, inadequate diet in early life may 
result in sensitivity to the lifestyle-related risk factors of CVD.99 In LMICs, where 
undernutrition is addressed in the maternal and child health programmes, there is an 
opportunity for joint efforts to tackle both group of diseases. 
 
There is a need for health system reform to strengthen primary care as a major policy to 
reduce the toll of CVDs.99 The consequent increase of diagnoses of CVDs will lead to a 
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corresponding need for health service capacity, which is currently over-stretched.97 The 
implementation of aggressive primary prevention programmes, without proper evaluation of 
priorities, can lead also to poorer health outcomes.97 
 
The social patterning of CVDs in LMICs needs to be framed along two perspectives, bearing 
in mind the availability of data and specific national contexts. The first perspective is the 
definition of the current pattern based on reliable population-based epidemiological data; the 
second is the detection of the potential relevance of different scenarios of CVD social 
patterning on policy development, using translational tools to anticipate future trends (e.g., 
findings in high-income countries).101 
 
Angola has no national surveillance system for NCDs, and periodic local population-based 
studies can help overcome the lack of information.97,102 The main purpose of this thesis’s 
research plan is the implementation of a study protocol that will collect information on risk 
factors, awareness, treatment and control rates, and prevalence of symptoms relevant to 
CVD to assist decision makers in the implementation of prevention and treatment policies 
and programs.  
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2. Aims 
Surveillance on CVDs and corresponding risk factors is essential to obtain an accurate 
characterization of their frequency and distribution over time, as well as to understand and 
predict the trends of such diseases. Therefore, the general purpose of this research project 
was to contribute to a better understanding of the epidemiology of CVDs risk factors in 
Angola, through the study of an adult Angolan community. 
 
For this purpose, a study protocol named CardioBengo was designed and implemented, 
creating a baseline and proposing a follow-up strategy to address the surveillance of risk 
factors (as reported in Paper I), in addition to a follow-up to a previous hypertension survey 
conducted in 2011 in the same population.103  
 
This thesis focuses specifically on the characterization of hypertension, diabetes, 
hypercholesterolemia, tobacco consumption and body mass index (BMI) categories in this 
population. We also aimed to analyse the awareness, treatment and control of hypertension, 
diabetes and hypercholesterolemia and to assess the clustering of these risk factors, proving 
additional data for the planning of future interventions.  
 
Therefore, this thesis includes reports that correspond to the following specific objectives: 
a) Estimate the incidence of hypertension in the last two years and the association with 
socio-demographic, anthropometric and behavioural characteristics (Paper II); 
b) Quantify the prevalence, awareness, treatment and control of hypertension, diabetes 
and hypercholesterolemia and the association with socio-demographic, 
anthropometric and behavioural characteristics (Paper III); 
c) Describe the tobacco consumption and its relationship to socio-demographic 
characteristics, and determine the nicotine level of dependence (Paper IV); 
d) Quantify the prevalence of body mass index categories and evaluate its relationship 
with socio-demographic characteristics (Paper V); 
e) Estimate the distribution of the population by cardiovascular risk categories and its 
eligibility for pharmacological treatment (Paper VI). 
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3. Methods 
The aims of this thesis were accomplished through the analysis of data from a community-
based survey, CardioBengo, designed and first implemented for this purpose. Furthermore, a 
parallel follow-up of a population previously studied in the same region was conducted.  
 
The CardioBengo protocol is based on the STEPS guidelines, covering more variables than 
the ones covered by this thesis, and thought of as a surveillance sentinel system for CVD 
monitoring. The work treated in this thesis is the baseline approach to the main CVD risk 
factors, which along with the follow-up of a previous sample, constitutes the first attempt to 
create and test the implementation of a cohort in this setting.  
 
A general description of the study site, participants, data collection and methodological 
issues is provided below. The selection of participants eligible for each analysis, the 
definition of variables and the statistical analysis depended on each specific objective, 
therefore described in detail in the published papers (Sections 4.1 to 4.5). 
 
3.1. Study site and population 
This study was conducted in the catchment area of the Centro de Investigação em Saúde de 
Angola (CISA), which includes the Dande Health and Demographic Surveillance System 
(Dande-HDSS). The Dande-HDSS monitors the structure, dynamics and geographical 
distribution of a population of 60,075 people, spread across 4,737 km2 and covering three 
communes (Caxito, Mabubas and Úcua) of the Dande Municipality in the Bengo Province 
(Figure 9),104,105 60 km north of Luanda, the capital of Angola.  
 
Figure 9. Dande - Health and Demographic Surveillance System Area 
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From the 69 hamlets in the Dande-HDSS, 26 are classified as urban areas (i.e., capitals of 
provinces or municipal headquarters, having agglomerations of 2,000 or more inhabitants 
and basic infrastructures) where the majority of the population lives (77%).104,105  
 
The median age within the Dande-HDSS is 19 years old, aligned with the predominance of 
young people, and the reduced number of elderly individuals: 41% are under 14 years old, 
55.5% are between 15 and 64 years old (33,342 individuals), and only 3.6% are 65 or over.15 
Women represent 55.1% of the age group between 15 and 64 years old, which rises to 
61.6% in the 65 or over population.104,105  
 
The Bengo province is the lesser-populated province of Angola (only 1.4% of 25.8 million 
total inhabitants). The Dande-HDSS reflects the national demographic structure made in 
2014 that also points to a young population (only 2.3% are 65 years old or over) with 50.3% 
between 15 and 64 years old; 51.5% are females, and 68% of the population is concentrated 
in urban areas.106 
 
3.2. Study design and participants 
3.2.1. Incidence of hypertension 
A prospective longitudinal study was conducted from a baseline of 1,464 individuals older 
than 18 years, recruited from the Dande-HDSS and evaluated from 11 October to 20 
December 2011.103 From 18 September to 20 December 2013, participants without 
hypertension at the baseline were approached and offered a new evaluation (Section 4.1). 
This work was integrated into the cross-sectional community-based survey (Section 3.2.2.), 
and the same data collection protocol was applied.  
 
3.2.2. Prevalence of risk factors 
A cross-sectional community-based survey, CardioBengo, was designed and first 
implemented to serve as a new baseline of the prevalence of risk factors among individuals 
between 15 and 64 years old (Section 3.3). From September 2013 to March 2014, 3,515 
individuals were contacted. Of these, we were able to examine 2,484 individuals: 750 
(21.3%) were unreachable, and 281 (8.0%) refused to participate. The sum of these values 
approaches the predicted nonparticipation rate of 30%, assumed in the representative sex- 
and age-stratified random sample calculated for this research (Section 3.3). 
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CardioBengo study protocol: a population
based cardiovascular longitudinal study in
Bengo Province, Angola
João M. Pedro1,2* , Edite Rosário1, Miguel Brito1,3 and Henrique Barros2,4
Abstract
Background: Cardiovascular diseases and other non-communicable diseases are major causes of morbidity and
mortality, responsible for 38 million deaths in 2012, 75 % occurring in low- and middle-income countries. Most of
these countries are facing a period of epidemiological transition, being confronted with an increased burden of
non-communicable diseases, which challenge health systems mainly designed to deal with infectious diseases. With
the adoption of the World Health Organization “Global Action Plan for the Prevention and Control of non-communicable
diseases, 2013–2020”, the national dimension of risk factors for non-communicable diseases must be reported on a
regular basis. Angola has no national surveillance system for non-communicable diseases, and periodic population-based
studies can help to overcome this lack of information. CardioBengo will collect information on risk factors, awareness rates
and prevalence of symptoms relevant to cardiovascular diseases, to assist decision makers in the implementation of
prevention and treatment policies and programs.
Methods: CardioBengo is designed as a research structure that comprises a cross-sectional component, providing
baseline information and the assembling of a cohort to follow-up the dynamics of cardiovascular diseases risk factors in
the catchment area of the Dande Health and Demographic Surveillance System of the Health Research Centre of Angola,
in Bengo Province, Angola. The World Health Organization STEPwise approach to surveillance questionnaires and
procedures will be used to collect information on a representative sex-age stratified sample, aged between 15 and
64 years old.
Discussion: CardioBengo will recruit the first population cohort in Angola designed to evaluate cardiovascular
diseases risk factors. Using the structures in place of the Dande Health and Demographic Surveillance System
and a reliable methodology that generates comparable results with other regions and countries, this study will
constitute a useful tool for the surveillance of cardiovascular diseases. Like all longitudinal studies, a strong
concern exists regarding dropouts, but strategies like regular visits to selected participants and a strong
community involvement are in place to minimize these occurrences.
Keywords: Cardiovascular risk factors, Incidence, Prevalence, Epidemiology, Angola, Sub-Saharan Africa
Background
Cardiovascular diseases (CVDs) are a leading cause of
death. In 2012 they were responsible for 17.5 million deaths
worldwide, and along with other non-communicable dis-
eases (NCDs) such as cancers, chronic respiratory diseases
and diabetes they constitute by far the major causes of
death that year. Around 75 % (28 million) of those deaths
happened in low- and middle-income (LMI) countries. Of
the 16 million of deaths caused by NCDs before the age of
70, 82 % took place in those countries [1].
CVDs and other NCDs share common risk factors
such as obesity, hypertension, hyperglycaemia or hyper-
cholesterolemia, smoking, physical inactivity, unhealthy
diets or alcohol [1, 2]. NCDs behavioural risk factors are
commonly associated with life styles whose conse-
quences usually manifest at older ages in high-income
countries. However, in the LMI countries NCDs are
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rising faster and affecting younger people, therefore
presenting earlier those consequences of adverse health
and economic outcomes [3, 4].
The growing burden of NCDs with their associated
premature mortality, are a major concern for health
systems decision-makers, especially in developing coun-
tries, were NCDs growth outpaced the reduction in
communicable diseases by 33 % between 1990 and
2010 [3]. The “Global Action Plan for the Prevention
and Control of NCDs, 2013–2020” adopted by all mem-
ber states of the World Health Organization (WHO)
defined nine voluntary global targets to be achieved by
2025, one being a 25 % reduction from 2010 levels in
NCD related preventable deaths (referred to as the
25x25 target) [5]. All signatories have committed to
report national levels of NCD risk factors on a regular
basis, reinforcing the key recommendations of the 2011
United Nations high-level meeting on NCDs which
included the strengthening of surveillance of NCD [6],
that allows a global and integrated mechanism to sup-
port the implementation of prevention and treatment
policies and programs.
The WHO STEPwise approach to Surveillance (STEPS)
was designed in 2007 to provide core data on the estab-
lished risk factors for the major NCDs based on standard-
ized questions and protocols that enable appropriate
comparisons across surveys. It uses a modular technique,
which allows to fit the specific needs and the available
resources for each setting [7].
STEPS was used in 36 African countries, between
2003 and 2013 [8], but not in Angola where four stud-
ies conducted between 2008 and 2014 provided the
available information on CVDs risk factors using other
methodologies: a survey in 667 adult students of
Health Sciences in Lubango, south of the country [9];
a study conducted in 615 active employees of a public
university in Luanda, the capital of Angola [10]; a
survey with 421 subjects from a rural community near
Luanda [11]; and a community-based survey with 1464
participants conducted by the Health Research Centre of
Angola (CISA) in the catchment area of the Dande
Health and Demographic Surveillance System (Dande-
HDSS) [12].
Using the Dande-HDSS structure for data collection
and management setting, we designed a new study,
named CardioBengo, to address the surveillance of the
major CVD risk factors with special emphasis on the
agreed selected NCD risk factors: tobacco use, harmful
alcohol use, salt intake, obesity, raised blood pressure,
raised blood glucose and diabetes and physical inactivity
but also covering the additional targets that focus on
treating people at high risk of heart attack and stroke
and on the availability of drugs to treat NCDs. Accord-
ingly, the study aimed to:
! Quantify the prevalence, awareness, treatment and
control of hypertension, hyperglycaemia and
hypercholesterolemia and their socio-demographic
and behavioural determinants, as a baseline for
future assessments;
! Describe tobacco, alcohol consumption, physical
activity and diet patterns;
! To run follow-up assessments every 3 years, to
monitor and understand trends in risk factors and
outcomes frequency.
Methods
Study design and setting
CardioBengo is a research to be conducted in the catch-
ment area of the Dande-HDSS, located in the Dande
Municipality, Bengo Province, 60 km north of Luanda, the
capital of Angola. Dande-HDSS monitors the structure,
dynamics and geographical distribution of a population of
60,075 people (53.5 % adults) that spreads across an area
of 4700 km2 with 70 hamlets across three communes
(Caxito, Mabubas and Úcua) [13]. This HDSS constitutes
the base for the identification of a representative popula-
tion sample to be invited to participate in the cohort
providing a baseline assessment and a longitudinal follow-
up evaluation planned at every 3 years, taking the same
approach used at baseline.
Sample size estimation and sampling
The sample size is calculated assuming a simple random
sample, based on the 23 % prevalence of hypertension
found for this population in a study conducted in 2011
[12], and anticipating a response rate of 70 %. The sam-
ple size estimates were generated for males and females
in five age groups between 15 and 64 years old, resulting
in a total of 3515 individuals. A random list will be
drawn from the Dande-HDSS population database.
Inclusion and exclusion criteria
The inclusion criteria are: i) living in the Dande-HDSS
study area at the time of the field work, ii) willingness
to participate in this study, and iii) age between 15 and
64 years. The exclusion criteria are: i) subjects with
missing anthropometric or blood pressure values and
ii) pregnant women; because their biochemical and
anthropometric parameters would vary from the non-
pregnant physiology they will be excluded from the
baseline analysis.
Pilot study
A pilot study was conducted to test data collection
instruments, procedures and to improve the training of
field workers. Adjustments in the language used in the
questionnaires were made, and the field logistics op-
timized to a model of five testing protocol stations,
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namely i) registry and socio-demographic data, ii) point
of care clinical tests, iii) anthropometric measures and
food habits, iv) blood pressure measurement and drug
treatment history and v) electrocardiogram, for the field
work facilities. The median time for each participant to
pass through all five stations was calculated in 2 h,
reaching to the conclusion that a maximum of 25 partic-
ipants in an 8 h day’s work is possible. All field workers
and health professionals selected to collaborate in the
study were involved on the pilot study and their skills
tested and improved, if necessary.
Enrolment of participants
One day before the arrival of the team that will implement
all the procedures related with the protocol, a field worker
visits the hamlets in order to prepare the necessary arrange-
ments for the field work, namely engaging with the local
authorities, involving them in the process of selection of an
adequate location to install the study facilities and in the
door-to-door contact of the prior selected participants, in
order to sensitize them to the objectives of the study and to
schedule their participation for the next days.
Selected individuals will be consider unreachable after
2 failed attempts of contact in their household at differ-
ent hours in weekdays, and a refusal will be recorded
when the contacted person explicitly says that he or she
doesn’t want to participate.
Each participant is expected to spend up to two hours
to complete the study tasks, receiving a small lunch at
the end, in order to compensate the fasting period previ-
ous to the exams. After the exams all participants will
receive a card summarizing their clinical and anthropo-
metric results and those with abnormal levels of blood
pressure, glucose, cholesterol or other clinical alteration
will be referred to the General Hospital of Bengo for a
follow-up evaluation with a medical doctor.
Study procedures
All procedures will be conducted by trained interviewers
from the Dande-HDSS and certified health professionals
(nurses, laboratory technicians and cardiopneumo-
graphic technician) able to communicate in Portuguese
(official language) and in the local languages. The proto-
col for data collection is based on the WHO STEPS
manual version 3.0 [7], translated to Portuguese, pre-
tested and piloted as referred above. All core items are
included and some of the expanded items adapted to the
specific context.
Demographic and social characteristics
Information on age, sex, marital status, current occupa-
tion, completed years of school frequency and household
income will be obtained using a questionnaire following
the STEPS manual [7].
Behavioural measurements
Information on smoking, namely current smoking status
and number of cigarettes smoked, will be collected as
described in the STEPS manual [7]. Additionally, a vali-
dated Portuguese version of the Fagerström test [14], is
used to assess smoking dependency. Alcohol intake, the
daily consumption of fruit, vegetables and oil or fat, will
be measured according STEPS manual [7]. The optional
module for dietary salt is also included in the question-
naire [7]. Physical activity and sedentary behaviour will
be assessed using all core and expanded items of the
STEPS manual [7].
Medication history
Following the STEPS guidelines [7], the history of eachindi-
vidual regarding hypertension, hyperglycaemia and hyper-
cholesterolemia, is obtained through questions evaluating
previous measurements of high blood pressure, glycaemia
and blood cholesterol. When any of these items are identi-
fied as positive, the participants will be asked about history
of recommendations or degree of awareness of such condi-
tions transmitted by a health professional. Any individual
will be considered under treatment if he/she indicates the
use of specific drug therapy and considered controlled if
he/she presents a normal measurement under a specific
drug therapy.
Female reproductive history
Data will be collected on menarche, reproductive history
(number of pregnancies and outcomes), pregnancy induced
hypertension, menopause and contraception methods used.
Clinical and anthropometric assessments
Physical exams will be performed with individuals wear-
ing light clothing, with no footwear and after an over-
night fast. For all participants, fasting conditions (more
then eight hours without eating) will be recorded. Waist
and hip circumferences will be measured to the nearest
0.1 cm using circumference tape SECA 203 (SECA
United Kingdom, Birmingham, UK). Body weight will be
measured to the nearest 0.1 kg using a digital scale
SECA 803 (SECA United Kingdom, Birmingham, UK).
Height will be measured to the nearest 0.1 cm in the
standing position using a portable stadiometer SECA
213 (SECA United Kingdom, Birmingham, UK). Body
mass index and waist to hip ratio will be calculated and
categorized according WHO guidelines [15, 16]. Blood
pressure will be measured using the automatic sphygmo-
manometer OMRON M6 Comfort (OMRON Healthcare
Europe B.V., Hoofddorp, The Netherlands), as recom-
mended [17]. Each participant will rest for 15 min before
measurements: seated, at the right arm, with an appro-
priate cuff size and 3 readings done at 3 min intervals.
An electrocardiogram and rhythm strip will be recorded
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from all participants using a 12-channel electrocardio-
graph AsCARD Mr.Grey V 201 (ASPEL, Zabierzów,
Poland), that will be recorded digitally using the data
base software CARDIO TEKA v001 (ASPEL, Zabierzów,
Poland). Respecting the right to privacy of the partici-
pants, the electrocardiogram will be conducted in the
most private manner behind close curtains.
Biological sample collection
Blood sugar will be measured using a blood glucose meter
ACCU-CHEK Aviva (Roche Diagnostic, Indianapolis, IN,
USA) with ACCU-CHEK AVIVA Glucose reactive strips
(Roche Diagnostic, Indianapolis, IN, USA). Total choles-
terol on the blood will be measured only for participants
with more then eight hours fasting, using a point-of-care
device ACCUTREND Plus (Roche Diagnostic, Indianapolis,
IN, USA) with ACCUTREND CHOLESTEROL reactive
strips (Roche Diagnostic, Indianapolis, IN, USA). A urine
sample will be collected for assessment of urinary creatin-
ine and microalbumin using test strips AUTION SCREEN
(Arkray Europe, Amstelveen, The Netherlands). Finger-
prick blood samples will be collected and spotted onto
Whatman™ 3MMChr filter paper (Fisher Scientific,
Pittsburgh, PA, USA). Blood spots on filter paper will
be left to air dry and them stored at 4 °C.
Referral of participants with clinical alterations
All participants with abnormal clinical results will be
referred to the General Hospital of Bengo for a medical
visit. A specific form was designed to follow clinical
characteristics and treatment prescriptions. The adher-
ence to treatment is evaluated according Morisky Medi-
cation Adherence Scale of 4 items [18].
Future study waves
It’s expected to follow-up the cohort every 3 years using
the same protocol, enabling the identification of trends
and associations between risk factors and outcomes.
Using the Verbal Autopsy System of the Dande-HDSS
adapted from the WHO standardized form [19], data
will be crossed and deaths of individuals in this cohort
can be identified and linked. For the follow-up of the
cohort and aiming to minimise losses, the tracking of
participants will be based on the periodic visits to all
households of the study area held in the scope of the
Dande-HDSS.
Quality control
The training of the field workers was conducted until
the required competency was achieved for their specific
tasks, and tested on the pilot study. A senior staff mem-
ber of Dande-HDSS, responsible for the participant’s
enrolment and process trough the survey, will supervise
all the fieldwork. Participants will be taken through the
testing protocol in a sequential method, to prevent loss of
data or stack in a particular station. Raw data from the
field will be supervised every week to ensure the quality of
data collected. Regular feedbacks between the field team
and research assistants are schedule. All equipment will
be maintained, serviced and calibrated according to man-
ufacturer’s specifications and schedules.
Data management
All questionnaires will be coded by experienced trained
personnel and data will be double entered into a Post-
greSQL® database. A series of logic checks will be per-
formed and if any outliers are encounter, discrepancies
will be followed up with research assistants and field su-
pervisors. All digital data will be stored in password-
protected files and hard copies of questionnaires ware-
housed in locked cabinets in the facilities of CISA, in
Angola. Dande-HDSS supervision team will manage the
access to the databases, ensuring the confidentiality of
personal records of the participants. Files were designed
to store all information related to participant identifica-
tion separated from the remaining data collected so that
all procedures, namely analysis, are maintained under
anonymity.
Statistical analysis
Descriptive data will be reported as absolute frequencies
and percentages, means and standard deviations as ap-
propriate. Contingency tables with Pearson chi-squared
tests and pairwise correlations will be used to identify
variables associated with hypertension, hyperglycemia
and hypercholesterolemia. Logistic regression models
will be fitted, adjusting for potential confounding factors.
Crude and adjusted odds ratios should be estimated for
the identified variables with significant association. Ad-
justed prevalence ratios, computed using Poisson regres-
sion models with robust estimator [20], will also be used
when appropriate. During follow-up, incidence rates will
be calculated as the number of new cases divided by the
total person-time at risk. Time at risk will be counted as
the time between 2 evaluations for subjects who remained
free of the index problem, and for the new cases, time at
risk will be assumed as the midpoint of the time interval
between evaluations. 95 % confidence intervals will be
calculated and a significance level of p < 0.05 will be set
for all determinations.
Discussion
The rise in CVDs and other NCDs is a major issue for
global health, particularly in LMI countries, though not
all countries have the resources to build national surveil-
lance systems to provide solid data on the epidemiology
of such diseases. In their absence and of the data from a
nationwide STEPS, monitoring of NCDs can be
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envisaged by structures such as the Dande-HDSS, which
may contribute for the surveillance of the major chronic
NCD risk factors in representative populations [21].
Due to unequal access to health care, periodic
population-based studies based in HDSS can help to
overcome the lack of health information, being use-
ful in detecting variables such as risk factors, aware-
ness rates and prevalence of symptoms, otherwise
difficult to register in a facility-based system [22].
Being in an early stage of an epidemiological transi-
tion, Angola presents at the same time, an increase in
premature deaths cause by NCDs and high rates of
maternal and chid mortality caused by infections dis-
eases [23]. The country stills records one of the highest
rates of maternal mortality in the world (460 deaths per
100,000 live births) [24]. In this sense, the inclusion of a fe-
male reproductive history in this study and the possibility
of cross information with morbidity and mortality data are
an important component for the study of maternal health.
As in any longitudinal study, there will be a risk of
dropout. Such problem is more common in cohort stud-
ies in Sub Saharan countries due to significant migration
patterns and absence of usual means of follow-up used
in high income-countries, such as central electronic
medical records or unique identifiers to link different
datasets [22, 25]. However, as described earlier, we
predict to have periodic visits to all participants to keep
them motivated between surveys, with a strong effort in
all contacts to explain the purpose of the study and
make people feel they are making a contribution. The
engagement of local authorities is a key factor is this
process, helping to build a relationship of trust with the
participants. Also, additional resources and strategies
can be applied to further follow-ups, such as the use of
cell phones to contact and schedule follow-up visits and
use weekend days to collect data.
Considering the settings where the protocol was ap-
plied, often in rural and inhospitable access hamlets,
with straw dwellings and precarious structures, it will be
necessary to create conditions for the application of the
survey, in case of lack of an appropriate local structure
(as a school, a church or a health centre). For this
matter, the team projected and prepared a kind of a tent,
using awnings and screens to ensure the comfort and
privacy of the participants in the study and use it as
study platform.
These harder conditions of the terrain and in the ab-
sence of local facilities to conduct laboratory tests or a
reliable chain of refrigeration to maintain the right stor-
age conditions for venous blood and urine, we choose to
conduct dry chemistry using point of care devices that
insure reliable results. In future follow-up actions, the
possibility to adopt other laboratory methodologies is
under consideration, such as the inclusion of the
determination of the ratio of apolipoprotein B to apoli-
poprotein A-1.
Even using the STEPS methodology for better compar-
isons, due to the methodological differences namely in
sampling frames and age groups used, direct compari-
sons between studies sometimes are not possible. The
majority of the studies regarding CVDs and their risk
factors only include individuals aged above 25 years.
Having this in mind, we decided to maintain individuals
aged 15–24 years in this study, because we want to
create a cohort with a long-term follow-up, detecting
how CVDs risk factors evolve in younger fractions of the
population. If require to better compare results with
other studies the necessary steps will be made to calculate
the adjusted prevalence’s.
In summary, CardioBengo can represent a solid base-
line to launch a cohort able to provide critical data for
the development of meaningful public health policy,
integrated in the Angolan National Plan of Sanitary
Development for the period 2012–2025, that predicts
the need of further knowledge on CVDs in Angola to
guide health promotions initiatives to the right group
and problem [26].
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3.4. Data collection  
In this study, we followed the STEPS guidelines to facilitate further comparisons at the 
regional and global levels of the results (e.g., use of patronised questions). Another reason 
for this choice is the adequacy of methods recommended for a low-resources setting like the 
Dande-HDSS (e.g., use of point of care devices).  
 
With experience from previous surveys, we implemented data collection procedures 
adequate to the population and conditions of the terrain. The selected individuals from the 
Dande-HDSS were contacted one or two days before the data collection, in a door-to-door 
method, to inform them of the purpose of the study and to schedule their observations for the 
next day if they agreed to participate. 
 
This team also made the necessary arrangements for the fieldwork: engaging with the local 
authorities, involving them in the process of selecting an adequate location to install the 
study facilities. The field logistics were optimised to a model of four testing protocol stations 
(Figure 10): 
1. Registry and socio-demographic data; 
2. Point of care clinical tests;  
3. Anthropometric measures;  
4. Blood pressure measurement and drug treatment history. 
 
Figure 10. Field work scheme 
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Considering the settings, often rural and inhospitable access hamlets, with straw dwellings 
and precarious structures, it was necessary to create the right conditions in the case an 
appropriate local structure (e.g., a school, a church or a health centre) was not available. For 
this matter, the team projected and prepared a tent, using awnings and screens to ensure 
the comfort and privacy of the participants during the clinical and anthropometric 
assessments. 
 
The questionnaire was built in Portuguese (Annexe 1), but the conductors of the collection 
interviews could adapt and translate it to the other major national languages: Umbundo and 
Quimbundo. All procedures were conducted by trained interviewers from the Dande-HDSS 
and certified nurses or laboratory technicians. 
 
This thesis’s chosen variables and its methods of collection are summarised in Table 2.  
 
Table 2. Variables and methods of data collection pertinent 
Category Variable Collection tool Reference 
Socio-demographic 
Sex Interview WHO STEPS92 
Age Interview WHO STEPS92 
Place of residence Dande - HDSS WHO STEPS92 
Education Interview WHO STEPS92 
Marital Status Interview WHO STEPS92 
Monthly Family Income Interview WHO STEPS92 
Anthropometric 
Body mass Index 
Digital scale SECA 803 
Stadiometer SECA 213 
WHO67 
Abdominal obesity Circumference tape SECA 203 WHO
67 
Behavioural 
Tobacco smoking Interview WHO STEPS92 
Nicotine dependence Interview Fagerström Test107 
Alcohol consumption Interview WHO STEPS92 
Clinical 
Blood Pressure 
Automatic 
sphygmomanometer OMRON 
M6 Comfort 
ASH/ISH34 
Blood glucose Blood glucose meter ACCU-CHEK Aviva WHO
46 
Blood total cholesterol 
ACCUTREND Plus with 
ACCUTREND 
CHOLESTEROL reactive 
strips 
WHO4 
Treatment history 
Awareness Interview WHO STEPS92 
Treatment Interview WHO STEPS92 
Control Clinical result WHO STEPS92 
 Methods | 49 
3.5. Ethical considerations 
All procedures were developed to guarantee data confidentiality and protection, in 
accordance with the 1964 Helsinki declaration and its later amendments. This study received 
the approval of the Ethics Committee of the Angolan Ministry of Health before the 
implementation process. 
 
All participants received an explanation of the purposes and design of the study (Annexe 2) 
and gave written informed consent (for participants under 18 years old, their parent or legal 
guardian gave constant), as presented in Annexe 3. A copy of the signed consent form, as 
well as instructions regarding the fasting period and contact information, was delivered to 
each participant and was also available in Umbundo and Quimbundo. 
 
After the procedures, participants received cards summarising their clinical and 
anthropometric results (Annexe 4) and a small lunch to compensate for the fasting period. 
Individuals with abnormal clinical results were referred to the General Hospital of Bengo for a 
medical visit (Annexe 5). 
 
3.6. Methodological Issues 
The methodological issues present during this study are related to two major characteristics 
of an SSA country setting: the harder conditions of the terrain and the follow-up of individuals. 
 
In the field, and in the absence of local facilities to conduct laboratory tests or a reliable chain 
of refrigeration to maintain the right storage conditions for venous blood, we chose to 
conduct dry chemistry using point of care devices that ensured reliable results. However, due 
to the high temperatures and humidity levels during field surveys, data collection was not 
possible in some cases, causing a greater amount of missing data than expected. 
 
Although the Dande-HDSS has existed since 2010, its primarily objective is to measure 
births, deaths and household conditions, not guarantee the traceability of the entire 
population. This population has a high mobility, both inside and outside of the Dande-HDSS 
area, without leaving contacts or references for further contacts. Also, the study area’s 
location, 60 km from the centre of the capital of Angola, promoted a daily flow of workers and 
students that left their homes in the morning only to return at the end of the day, missing the 
scheduled observation days.   
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These problems are common in cohort studies in SSA due to the fast migration movements 
of populations that follow the job opportunities related to natural resource exploration, 
growing urban areas and the natural cycle of croups.108 The absence of efficient alternative 
means of follow-up used in high-income countries, such as electronic or postal mail, family 
doctor appointments, central electronic medical records or unique identifiers to link different 
datasets, increases these loss. 109-110 In recent years, the use of cell phones has been 
implemented as a traceability tool; however, the use of the same number for long periods is 
not common in the general population due to the quick access to deportable numbers and 
cell phone companies’ mass campaigns with promotions and discounts. 
 
Also, some variables were self-reported (education, alcohol and tobacco consumption, 
previous measurements and treatment), which may have resulted in self-report bias. 
Participants were asked not to eat anything eight hours before participating in the study; 
however, it was difficult to measure adherence to this appeal, which adds uncertainty to the 
measures of blood glucose and cholesterol. 
 
In CardioBengo, we chose not to examine age groups over 65 years old (known for higher 
rates of the conditions studied) due to their low representation in the general population (only 
3.6% in the Dande-HDSS), but instead to include younger participants (15 to 24 years), 
allowing us a better representation of the demographic structure and creating a stronger 
baseline for future surveys.  
 
Finally, our study findings should be interpreted cautiously because, even with the similarities 
between the Dande-HDSS and the demographic structure of the country, the distribution of 
nonrespondents in our study was uneven, with a higher proportion of loss for younger people 
and men; this may have caused instability in the estimates in some strata. 
 
It is therefore not possible to extrapolate our findings to a larger population at the country 
level, and this was not an objective of this study. However, it was possible to create a new 
baseline that may constitute the larger comprehensive community-based study in Angola for 
CVDs and associated risk factors 
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Abstract 
 
Background: Hypertension is worldwide the most common risk factor for cardiovascular 
diseases. However, data on incidence is lacking for sub-Saharan Africa. This study in Bengo 
Province, Angola, reports on the incidence of hypertension and socio-demographic, 
behavioral and anthropometric characteristics. 
 
Methods: A community sample of 303 individuals at risk for hypertension was evaluated 
after 2-years of follow-up, using World Health Organization STEPwise approach to 
Surveillance procedures. Cumulative incidence and relative risk were calculated, and 
Cochran-Matel-Haenszel method was used to compute sex-age-adjusted relative risk. 
 
Results: The 2-years cumulative incidence of hypertension was 12.2%, similar in women 
(12.2%) and men (12.3%), but significantly higher in those >40 years (21.3% versus 8.1%) 
and living in rural areas (25.0% versus 10.3% in urban areas). Regular alcohol drinkers and 
overweight or obese individuals presented a significantly higher risk of developing 
hypertension (2.5 and 2.3, respectively). Among incident cases there was a low frequency of 
awareness (37.8%) and treatment (21.4%), without any controlled case. 
 
Conclusions: This first time estimate of the incidence of hypertension in Angola, showed 
risk is high, and that much remains to be done regarding prevention and access to treatment. 
 
Keywords: Hypertension; Incidence; Awareness; Cardiovascular diseases; Sub-Saharan 
Africa. 
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Introduction 
Non-communicable diseases (NCD) are the principal cause of death worldwide, except in 
Africa where infection remains the first cause of mortality. In Africa, the frequency of NCD is 
rising rapidly, and by 2030, it will surpass the death burden of communicable diseases [1]. 
 
Cardiovascular diseases (CVD) were the leading NCD as cause of death in 2012, 
responsible for 17.5 million deaths worldwide, mostly occurring in low- and middle-income 
countries [1]. A large proportion of CVD depends on the exposure to modifiable risk factors 
(tobacco, alcohol, diet and physical activity) that influence metabolic pathways and ultimately 
results in obesity and/or hypertension [1, 2]. Hypertension is estimated to have contributed to 
9.4 million deaths in 2010, and to 7% of the worldwide disease burden, measured as 
disability-adjusted life years [3].  
 
Hypertension is the most common risk factor for CVD in sub-Saharan Africa (SSA), with the 
prevalence of hypertension documented in multiple systematic reviews [4-7]. But, to our 
knowledge, there isn’t any determination of incidence in the general adult population in this 
part of the world. Incidence is the true measure of risk and allows a better understanding of 
the operating determinants of complex diseases. However, social instability and a fast-
growing economy, which increases mobility and clustering of populations, common in many 
SSA countries, challenge the design and implementation of follow-up studies [8]. During four 
decades, from 1966 to 2009, only 41 longitudinal studies on CVD and related risk factors 
were conducted in Africa (only 1 on hypertension in 1973, in Ghana), covering just 11 
countries and clustering in South Africa and Nigeria [9]. Only 10 were community-based 
cohorts, presenting methodological shortcomings of small sample size and high dropout 
rates [9]. 
 
Angola, located in the Atlantic coast of Middle Africa, faced a long period of civil war that 
impeded the development of health care and educational infrastructures, and forced the 
relocation of people to safer places, namely major cities, such as the capital, Luanda. The 
economic growth and urbanization, started in 2002 with the end of the civil war, might 
ultimately result in a further increased prevalence of risk factors for NCD and CVD-related 
mortality, which represented 9% of adult deaths in 2013 [10].  
 
Three studies provided information on the prevalence of hypertension in Angola: a survey of 
adult students of Health Sciences in Lubango, that reported a prevalence of 23.5% [11]; a 
study of employees from the public university Agostinho Neto, Luanda, described a 
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prevalence of 45.2% [12]; and a survey of the adult community of Bengo where a 23% 
prevalence of hypertension was found in 2011 [13]. 
 
The current prospective longitudinal study reports on the incidence of hypertension at the 2 
years follow-up of a sample of adult’s residents in Bengo Province, who were identified at 
risk for hypertension during a community survey. 
 
Methods 
Study site 
This study was conducted in the catchment area of the Centro de Investigação em Saúde de 
Angola (CISA), that includes the Dande Health and Demographic Surveillance System 
(Dande-HDSS) that monitors the structure, dynamics, and geographical distribution of a 
population of 60,075 (53.5% 18 years and older), spread across 4,700 km2 covering 3 
communes (Caxito, Mabubas and Úcua) of the Dande Municipality, in Bengo Province, 60 
km north of Luanda, the capital of Angola [14]. 
 
Study design 
This is a prospective cohort study. A representative sex- and age-stratified random sample 
was drawn from the Dande-HDSS database and 1464 individuals older than 18 years were 
recruited and evaluated from 11 October to 20 December 2011 [13]. Then, from 18 
September to 20 December 2013, participants with normal blood pressure at the initial round 
were approached and offered a new evaluation. Eligible individuals were considered 
unreachable after 2 failed attempts of contact in their household at different hours in 
weekdays, and as a refusal if explicitly communicates their willingness in not participating. 
 
Data collection 
Data were collected by trained interviewers and certified nurses, able to communicate in 
Portuguese (official language) and in other spoken local languages. The protocol for data 
collection was the same used at baseline [13]. Socio-demographic characteristics and 
behavioural exposures (i.e., alcohol and tobacco consumption) were collected using 
structured questionnaires adapted from the World Health Organization STEPwise approach 
to Surveillance (STEPS) manual [15], translated to Portuguese, pre-tested, and piloted 
before data collection.  
 
Physical evaluation was performed after an overnight fast, with participants in light clothing 
and no footwear [16]. Waist and hip circumferences were measured to the nearest 0.1 cm 
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using circumference tape SECA 203 (SECA United Kingdom, Birmingham, UK). Body weight 
was measured to the nearest 0.1 kg using a digital scale SECA 803 (SECA United Kingdom, 
Birmingham, UK). Height was measured to the nearest 0.1 cm in the standing position using 
a portable stadiometer SECA 213 (SECA United Kingdom, Birmingham, UK). Body Mass 
Index (BMI) was calculated as weight (kg) divided by squared height (m2). Subjects were 
categorized according to WHO recommendations: underweight and normal (<24.9 kg/m2), 
overweight and obese (≥25 kg/m2) [16]. The waist-to-hip ratio was calculated as the 
circumference of the waist (cm) to that of the hips (cm), and abdominal obesity defined as 
≥0.9 for men and ≥0.85 for women [17]. 
 
Blood pressure was measured using the automatic sphygmomanometer OMRON M6 
Comfort (OMRON Healthcare Europe B.V., Hoofddorp, The Netherlands) as recommended 
[18]. After a 15-minute rest, 3 readings were taken, 3 minutes apart. Measurements were 
made with the participant seated, on the right arm, and using the appropriate cuff size. For 
data analysis, the average of the last 2 readings was used [15]. Hypertension was defined as 
a systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg and/or 
use of anti-hypertensive drug therapy during the previous 2 weeks [19]. 
 
Following STEPS guidelines [15], information on a diagnosis of hypertension during the 
follow-up period was obtained by questioning previous measurements of blood pressure. In 
case of a positive answer, participants were inquired about their awareness of the diagnosis 
done by a health care worker. Any individual was considered under treatment if he/she 
indicated the use of specific medication, and considered controlled if he/she had an actual 
normal blood pressure reading. 
 
For analysis, age was divided into 2 groups: younger or equal to 40 years, and 41 years or 
older. Frequent alcohol drinkers were defined as consumers of any alcohol 3 or more days 
per week and current smokers as those who reported smoking at least 1 cigarette per day. 
Education was categorized according the number of completed schooling years as none, and 
1 or more. The area of residence was classified as rural or urban as previously reported [14]. 
 
Ethics approval and consent to participate 
All procedures performed in this study involving human participants were in accordance with 
the ethical standards of the Ethics Committee of the Angolan Ministry of Health, that 
approved the study protocol, and with the latest version of the Helsinki declaration. Written 
informed consent was obtained from all individual participants included in the study. All 
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participants with blood pressure readings in the range of values defined as hypertension 
were referred to the General Hospital of Bengo for a follow-up evaluation with a cardiologist. 
 
Follow-up  
At baseline 1,464 subjects were evaluated and hypertension was diagnosed in 322 
individuals [13]. Among the remaining 1,142 participants, 108 women were pregnant at the 
time of baseline evaluation and were excluded because of the expected alterations in 
anthropometric measurements and pregnancy-related blood pressure variation [20]. From 
the 1,034 eligible individuals, 9 died during the 2 years period, 6 refused to participate, 211 
were known to have migrated outside the study area and unreachable, and 488 were not 
traceable during the survey time (Figure 1). From the 320 evaluated individuals (30.9% of the 
eligible participants), 17 were pregnant women, and thus not considered for analysis. 
Therefore, 303 remained for the present analysis. The median (interquartile range) follow-up 
period was 2.0 years (1.9-2.2 years). 
 
Compared with subjects lost to follow-up participants showed no significant differences at 
baseline in the prevalence of smoking and drinking, abdominal obesity and BMI categories, 
and mean systolic or diastolic blood pressure. However, participants were significantly older, 
more frequently women, less educated, and more likely to live in rural areas (Table 1). 
 
Statistical analysis 
Data was double entered into a PostgreSQL® database system and imported into SPSS® 
version 22 (IBM, New York, USA) for statistical analysis. Data is presented as absolute 
frequencies and percentages, and means and standard deviations (SD) when appropriate. 
Pearson’s chi-squared test and the Mann–Whitney U test were used to compare the 
characteristics of individuals in the follow-up group and those who were lost to follow-up. 
Cumulative incidence and relative risk (RR) were calculated for the 2-years period. The 
Cochran-Matel-Haenszel method was used to compute sex-age-adjusted RR [21]. A 95% 
confidence interval (95% CI) was computed for each point estimate and a significance level 
of p<0.05 was considered. 
 
Results 
Participant’s mean age was 33.9 years (SD 12.8), 62.4% of them being women, a fifth had 
no formal education and 13.2% lived in rural areas. The prevalence of daily smoking was 
8.9% and that of frequent drinking 43.9%, almost a quarter of the sample presented 
overweight or obesity, and two fifths showed abdominal obesity (Table 1). 
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The crude cumulative incidence of hypertension is 12.2%, similar according to sex and 
education, but higher above 40 years (21.3% versus 8.1%) and in rural areas (25.0% versus 
10.3%) (Table 1). 
 
A significantly higher risk of developing hypertension was found in overweighed and obese 
participants (adjusted RR = 2.3; 95% CI: 1.3 to 4.8) and among regular drinkers (adjusted 
RR = 2.5; 95% CI: 1.3 to 4.1). No significant association was observed with smoking 
(adjusted RR = 0.9; 95%: 0.3 to 2.2) or abdominal obesity (adjusted RR = 1.7; 95%: 0.8 to 
3.4) (Table 1). 
 
Among the 37 newly identified cases, 14 (37.8%; 95% CI: 24.1 to 53.9) were aware of their 
status, but only three ever received medication (21.4%; 95% CI: 7.6 to 47.6), of which 2 were 
on prescribed medication, none had their hypertension controlled. Awareness level was 
higher in the older group, namely in women (57.1%; 95% CI: 32.6 to 78.6) but treatment was 
more frequent in younger men (66.7%; 95% CI: 20.8 to 93.8). 
 
Discussion  
To the best of our knowledge, this is the first study that provides a measurement of the 
incidence of hypertension in SSA communities. In SSA, trends of hypertension, a surrogate 
to approach incidence, are based on cross-sectional studies like the one conducted in 
Cameroon that found a significantly increased by 2 to 5-fold in rural and urban men and 
women over a ten-year period [22]. Another way is the use of pooled prevalence from 
different countries that shows an increased from 19.7% in 1990, to 27.4% in 2000 and 30.8% 
in 2010 for all Africa [6]. A review of studies focused on West Africa showed that the crude 
prevalence of hypertension increased progressively from 12.9% in the 1980s to 34.4% in 
2010-2014 [23]. 
 
Looking to other countries and regions, the annual age-standardized incidence in a German 
adult population aged 45 to 83 years was 8% to 9% in 2002-2006 and 5% to 6% for the next 
5 years of follow-up [24] and for a Portuguese urban population the overall incidence rate 
was 47.3 per 1000 person-years, higher in men [25]. Within the China Health and Nutrition 
Survey an incidence rate of hypertension of 2.9 per 100 person-years was found in 1991-
1997 and significantly increased to 5.3 per 100 person-years in 2004-2009 [26]. The 
incidence now calculated for our study population is higher then described for non-SSA 
countries, concurring with the pooled increase of hypertension predicted for the region by 
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WHO, in contrast to many countries worldwide where the rates of CVD risk factors are slowly 
decreasing [27]. 
 
In our sample, the risk of developing hypertension increases with age, drinking alcohol and 
obesity. The increased risk of hypertension in the presence of these factors is well 
recognized and the fact that we also observed it favours the validity of our estimates despite 
the large attrition observed in our sample [1-2, 4-7]. Men are generally at greater risk for CVD 
than are age-matched, premenopausal women, with higher blood pressure values than in 
women at similar ages. After menopause, however, blood pressure increases in women to 
levels even higher than in men [28]. Smoking has not been conclusively proven to cause 
hypertension, but smokers were shown to be at higher risk for elevated blood pressure, 
particularly after smoking, and present a much higher risk of CVD events than non-smokers 
[29]. In our sample, and although there was a low frequency of smokers, we also did not find 
a significant association with risk of hypertension, with the crude risk close to one in both 
genders. However, as smoking is increasing in Africa [1] and due to other well-known health 
consequences of smoking this finding cannot result in overlooking the importance of tobacco. 
As found in 2011 in the region, awareness of the hypertensive status was more frequent in 
the older group but overall it seemed to increase (37.8% vs. 21.6%) [13], being similar to the 
pooled rate in Africa of 33.7% in 2010 [6], but higher than the 27% found in SSA [7]. 
Treatment was reported by 8.1% of the affected individuals (13.9% in 2011) and lower than 
the polled rate of 18% of treated individuals in these studies. Furthermore, none presented 
controlled blood pressure, opposed to the 7% with controlled blood pressure in SSA studies 
[7]. However, the number of treated patients was too small to allow conclusions. 
 
These findings stress the need to implement access to affordable anti-hypertensive drugs 
and the inclusion of NCDs prevention and clinical management in primary care, to reduce the 
future burden of morbidity and early mortality associated with hypertension [30]. According to 
the Dande-HDSS Verbal Autopsy System, among the 407 reported deaths in adults (>15 
years old) that occurred from 2009 to 2012, 59 (14.5%) were due to circulatory system 
diseases, the main cause of death attributable to a specific disease in this population for this 
period [31]. 
 
The study limitations need to be recognized. It is based on a relatively small sample, 
reflecting a high attrition rate, with almost two thirds of eligible individuals not being found. 
This problem, common in cohort studies in SSA, reflects important migration movements and 
the absence of efficient alternative means of follow-up as used in high income-countries, 
such as electronic or postal mail, family doctor appointments, central electronic medical 
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records or unique identifiers to link different datasets [32, 33]. The surveillance system in 
place, the Dande-HDSS, which primarily assesses births, deaths, and household conditions, 
was not able to guarantee the traceability of a large proportion of this population, with high 
mobility. Expecting such constraints a 2-year follow-up period was defined, but even within a 
short time frame it was only possible to reach 30% of the eligible individuals. This attrition 
results in a possible bias due to the fact that individuals who were evaluated were 
significantly older and with a larger presence of women. These limit external validity but 
looking at the founded impact of determinants expected to increase the incidence of 
hypertension, and that no differences were found regarding baseline blood pressure between 
the group lost to follow-up and followed, a major indicator of risk of developing hypertension 
[34], we can be confident about the importance of the measured incidence as an indicator of 
the expected burden of cardiovascular related outcomes in this population. 
 
Conclusions 
This study provides the first estimate of the incidence of hypertension in an Angolan adult 
population. Despite the limitations described, our results are align with others from the SSA 
showing that hypertension frequency is increasing, with low levels of awareness, access to 
treatment and difficulties in controlling blood pressure. 
 
Health care systems in SSA, mainly focused in communicable diseases, need to address the 
announced global epidemic of CVD and their associated risk factors, and to reliably 
recognize the perception and impact of these diseases in the populations through large 
community based studies [1, 30].  
 
For this specific population, and considering the relative risk of hypertension in the presence 
of overweight or obesity and alcohol use, health promotion initiatives need to focus these risk 
factors, and as early as possible, time to minimize new cases of hypertension and related 
early mortality. Since young people are a major target of campaigns to prevent infectious 
diseases, such opportunities could also be used to alert to shared and additional behavioural 
factors associated with NCD [30]. 
 
Data Availability 
The data used to support the findings of this study were provided by Dande-HDSS Data 
Base under license, and so cannot be made freely available. Access to these data will be 
considered upon request, with permission of the Dande-HDSS administrator. Inquiries can 
me made to info@cisacaxito.org. 
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Abstract
Objectives: To estimate the prevalence, awareness, treatment 
and control of hypertension, diabetes and hypercholesterol-
aemia in an Angolan population aged 15 to 64 years and to 
determine relationships with sociodemographic, behavioural 
and anthropometric characteristics. 
Methods: A total of 2 354 individuals were assessed for behav-
ioural, sociodemographic and physical characteristics in a 
cross-sectional, community-based survey. Post-stratification 
survey weights were applied to obtain prevalence levels. 
Adjusted odds ratios for each variable related to the condi-
tions were calculated using logistic regression models.
Results: Overall, the prevalence of hypertension was 18.0%, 
diabetes 9.2% and hypercholesterolaemia 4.0%. Among 
hypertensive individuals, the awareness rate was 48.5%; 
15.8% were on treatment and 9.1% had their blood pressure 
controlled. Only 10.8% were aware they had diabetes, 4.5% 
were on treatment and 2.7% were controlled. The awareness 
level for hypercholesterolaemia was 4.2%, with 1.4% individu-
als on treatment and 1.4% controlled.
Conclusions: The prevalence levels of hypertension and diabe-
tes, which were higher than previous findings for the region, 
together with the observed low rates of awareness, treatment 
and control of all conditions studied, constitute an additional 
challenge to the regional health structures, which must rapidly 
adapt to the epidemiological shift occurring in this popula-
tion.
Keywords: epidemiology, hypertension, diabetes, hypercholester-
olaemia, sub-Saharan Africa
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Cardiovascular disease (CVD), a major cause of 
non-communicable diseases (NCDs), was responsible for 17.5 
million deaths worldwide in 2012, most occurring in low- and 
middle-income countries (LMIC). In Africa, the frequency 
of NCDs is rising rapidly, reflecting the combined effect of 
population growth and ageing, as well as nutritional and 
epidemiological transitions.1
A large proportion of CVD is the result of exposure to 
modifiable risk factors (tobacco and alcohol consumption, 
unhealthy diet and physical inactivity), which influence metabolic 
pathways and ultimately result in obesity, hypertension, 
diabetes or hypercholesterolaemia.1,2 Together, these known 
adverse conditions explain approximately half of CVD cases, as 
demonstrated in the MONICA project and the INTERHEART 
study.3,4 
Among the African population participating in the 
INTERHEART study, five risk factors (smoking, diabetes, 
hypertension, abdominal obesity and an elevated apolipoprotein 
B to apolipoprotein A-1 ratio) accounted for 89.2% of the 
population-attributable risk for the first myocardial infarction.5 
The same study suggested that uncontrolled major risk factors 
have a larger impact on the burden of CVD in Africa than 
elsewhere in the world.5 
If  the current trends persist, the risk of dying from NCDs 
will increase in the African region. However, this rising risk 
could be reversed by reaching the proposed targets for six 
behavioural and physiological risk factors (tobacco and alcohol 
use, salt intake, obesity and increased blood pressure and glucose 
levels) out of the nine global targets proposed by the World 
Health Organisation (WHO) in the Global Action Plan for the 
Prevention and Control of NCD 2013–2020.6,7
To follow the achievement of those goals, there is a need for 
sound and updated epidemiological data from all regions of the 
world. The majority of published studies for the African region 
are conducted at hospital services, which does not allow one 
to detect risk factors, awareness rates and prevalence of such 
conditions in the general population.8-10 To provide core data on 
established risk factors for the major NCDs within the context 
of low-resource settings, WHO designed the STEPwise approach 
to Surveillance (STEPS).11 STEPS uses a modular structure with 
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standardised questions and protocols, allowing adjustment of its 
application and appropriate comparisons across surveys.11 
In Angola, infectious disease and maternal and child health-
related problems remain the major causes of morbidity and 
mortality.12 However, an increased burden of NCDs has been 
observed, particularly CVD, which was responsible for 9% of 
adult deaths in 2013.13 Beyond general vital statistics, specific 
epidemiological information on CVD risk factors in Angola is 
based on only four local studies published after 2000: a survey 
of 667 adult students of Health Sciences in Lubango (prevalence 
of hypertension of 23.5%),14 a study conducted among 615 
active employees of the University Agostinho Neto, Luanda 
(prevalence of hypertension 45.2% and hypercholesterolaemia 
11.1%),15 1 464 participants surveyed in the Dande Health and 
Demographic Surveillance System (Dande-HDSS) catchment 
area (23% prevalence of hypertension),16 and a study of 421 
subjects from a rural community of Angola (2.8% prevalence 
of diabetes).17 
Building on the work carried out by Pires and colleagues,16 
and based on the STEPS methodology,11 this study aimed to 
expand the sample population to the 15- to 24-year-old group, 
and to estimate the prevalence, awareness, treatment and control 
of hypertension, diabetes and hypercholesterolaemia, and its 
association with sociodemographic (gender, age, education 
and area of  residence), behavioural (alcohol and tobacco 
consumption) and anthropometric [body mass index (BMI) and 
abdominal obesity] variables among 15- to 64-year-olds in the 
Dande-HDSS population.
Methods
A cross-sectional, community-based survey was conducted 
from September 2013 to March 2014 in the catchment area of 
the Dande-HDSS, located in Dande municipality of Bengo 
Province, Angola.18 A representative gender- and age-stratified 
random sample list of 3 515 individuals, aged between 15 and 
64 years, was drawn, as described previously.19 Of these, we 
were able to examine 2 484 (70.7%) individuals, 750 (21.3%) 
were unreachable and 281 (8.0%) refused to participate, thus 
approaching the predicted non-participation rate of 30%.19 
For analysis, we excluded participants with missing 
anthropometric values (n = 14) and pregnant women (n =116) 
due to the fact that anthropometric parameters vary during 
pregnancy. Therefore 2 354 individuals (67.0%) were included in 
the final analysis.
Information on age, completed years of school education, 
alcohol and tobacco consumption, and the previous 
measurement of any of the conditions under investigation, were 
collected through a structured interview conducted by trained 
interviewers, following a previously published protocol for data 
collection based on the WHO STEPS manual version 3.0.11,19
For this analysis, age was categorised into five 10-year age 
groups: 15 to 24, 25 to 34, 35 to 44, 45 to 54 and 55 to 64 
years old. Education was categorised according to the number 
of completed years of schooling: none, one to four years, five 
to nine years, and 10 years or more. Area of residence was 
classified as rural or urban, as previously described.18 Alcohol 
consumption was defined as none if  participants reported 
no alcohol consumption; occasional if  participants reported 
drinking alcohol two or less days per week; and frequent if  
drinking any alcohol three or more days per week. Current 
tobacco smokers were defined as participants who reported 
smoking at least one cigarette per day. 
Previous measurements of blood pressure, and glucose or 
cholesterol levels in the last year were requested from all 
participants. In the case of a positive answer, participants 
were questioned about their awareness of a previous diagnosis 
of hypertension, diabetes or hypercholesterolaemia made by 
a healthcare worker. Any individual was considered under 
treatment if  he/she indicated the use of a specific medication; 
a participant was considered controlled if  they had a current 
normal value.
Certified health professionals conducted all anthropometric 
and clinical measurements, as described previously.19 
Anthropometric measurements were performed with individuals 
wearing light clothing and no footwear, and an overnight fast 
was requested of all participants.
Body mass and height were measured using a digital scale 
SECA 803 (SECA United Kingdom, Birmingham, UK) and 
a portable stadiometer SECA 213 (SECA United Kingdom, 
Birmingham, UK). BMI was defined as the body mass (kg) 
divided by the square of the body height (m2), and further 
categorised according to WHO as underweight (< 18.5 kg/m2), 
normal (18.5 to 24.99 kg/m2), overweight (25.0 to 29.99 kg/m2) 
and obese (≥ 30 kg/m2).20 
Waist and hip circumferences were measured using 
circumference tape SECA 203 (SECA United Kingdom, 
Birmingham, UK). The waist-to-hip ratio was calculated as the 
circumference of the waist (cm) to that of the hips (cm), and 
abdominal obesity was defined as waist-to-hip ratio ≥ 0.9 for 
men and ≥ 0.85 for women.21 
Blood pressure was measured on the right arm with the 
automatic sphygmomanometer OMRON M6 Comfort (OMRON 
Healthcare Europe BV, Hoofddorp, The Netherlands), with the 
individual seated, and using an appropriate cuff size. Three 
readings were done at three-minute intervals. The mean value 
of the last two measurements was used to determine the blood 
pressure. Hypertension was defined as systolic blood pressure of 
≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/
or use of antihypertensive drugs during the previous two weeks.22 
Blood sugar was measured using a blood glucose meter 
ACCU-CHEK Aviva (Roche Diagnostic, Indianapolis, IN, 
USA) with ACCU-CHEK Aviva glucose reactive strips (Roche 
Diagnostic, Indianapolis, IN, USA). The definition of diabetes 
followed WHO diagnostic criteria of 126 mg/dl (6.9 mmol/l) 
glucose in a fasting blood sample,23 and/or use of antidiabetic 
drugs during the previous two weeks. 
Total cholesterol in the blood was measured using a point-of-
care device ACCUTREND Plus (Roche Diagnostic, Indianapolis, 
IN, USA) with ACCUTREND cholesterol reactive strips (Roche 
Diagnostic, Indianapolis, IN, USA). Hypercholesterolaemia was 
defined according to WHO diagnostic criteria for STEPS, with 
cholesterol ≥ 240 mg/dl (6.2 mmol/l) in a fasting blood sample,2,11 
and/or use of anticholesterol drugs during the previous two weeks.
All procedures performed in this study were in accordance 
with the standards of the ethics committee of the Angolan 
Ministry of Health and with the 1964 Helsinki declaration and 
its later amendments. Written informed consent was obtained 
from all individual participants included in the study (in the case 
of those under 18 years old, from their parent or legal guardian). 
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A copy of the signed consent form, as well as instructions 
regarding the fasting period and contact information, were 
delivered to each participant.
Statistical analysis
Data were double entered into a PostgreSQL® database and 
SPSS® version 22 (IBM Corp, Armonk, NY, USA) was used 
for statistical analysis. Post-stratification survey weights 
were calculated using the known gender and categorical age 
distribution of the Dande-HDSS population,17 and these were 
used in all further calculations. Descriptive data are reported 
as absolute frequencies and percentages or means and standard 
deviations (SD), as appropriate. 
To facilitate comparisons with other studies, the prevalence 
of the three conditions under study was determined for three 
age groups: 15 to 64, 18 to 64 and 25 to 64 years. Logistic 
regression models were fitted to the categorical variable of 
age because of its known effect on hypertension, diabetes and 
hypercholesterolaemia. Gender-specific adjusted odds ratios 
(OR) were estimated for each variable (age, residence, education, 
BMI, abdominal obesity, tobacco and alcohol consumption) 
related to the conditions studied. A 95% confidence interval 
(95% CI) and a significance level of p < 0.05 were set for all 
applicable determinations.
Results
The mean age of this population was 32.5 years (SD 13.6) with 
63.0% (n = 1 482) women and the majority (81.0%) living in urban 
settings. Nearly 10% had never received any formal education, 
with men having completed more school years. Overall, almost a 
quarter of participants had abdominal obesity (36.5% of women 
and 12.4% of men), 6.8% were obese (10.6% of women and 2.8% 
of men), 6.2% were smokers (2.7% of women and 10.0% of men) 
and approximately two-fifths consumed alcohol occasionally or 
frequently, with a higher proportion of frequent drinkers among 
men (24.6 vs 10.9%) (Table 1).
The prevalence of hypertension in the general population 
was 18.0%, reaching 20.0% in those over 18 years of age, and 
26.6% in those aged 25 to 64 years (Table 2). This prevalence was 
always higher among women than men, but with no statistically 
significant relationship (data not shown). 
The overall prevalence of diabetes among participants aged 
15 to 64 years was 9.2%; the prevalence among those over 18 
years old was 9.8%, and 11.9% in those aged over 25 years (Table 
2). Men had a higher OR than women for diabetes of 1.4 (95% 
CI: 1.0–1.8, data not shown).
Similar to that of hypertension and diabetes, the prevalence 
of hypercholesterolaemia was higher in the older age groups, 
with an estimated 5.5% in participants aged 25 to 64 years, and 
a lower prevalence of 4.0% in the overall population (Table 2). 
Women had an OR of 2.3 (95% CI: 1.3–4.0, data not show) for 
hypercholesterolaemia. 
Only five participants (0.2%; 95% CI: 0.1–0.4, data not shown) 
presented all three conditions, but 22.0% (95% CI: 18.4–26.2, 
data not shown) of hypertensive participants had an associated 
condition, as did 37.2% (95% CI: 31.1–43.7, data not shown) 
of participants with diabetes and 47.9% (95% CI: 36.7–59.3, 
data not shown) of those with hypercholesterolaemia. The most 
common associations were hypertension and diabetes, present in 
71 individuals (3.0%; 95% CI: 2.4–3.7, data not shown). 
The prevalence of hypertension was higher in rural areas (26.9 
vs 15.9% in urban areas) for both genders. Individuals with lower 
levels of education had a higher prevalence of hypertension, 
with women with no formal education presenting an OR for 
hypertension of 4.3 (Table 3). 
Table 1. Socio-demographic, anthropometric and behavioral 
characteristics of the population (Caxito, 2016)
Age (years) (n = 2 354)
All participants 
(n = 2 354)
Female
(n = 1 222)
Male 
(n = 1 132)
% (95% CI)* % (95% CI)* % (95% CI)*
15–24 36.2 (34.3–38.1) 30.1 (27.6–32.7) 42.7 (39.9–45.6)
25–34 25.9 (24.2–27.7) 25.4 (23.0–27.9) 26.5 (24.0–29.1)
35–45 16.1 (14.7–17.6) 18.7 (16.6–20.9) 13.3 (11.5–15.4)
45–54 12.6 (11.3–14.0) 15.3 (13.4–17.4) 9.7 (8.1–11.6)
55–64 9.2 (8.1–10.4) 10.6 (9.0–12.4) 7.8 (6.3–9.5)
Residence (n = 2 354)
Urban 81.0 (79.4–82.5) 81.2 (78.9–83.3) 80.8 (78.4–83.0)
Rural 19.0 (17.5–20.6) 18.8 (16.7–21.1) 19.2 (17.0–21.6)
Education (years completed) (n = 2 348)
None 9.3 (8.2–10.5) 16.6 (14.6–18.8) 1.4 (0.9–2.3)
1–4 23.1 (21.5–24.9) 34.5 (31.9–37.2) 10.9 (9.2–12.8)
5–9 42.2 (40.2–44.2) 35.7 (33.1–38.5) 49.2 (46.3–52.1)
> 10 25.4 (23.7–27.2) 13.1 (11.4–15.2) 38.5 (35.7–41.4)
BMI class (kg/m2) (n = 2 354)
Underweight (< 18.5) 11.3 (10.1–12.6) 10.2 (8.7–12.1) 12.5 (10.7–14.5)
Normal (18.5–24.9) 66.1 (64.1–67.9) 58.7 (55.9–61.4) 74.0 (71.4–76.5)
Overweight (25.0–29.9) 15.8 (14.4–17.3) 20.5 (18.4–22.9) 10.7 (9.0–12.6)
Obese (≥ 30) 6.8 (5.9–7.9) 10.6 (9.0–12.4) 2.8 (2.0–4.0)
Abdominal obesity (n = 2 354)
No 75.1 (73.3–76.8) 63.5 (60.8–66.2) 87.6 (85.6–89.4)
Yes 24.9 (23.2–26.7) 36.5 (33.8–39.2) 12.4 (10.6–14.4)
Tobacco smoking (n = 2 342)
Non-current 93.8 (92.7–94.7) 97.3 (96.2–98.1) 90.0 (88.1–91.6)
Current 6.2 (5.3–7.3) 2.7 (1.9–3.8) 10.0 (8.4–11.9)
Alcohol consumption (n = 2 335)
No consumption 63.8 (61.8–65.7) 69.5 (66.9–72.0) 57.6 (54.7–60.4)
Occasional (< 3 days per week) 18.8 (17.2–20.4) 19.6 (17.5–21.9) 17.8 (15.7–20.2)
Frequent (≥ 3 days per week) 17.5 (16.0–19.1) 10.9 (9.2–12.7) 24.6 (22.2–27.2)
*Post-stratification weights used as described in the methods section.
Table 2. Prevalence of hypertension, diabetes and hypercholesterolaemia by gender and age (Caxito, 2016)
All Participants Female Male
15–64 years 
(n = 2 354)
18–64 years 
(n = 2 100)
25–64 years 
(n = 1 503)
15–64 years 
(n = 1 222)
18–64 years 
(n = 1 116)
25–64 years 
(n = 854)
15–64 years 
(n = 1 132)
18–64 years 
(n = 984)
25–64 years 
(n = 649)
Hypertension, % (95% CI) 18.0 
(16.5–19.6)
20.0 
(18.4–21.8)
26.6 
(24.4–28.9)
20.0 
(17.8–22.3)
21.8
(19.5–24.3)
27.8 
(24.9–30.8)
15.9 
(13.9–18.1)
18.1 
(15.8–20.6)
25.1 
(21.9–28.6)
Diabetes, % (95% CI) 9.2 
(8.1–10.4)
9.8 
(8.6–11.2)
11.9 
(10.3–13.6)
8.9 
(7.4–10.6)
9.3 
(7.8–11.2)
10.8 
(8.9–13.0)
9.6 
(8.0–11.4)
10.4 
(8.7–12.5)
13.5 
(11.0–16.3)
Hypercholesterolaemia, % 
(95% CI)
4.0 
(3.2–5.0)
4.4 
(3.5–5.5)
5.5 
(4.4–6.9)
5.6 
(4.3–7.2)
6.0 
(4.7–7.8)
7.4 
(5.7–9.5)
2.0 
(1.2–3.2)
2.4 
(1.5–3.8)
2.9 
(1.8–4.8)
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Hypertension was higher among the obese (34.9% of women 
and 48.5% of men) and individuals with abdominal obesity 
(32.5% of women and 45.7% of men), with a higher OR in men 
for both conditions (Table 3). Hypertension prevalence was also 
higher among current smokers (50.0% in women and 20.4% in 
men) and frequent alcohol drinkers (28.0% in women and 24.3% 
in men). Men presented a higher OR for hypertension than 
women, related to the consumption of alcohol (Table 3). 
Residents in urban areas presented a higher prevalence of 
diabetes, with a significantly higher OR for diabetes in men. 
Participants with lower education levels had a higher prevalence 
of diabetes, but without statistical significance (Table 4). 
With regard to anthropometric variables, there was a higher 
prevalence of diabetes among obese participants (17.1% in 
women and 24.2% in men) and those with abdominal obesity 
(8.8% in women and 24.3% in men). Men with obesity (2.4 
vs underweight) and abdominal obesity (2.3 vs no abdominal 
obesity) presented higher ORs for diabetes than women (2.1 for 
obese vs underweight and 1.5 for abdominal obesity) (Table 4).
For current smokers and occasional consumers of alcohol 
the prevalence of diabetes was higher, but with no significant 
relationship (Table 4). No significant relationships were found 
with education, residence, BMI, abdominal obesity, tobacco 
smoking and alcohol consumption; however, the prevalence 
of  hypercholesterolaemia was higher among less educated 
individuals, the obese, smokers and frequent alcohol drinkers 
(Table 5).
The majority of the population (61.5%; n = 1 460) reported 
previous measures of blood pressure, and nearly half (48.5%) of 
the hypertensive participants were aware of their condition. Only 
32.5% of the aware hypertensive participants were on treatment 
and 57.7% of them had their blood pressure controlled. This 
represented only 9.1% of all hypertensive participants (Fig. 1). 
Only 7.3% (n = 172) of the population reported previous 
measurement of glycaemia, with a low awareness rate of 
10.8% among participants with diabetes in this study. Of the 
aware participants, 41.7% were receiving treatment (4.5% of 
all hyperglycaemic participants) and 60.0% had a controlled 
blood sugar level (Fig. 1). Only 2.9% (n = 68) of participants 
reported previous measures of cholesterolaemia and only 4.2% 
of individuals with hypercholesterolaemia were aware of their 
condition (Fig. 1). 
The hypertension awareness rate was higher among women 
(62.7%; 95% CI: 55.9–69.0) and older participants, without 
a difference regarding education level (Table 6). The diabetes 
awareness rate was higher among men (58.3%; 95% CI: 38.8–
75.5), older participants and those with higher education levels 
(Table 7). The hypercholesterolaemia awareness rate was higher 
Table 3. Prevalence of hypertension and relation with other factors by gender (Caxito, 2016)
Associated factor
All Participants
(n = 2 354)
Female 
(n = 1 222)
Male 
(n = 1 132)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa, b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa, b
(95% CI)*
Total 18.0 (16.5–19.6) 20.0 (17.8–22.3) – 15.9 (13.9–18.1) –
Age (years)
15–24 2.8 (1.9–4.2) 1.9 (0.9–3.9) 1 3.5 (2.2–5.6) 1
25–34 12.3 (9.9–15.2) 10.6 (7.7–14.6) 6.6 (2.8–15.4) 14.3 (10.8–18.8) 4.6 (2.6–8.2)
35–44 25.6 (21.5–72.0) 26.8 (21.4–32.9) 20.3 (8.9–46.5) 23.8 (17.7-31.2) 8.7 (4.7-16.0)
45–54 38.7 (33.4–44.4) 39.6 (32.8–39.6) 36.6 (16.0–83.8) 37.3 (28.8–46.6) 16.2 (8.7–30.0)
55–64 51.6 (45.0–58.2) 53.5 (44.9–61.9) 63.4 (27.1–147.9) 48.9 (38.7–59.1) 26.4 (13.9–50.0)
Residence
Urban 15.9 (14.3–17.6) 17.6 (15.3–20.1) – 14.0 (11.9–16.4) –
Rural 26.9 (23.0–31.2) 30.0 (24.4–36.2) – 23.5 (18.4–29.6) –
Education (years completed)
None 45.4 (38.9–52.0) 45.5 (38.8–52.4) 4.3 (1.8–10.2) 46.7 (24.8–69.9) 2.0 (0.6–6.5)
1–4 24.9 (21.4–28.7) 23.3 (19.5–27.6) 2.4 (1.0–5.4) 29.8 (22.5–38.4) 0.8 (0.5–1.5)
5–9 12.7 (10.8–14.9) 10.3 (7.8–13.6) 2.2 (0.9–5.1) 14.5 (11.8–17.7) 0.9 (0.6–1.4)
> 10 10.4 (8.2–13.1) 4.4 (2.1–8.8) 1 12.6 (9.8–16.1) 1
BMI class (kg/m2)
Underweight (< 18.5) 11.0 (7.8-15.3) 12.9 (8.1-19.0) 1 9.3 (5.5-15.2) 1
Normal (18.5–24.9) 15.2 (13.5–17.1) 17.0 (14.4–19.9) 1.1 (0.6–2.1) 13.7 (11.5–16.2) 1.3 (0.7–2.5)
Overweight (25.0–29.9) 25.8 (21.6–30.5) 23.9 (19.0–29.5) 1.2 (0.6–2.3) 29.2 (21.8–37.8) 2.2 (1.1–4.7)
Obese (≥ 30) 37.3 (30.2–45.0) 34.9 (27.2–43.4) 2.0 (1.0–4.1) 48.5 (32.5–64.8) 5.1 (1.9–13.4)
Abdominal obesity
No 12.1 (10.6–13.7) 12.6 (10.5–15.2) 1 11.6 (9.7–13.7) 1
Yes 35.7 (31.9–39.6) 32.5 (28.3–37.0) 1.6 (1.2-2.3) 45.7 (37.7–54.0) 2.8 (1.8–4.3)
Tobacco smoking
Non-current 17.3 (15.8–18.9) 18.9 (16.7–21.2) – 15.5 (13.4–17.8) –
Current 26.7 (20.2–34.4) 50.0 (34.1–65.9) – 20.4 (14.0–28.7) –
Alcohol consumption
No consumpion 14.2 (12.6–16.1) 18.1 (15.7–20.9) 1 9.1 (7.2–11.6) 1
Occasional (< 3 days per week) 23.5 (19.8–23.5) 21.4 (16.7–27.1) 0.9 (0.6–1.4) 26.0 (20.4–32.5) 2.5 (1.6–4.0)
Frequent (≥ 3 days per week) 25.5 (21.5–25.5) 28.0 (21.1–36.2) 1.7 (1.1–2.7) 24.3 (19.6–29.7) 2.5 (1.7–3.9)
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
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Table 4. Prevalence of diabetes and relation with other factors by gender (Caxito, 2016)
Associated factor
All participants
(n = 2 348)
Female 
(n = 1 220)
Male 
(n = 1 128)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Total 9.2 (8.1–10.4) 8.9 (7.4–10.6) 1 9.6 (8.0–11.4) 1.4 (1.0–1.8)
Age (years)
15–24 4.4 (3.2–6.0) 4.4 (2.7–7.0) 1 4.4 (2.9–6.6) 1
25–34 5.6 (4.0–7.7) 3.2 (1.8–5.9) 0.8 (0.3–1.7) 8.0 (5.4–11.6) 1.9 (1.0–3.5)
35–44 13.2 (10.2–17.0) 12.7 (9.0–17.7) 3.3 (1.7–6.2) 13.9 (9.3–20.3) 3.4 (1.8–6.5)
45–54 19.3 (15.2–24.2) 17.6 (12.9–23.7) 4.8 (2.6–9.0) 22.2 (15.4–30.9) 6.2 (3.3–11.6)
55–64 17.2 (12.8–22.8) 15.5 (10.3–22.7) 4.0 (2.0–8.0) 20.7 (13.5–30.4) 5.6 (2.8–11.0)
Residence
Urban 9.8 (8.5–11.2) 9.2 (7.5–11.1) 1.6 (0.9–2.8) 10.4 (8.6–12.6) 2.6 (1.4–4.9)
Rural 6.8 (4.8–9.5) 7.4 (4.7–11.6) 1 6.0 (3.6–10.1) 1
Education (years completed)
None 11.5 (7.9–16.5) 11.9 (8.1-17.1) – 6.7 (1.2-29.8) –
1–4 11.7 (9.2–14.6) 10.0 (7.5-13.3) – 17.2 (11.5-24.9) –
5–9 8.3 (6.7–10.1) 7.1 (5.1–9.9) – 9.0 (6.9–11.6) –
> 10 7.7 (5.9–10.2) 6.2 (3.4–11.1) – 8.3 (6.1–11.3) –
BMI class (kg/m2)
 Underweight (< 18.5) 7.5 (4.9–11.4) 4.0 (1.7–9.0) 1 10.7 (6.6–16.9) 1
 Normal (18.5–24.9) 7.8 (6.6–9.2) 7.7 (5.9–9.9) 2.0 (0.7–5.1) 7.9 (6.3–9.9) 0.7 (0.4–1.2)
 Overweight (25.0–29.9) 12.4 (9.4–16.1) 10.4 (7.2–14.7) 2.4 (0.9–6.5) 16.5 (11.0–24.2) 1.1 (0.5–2.3)
Obese (≥ 30) 18.6 (13.4–25.4) 17.1 (11.5–24.5) 3.9 (1.4–11.1) 24.2 (12.8–41.0) 1.7 (0.6–4.5)
Abdominal obesity
No 7.0 (5.9–8.3) 3.5 (2.3–5.2) 1 7.5 (6.0–9.3) 1
Yes 15.9 (13.1–19.0) 8.8 (6.4–12.2) 1.5 (1.0–2.3) 24.3 (17.9–32.0) 2.3 (1.4–3.8)
Tobacco smoking
Non-current 8.8 (7.6–10.0) 8.6 (7.2–10.4) – 8.9 (7.3–10.8) –
Current 14.4 (9.6–21.0) 17.6 (8.3–33.5) – 13.3 (8.2–20.8) –
Alcohol consumption
No consumption 8.9 (7.6–10.5) 8.7 (6.9–10.8) – 9.2 (7.2–11.7) –
Occasional (< 3 days per week) 10.5 (8.0–13.7) 10.1 (6.9–14.6) – 11.0 (7.4–16.1) –
Frequent (≥ 3 days per week) 8.8 (6.4–12.0) 8.3 (4.7–14.3) – 9.1 (6.2–13.0) –
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
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Table 5. Prevalence of hypercholesterolaemia and relation with other factors by gender (Caxito, 2016)
Associated factor
All participants 
(n = 1 781)
Female 
(n = 978)
Male 
(n = 803)
Prevalence
% (95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Prevalence
% (95% CI)*
Adjusted ORa,b
(95% CI)*
Total 4.0 (3.2–5.0) 5.6 (4.3–7.2) 2.3 (1.3–4.0) 2.0 (1.2–3.2) 1
Age (years)
15–24 0.7 (0.3–1.8) 1.1 (0.4–3.2) 1 0.3 (0.1–1.9) 1
25–34 2.5 (1.4–4.3) 2.8 (1.4–5.7) 2.6 (0.6–10.8) 2.5 (1.1–5.3) 5.0 (0.8–31.6)
35–44 3.6 (2.0–6.4) 5.4 (2.9–9.6) 5.2 (1.4–20.0) 0.9 (0.2–4.7) 2.1 (0.2–24.4)
45–54 9.4 (6.3–13.7) 10.8 (6.9–16.7) 11.9 (3.30–42.7) 5.7 (2.5–12.8) 13.7 (2.1–88.1)
55–64 11.4 (7.6–16.8) 15.4 (10.0–23.0) 17.2 (4.8–61.9) 4.5 (1.6–12.5) 9.0 (1.2–69.5)
Residence
Urban 3.9 (3.0–5.0) 5.6 (4.2–7.4) – 1.8 (1.0–3.2) –
Rural 4.2 (2.5–7.0) 5.3 (2.8–9.8) – 3.5 (1.5–7.9) –
Education (years completed)
None 10.8 (7.0–16.2) 10.7 (6.9–16.3) – 11.1 (2.0–43.5) –
1–4 5.7 (3.9–8.3) 6.4 (4.3–9.5) – 2.5 (0.7–8.8) –
5–9 2.6 (1.7–4.1) 3.3 (1.9–5.9) – 2.0 (1.0–3.9) –
>10 2.0 (1.0–3.7) 2.3 (0.8–6.5) – 1.9 (0.9–4.0) –
BMI class (kg/m2)
 Underweight (<18.5) 2.3 (0.9–5.7) 3.2 (1.1–9.1) – 1.2 (0.2–6.5) –
 Normal (18.5–24.9) 3.5 (2.6–4.7) 5.1 (3.6–7.3) – 1.9 (1.1–3.3) –
 Overweight (25.0–29.9) 5.3 (3.3–8.3) 6.0 (3.6–10.1) – 3.8 (1.5–9.3) –
Obese (≥ 30) 6.7 (3.5–12.2) 8.6 (4.6–15.5) – –a –
Abdominal obesity
No 2.4 (1.7–3.4) 3.5 (2.3–5.2) – 1.5 (0.8–2.7) –
Yes 8.1 (6.0–10.9) 8.8 (6.4–12.2) – 5.9 (2.9–11.6) –
Tobacco smoking
Non-current 3.7 (2.9–4.8) 5.1 (3.9–6.7) – 2.0 (1.2–3.3) –
Current 6.4 (3.1–12.6) 17.9 (7.9–35.6) – 2.5 (0.7–8.6) –
Alcohol consumption
No consumption 4.3 (3.2–5.6) 5.7 (4.2–7.7) – 2.2 (1.2–4.1) –
Occasional (< 3 days per week) 2.7 (1.4–5.0) 4.6 (2.5–8.6) – –c –
Frequent (≥ 3 days per week) 3.9 (2.2–6.7) 5.6 (2.6–11.6) – 2.5 (1.1–5.7) –
*Post-stratification weights used as described in the methods section.
aAdjusted for age (categorical: 15–23, 25–34, 35–44, 45–54, and 55–64).
bOnly variables with relations with statistical significance shown.
cNo cases in this category.
Table 6. Awareness, treatment and control rates of hypertension by gender (Caxito, 2016)
Awareness Treatment Control
All (n = 209) Female (n = 131) Male (n = 78) All (n = 68) Female (n = 41) Male (n = 27) All (n = 39) Female (n = 25) Male (n = 14)
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Education (years 
completed)
none 21.5 
(16.5–27.6)
34.4 
(26.8–42.8)
0 17.6 
(10.4–28.4)
26.8 
(15.7–41.9)
3.7 
(0.7–18.3)
10.3
(4.1–23.6)
16.0 
(6.4–34.7)
0
1–4 31.1 
(25.2–37.7)
40.5 
(32.4–49.0)
15.4 
(9.0–25.0)
27.9 
(18.7–39.6)
39.0 
(25.7–54.3)
11.1 
(3.9–28.1)
25.6 
(14.6–41.1)
40.0 
(23.4–59.3)
0
5–9 28.2 
(22.6–34.7)
22.1 
(15.9–30.0)
38.5 
(28.4–49.6)
29.4 
(19.9–41.1)
26.8 
(15.7–41.9)
33.3 
(18.6–52.2)
33.3 
(20.6–49.0)
36.0 
(20.2–55.5)
28.6 
(11.7–54.6)
> 10 19.1 
(14.4–25.0)
3.1 
(1.2–7.6)
46.2 
(35.5–57.1)
25.0 
(16.2–36.4)
7.3 
(2.5–19.4)
51.9 
(34.0–69.3)
30.8 
(18.6–46.4)
8.0 
(2.2–25.0)
71.4 
(45.4–88.3)
Age (years)
15–24 2.9 
(1.3–6.1)
0.8 
(0.1–4.2)
6.4 
(2.8–14.1)
1.5 
(0.3–7.9)
2.4 
(0.4–12.6)
0 2.6 
(0.5–13.2)
4.0 
(0.7–19.5)
0
25–34 16.7 
(12.3–22.4)
12.2 
(7.7–18.9)
24.4 
(16.2–34.9)
26.5 
(17.4–38.0)
24.4 
(13.8–39.3)
29.6 
(15.9–48.5)
33.3 
(20.6–49.0)
32.0 
(17.2–51.6)
35.7 
(16.3–61.2)
35–44 19.6 
(14.8–25.5)
19.1 
(13.3–26.7)
20.5 
(13.0–30.8)
20.6 
(12.7–31.6)
19.5 
(10.2–34.0)
22.2 (
10.6–40.8)
25.6 
(14.6–41.1)
24.0 
(11.5–43.4)
28.6 
(11.7–54.6)
45–54 31.1 
(25.2–37.7)
37.4 
(29.6–45.9)
20.5 
(13.0–30.8)
23.5 
(15.0–34.9)
26.8 
(15.7–41.9)
18.5 
(8.2–36.7)
17.9 
(9.0–32.7)
20.0 
(8.9–39.1)
14.3 
(4.0–39.9)
55–64 29.7 
(23.9–36.2)
30.5 
(23.3–38.9)
19.4 
(19.4–39.0)
27.9 
(18.7–39.6)
26.8 
(15.7–41.9)
29.6 
(15.9–48.5)
20.5 
(10.8–35.5)
20.0 
(8.9–39.1)
21.4 
(7.6–47.6)
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among women (66.7%; 95% CI: 20.8–93.9), older age groups 
and higher education levels (Table 8). The treatment rate of 
all conditions was more prevalent in the older age groups and 
higher education levels, but the control rate was more frequent 
in younger participants.
Among the individuals who were aware of any of the 
three conditions, the advice most often given by healthcare 
professionals to follow non-pharmacological approaches for 
the management of cardiovascular risk factors was a change 
in dietary habits, with a decrease in salt and fat intake, and 
increased fruit and vegetable intake (Table 9). 
Discussion 
The prevalence of hypertension among participants in the range 
of 15 to 64 years old was 18.0%. This value rose to 26.6% among 
participants aged 25 to 64 years, which is slightly higher than 
those previously described for Angola over the last eight years,14-
15 particularly a study conducted in the same region in 2010,16 
and the WHO age-standardised (25 to 64 years old) estimated 
hypertension prevalence for 2014 in Angola of 23.9% (95% CI: 
16.3–31.1).1 More recently, a cross-sectional study conducted in 
Uganda, South Africa, Tanzania and Nigeria encountered an 
overall age-standardised prevalence of hypertension of 25.9%.24 
The estimated 9.2% prevalence of diabetes (9.8% in urban 
and 6.8% in rural areas) was higher than previous reports from 
Angola of 5.7% among an urban population (aged 20 to 72 
years) in 2010,15 and 2.8% for a rural community (aged 30 to 
69 years) in 2009.17 The value of 9.8% estimated in individuals 
older than 18 years is in the middle range of prevalence levels 
encountered in STEPS surveys, with values from 3.0% in Benin 
to 22.5% in Niger.25,26 This value also falls within the confidence 
intervals of the WHO estimate of 12.1% (95% CI: 5.6–18.9) for 
increased blood glucose levels in those over 18 years in Angola 
for 2014.1 
This rise in diabetes is aligned with the global tendency for 
this disease, which has increased faster in LMIC than in high-
income countries since 1980.27 Since the end of the Angolan 
civil war in 2002, the population has been increasing and ageing. 
This, together with changes in food habits and the urbanisation 
process, may have led to the increased prevalence of diabetes in 
this region.
The prevalence of  hypercholesterolaemia (5.3% among 
participants 25 and 64 years old) in this study was lower than 
that found in a previous study in Luanda among an older urban 
population.15 However, this value falls within a wide range of 
values from several STEPS surveys measuring the prevalence 
of total cholesterol, from 2.1% in Mozambique to 26.0% in 
Tanzania.25,26 This prevalence may also be tied to the ageing 
population and changes in dietary habits that most African 
countries are currently facing.28 There is a lack of solid knowledge 
regarding the prevalence levels of hypercholesterolaemia in 
Africa, mainly owing to the difficulties in determining values of 
blood cholesterol in African communities because of the high 
cost of laboratory tests. This situation presents a challenge when 
comparing research results. 
As described in other studies worldwide, the clustering of risk 
factors helps to explain the known impacts of age, education 
and obesity on the occurrence of hypertension, diabetes and 
hypercholesterolaemia. The prevalence of these three conditions 
was higher among individuals with less education, and increased 
with age and BMI. 
Obesity represents a major concern as a risk factor for 
CVD and NCDs in general, and is connected with the current 
nutritional transition in Africa, with a shift in the composition 
and structure of diets traditionally low in fat and high in 
unrefined carbohydrates toward higher intakes of  refined 
carbohydrates, added sugars, fats and animal-source foods.28 This 
Table 9. Non-pharmacological advice by health professionals  
to aware participants (Caxito, 2016)
Hypertension 
(n = 209)
Diabetes 
(n = 24)
Hypercholes-
terolaemia 
(n = 3)
Advice % (95% CI) % (95% CI)* % (95% CI)*
Reduce salt in your diet 78.5 (72.4–83.5) 100.0 100.0
Reduce fat in your diet 61.7 (55.0–68.0) 91.7 66.7
Eat at least five servings of fruit and/
or vegetables each day 58.4 (51.6–64.8) 70.8 66.7
Reduce or stop alchool consumption 51.2 (44.5–57.9) 83.3 33.3
Start or do more physical activity 34.4 (28.3–41.1) 75.0 66.7
Quit using tobacco or don’t start 31.1 (25.2–37.7) 45.8 0
Maintain a healthy body weight or 
lose weight 30.1 (24.3-36.7) 75.0 66.7
*Due to the small sample size, the 95% CI was not determined.
Table 7. Awareness, treatment and control rates of diabetes by gender 
(Caxito, 2016)
Awareness Treatment Control
All 
(n = 24)
%
Female 
(n = 10)
%
Male 
(n = 14)
%
All 
(n = 10)
%
Female 
(n = 6)
%
Male 
(n = 4)
%
All 
(n = 6)
%
Female 
(n = 5)
%
Male 
(n = 1)
%
Education 
(years 
completed)
None 12.5 30.0 0.0 20.0 33.3 0 16.7 20.0 0
1–4 4.2 10.0 0.0 10.0 16.7 0 16.7 20.0 0
5–9 33.3 30.0 35.7 50.0 33.3 75.0 50.0 40.0 100.0
> 10 50.0 30.0 64.3 20.0 16.7 25.5 16.7 20.0 0
Age (years)
15–24 8.3 20.0 0.0 20.0 33.3 0 33.3 40.0 0
25–34 12.5 10.0 14.3 10.0 16.7 0 16.7 20.0 0
35–44 20.8 10.0 28.6 20.0 16.7 25.5 16.7 20.0 0
45–54 25.0 20.0 28.6 10.0 16.7 0 0 0 0
55–64 33.3 40.0 28.6 40.0 16.7 75.0 33.3 20.0 100.0
Table 8. Awareness, treatment and control rates of  
hypercholesterolemia by gender (Caxito, 2016)
Awareness Treatment Control
All 
(n = 3)
%
Female 
(n = 2)
%
Male 
(n = 1)
%
All 
(n = 1)
%
Female 
(n = 1)
%
Male 
(n = 0)
%
All 
(n = 1)
%
Female 
(n = 1)
%
Male 
(n = 0)
%
Education 
(years 
completed)
None 0 0 0 0 0 0 0 0 0
1–4 33.3 50.0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
> 10 66.6 50.0 100.0 100.0 100.0 0 100.0 100.0 0
Age (years)
15–24 0 0 0 0 0 0 0 0 0
25–34 0 0 0 0 0 0 0 0 0
35–44 33.3 50.0 0 100.0 100.0 0 100.0 100.0 0
45–54 66.6 50.0 100.0 0 0 0 0 0 0
55–64 0 0 0 0 0 0 0 0 0
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shift may have had an impact on the rise in incidence of diabetes 
over the past decades, revealed in recent literature reviews,29-31 as 
well as a WHO estimation of the rise in median prevalence of 
elevated total cholesterol for this region.2 
Similar to this nutritional transition, the process of 
urbanisation underway in the region must be taken into 
consideration for future interventions. Living in an urban area 
has been associated with a two-fold increase in the prevalence of 
diabetes among this population, as described in other studies.1,29-31 
Information regarding the awareness, treatment and control 
rates for the three conditions investigated is scarce for the 
African continent, except for hypertension; there are also some 
available data with regard to diabetes. Our findings for awareness 
of hypertension were higher than those calculated in 2010 for 
Africa, with an estimated 33.7% pooled awareness rate.32 Current 
values for awareness, treatment and control of hypertension are 
higher than in 2011 in the same population; results for awareness 
were 21.6% (95% CI: 17.0–26.9) in 2011 and 48.5% in the present 
study. Values for participants who were aware of their condition 
and on pharmacological treatment (13.9%, 95% CI: 5.9–29.1) 
increased to 32.5%; approximately one-third of participants 
were controlled in 2011 and more than half were controlled in 
our study. This may have resulted from the positive effect of 
identification of hypertensive individuals and medical follow up 
after the first survey in 2011. 
Nonetheless, the levels of awareness about hypertensive status 
are still low, a situation common in Africa,33 with levels much 
lower than those in North America and Europe.34 A similar 
framework exists for diabetes awareness in Africa, with fewer 
than 50% of participants in one study aware of their condition.29 
No data were found for awareness of total cholesterol levels. 
The lack of primary healthcare facilities in this region, 
especially in rural areas, makes the low levels of previous 
measurements plausible. Furthermore, the current training of 
Angolan health professionals and the availability of clinical 
equipment are still focused on infectious diseases, not considering 
CVD a priority. Therefore initiatives promoting the awareness 
of CVD are lacking in the region, and proper monitoring of 
patients’ conditions does not occur. 
Moreover, the information available to the population is 
not enough to convince patients to take lifelong medication in 
order to treat a condition, which is usually asymptomatic. Only 
one-third of participants with any of these conditions had access 
to treatment, which demonstrates the inadequacy of the region’s 
health system to help patients manage risk factors. Economic 
difficulties and the lack of drugs to address CVD may also help 
explain the low levels of treatment and control found.
Nevertheless, a positive note should be made as to the 
number of patients who had controlled levels of blood pressure, 
blood sugar and cholesterolaemia in this specific population. 
Considering that they were younger and better educated, they 
could have had easier access to drugs and health facilities. Also 
noteworthy, in the absence of access to drugs, physicians’ advice 
in most cases is to adopt non-pharmacological approaches to 
reducing modifiable risk factors, mainly associated with diet.
Strengths and limitations of the study
Our study findings should be interpreted cautiously because 
the Dande-HDSS was developed as a district-level surveillance 
system in an urban and rural setting and is therefore not 
representative of the demographic structure of the country. In 
addition, age groups over 65 years old (known for higher rates 
of the conditions studied) were not considered owing to their low 
representation in the general structure of the population (3.6% 
of the Dande-HDSS population),18 which is a common practice 
for surveys conducted in sub-Saharan Africa.
Internal migration and the geographical isolation of some 
hamlets within the Dande-HDSS, together with the fact that 
working individuals were unavailable during the daytime,17 were 
reflected in the sampling definition, with a 30% non-participation 
rate. The distribution of non-respondents was uneven, with a 
higher proportion of younger people and men (data not shown). 
This may have caused instability in the estimates in some strata.
Participants were requested not to eat anything eight hours 
before participating in the study; however, it was difficult to 
measure adherence to this request, which adds uncertainty to 
the measures of blood glucose and cholesterol. We used dry 
chemistry devices to measure glycaemia and cholesterolaemia, 
but owing to high temperatures and humidity during field 
surveys, data collection was not possible in some cases, causing a 
higher number of missing data than expected.
Due to the many variables covered in the survey and to 
avoid drop-out of participants in future rounds, additional 
questions relating to awareness, pharmacological treatments 
and non-pharmacological approaches were conducted in a more 
detailed form in individual follow-up visitations. These are not 
dealt with extensively in this article. Also the low number of 
aware individuals and consequently under-treatment limited the 
statistical analysis of data regarding these aspects.
It is therefore not possible to extrapolate our findings to a 
larger population at country level. However, this study reveals 
new data about the prevalence, awareness, treatment and control 
of diabetes and hypercholesterolaemia, and it is the most 
comprehensive community-based study conducted to date in 
Angola.
Future direction
The inclusion of younger participants (15 to 24 years) allows 
a better representation of the demographic structure of the 
country and creates a baseline for future surveys. The emphasis 
for future interventions should be aimed at younger populations 
in which the prevalence of major risk factors is still low, so as to 
make a difference in the long term.
In all LMIC, NCDs are the leading cause of death and 
disability, killing nearly eight million people under 60 years 
old in 2013.25 Over the past decade, the focus of assistance in 
these countries has primarily addressed maternal and child 
health and infectious diseases. Without setting these aside, there 
is an opportunity to use structures that are already in place, 
to maximise resources. The international community should 
consider expanding the mandate of current programmes to 
include outcome-orientated measures for improving general 
health and lifestyles. 
Many of the methods of NCD prevention, management and 
treatment, which are responsible for the decline in some of these 
diseases in high-income countries, are inexpensive but are not 
widely used in LMIC. These methods could be implemented 
through established global health strategies, such as increased 
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use of low-cost drugs,35 and improved access to NCD services 
for young adults and people with low educational attainment.36
Conclusions
This report reinforces the available data for the main CVD 
risk factors in Angola and helps to build the basis for further 
prospective studies, especially among the younger group in 
this region. We provide the first evidence that hypertension 
prevalence is rising, together with diabetes, when compared with 
previous studies in the region. 
Despite being a growing economy, Angola’s primary health 
system may not be currently able to provide an adequate answer 
to the changing health needs of this population. A gradual 
shift from infectious diseases to NCDs is underway and this 
puts additional stress on the reinforcement of primary care 
intervention in the region.
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Abstract
There is concern about the potentially increasing use of tobacco in Angola. However, infor-
mation on the frequency and determinants of this use is not systematised. This study aimed
to estimate the prevalence of tobacco consumption and nicotine dependence among smok-
ers in an Angolan population and considering individual socio-demographic and behavioural
characteristics. A community-based survey with 2,472 respondents (age range: 15–64
years) was conducted in 2013–2014 in the country’s Bengo Province. The collection meth-
odology for assessing each type of tobacco consumption and its daily quantification followed
the World Health Organization STEPwise approach to chronic disease risk factor surveil-
lance. The Fagerstro¨m Test for Nicotine Dependence was also used to assess smokers.
Mean values for prevalence of tobacco use and nicotine dependence were estimated by sex
and by previously defined variables. Daily smoking (6.1%) was found to be higher for males
(10.0%) them among females (2.6%), and the amount of ex-smokers (7.5%) was higher
them smokers. Only 0.2% of those surveyed reported use of smokeless (chewing) tobacco.
One-third of ever-smokers reported having started smoking daily before age 18. Nicotine
dependence levels were classified as very low or low in 83.6% of the smokers. Daily smok-
ing prevalence increased with age, and was higher in rural areas and among individuals with
no formal education, lower incomes, and alcohol consumption. This population presented a
low smoking prevalence, along with a low number of daily smoked cigarettes and low levels
of nicotine dependency, despite the low prices of, and easy access to, manufactured ciga-
rettes. These two factors conjugated with the current absence of an Angolan policy for
tobacco control, enhance the susceptibility for rising overall tobacco use in the near future.
Introduction
Tobacco is a major risk factor for multiple non-communicable diseases (NCDs), including
cancer, chronic lung diseases, and cardiovascular diseases. Tobacco use presently accounts for
around seven million deaths every year worldwide [1], and this is projected to increase to eight
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million by 2030 [2]. A 30% relative reduction until 2025 in the prevalence of current tobacco
use in people aged 15 years or older is one of the nine voluntary global targets defined to
reduce the preventable and avoidable burdens of morbidity, mortality, and disability due to
NCDs [3].
Low- and middle-income countries are facing increased in tobacco use, while the opposite
is occurring in high-income countries [4,5,6]. It is also estimated that nearly 80% of the world’s
tobacco smokers are from low- or middle-income countries [7].
Although information on the prevalence, trends, patterns, and determinants of tobacco use
is still limited for sub-Saharan Africa [8,9], there is evidence of increasing use in some coun-
tries [9]. Smoking is expected to increase in the region as a result of the tobacco industry’s
strategy of creating new consumers to offset the declines in traditional markets [10,11].
In Angola, which ratified the Framework Convention on Tobacco Control in 2007, there is
no national survey on tobacco consumption, and the defined policies in the convention that
aim at effective tobacco prevention and control have not been fully implemented, especially
regarding smoke-free environments, taxation, health warnings on tobacco product packages,
and bans on advertising, promotion, and sponsorship of such products [12,13,14]. The leading
causes of mortality and morbidity in Angola are communicable, maternal, neonatal, and nutri-
tional diseases, but the rates of premature deaths due to NCDs are rising [15]. The urbaniza-
tion process and westernization of life habits in Africa is followed by increased exposure to
behavioural risk factors for NCDs, such as alcohol consumption and tobacco use [3,4].
Tobacco, one of Angola’s major industries, was established in the country during the Portu-
guese Colonial War (1961–1974) and has experienced 400% growth since 2002, although there
are no tobacco plantations or manufacturing industries in the country [16]. The going market
price for a pack of 20 cigarettes is around $1, and since 2009, British American Tobacco has
held a monopoly in the country’s tobacco industry [14,16].
There is concern about the increasing use of tobacco in Angola following rapid economic
growth, given the low prices for tobacco products and in the absence of restrictive legislation
or organized health promotion campaigns. However, there is scarce information on the fre-
quency and determinants of tobacco use in representative samples, further limiting health plan
efforts and evaluation of interventions. The present study is the first report on the use of
tobacco and the level of nicotine dependence among smokers in a large Angolan community
sample of people aged 15–64 years.
Materials and methods
Results presented herein were extracted from a community-based survey conducted in the
catchment area of the Dande Health and Demographic Surveillance System (Dande HDSS)
[17], located in the Dande Municipality of Bengo Province, between 18 September 2013 and
28 March 2014. This study, named CardioBengo, constituted a larger survey of cardiovascular
risk factors [18], and was based on the World Health Organization STEPwise approach to Sur-
veillance (STEPS) to Chronic Disease Risk Factor manual (core and expanded version 3.0)
[19].
Sample characterization
The CardioBengo baseline survey was created and implemented with a representative sex- and
age-stratified random sample of the Dande HDSS population aged 15–64 years as its basis
[18]. Those aged 65 and older were not included because of their low representation in the
general population (only 3.6% in the Dande HDSS) [17]. Younger participants (15–24 years)
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allowed a better representation of the demographic structure and created a stronger baseline
for future surveys.
A total of 3,515 individuals were selected. After two failed attempts to contact them at their
homes on different hours on weekdays, 1,025 were considered unreachable and six refused to
participate, resulting in a final sample of 2,484 individuals. From these, 12 were excluded from
the final analysis herein because of missing information on tobacco variables; thus, the final
sample was 2,472.
Study variables
Information on sex, age, education, family income, and alcohol consumption was collected
through interviews [18,19] conducted by trained interviewers in Portuguese, and if necessary
in the local language of Kimbundu. For analysis, age was categorized into five 10-year groups:
15–24, 25–34, 35–44, 45–54, or 55–64. Education was categorized by number of completed
years of school: none, 1–4, 5–9, or 10 or more. Monthly family income was recorded in the
Angolan kwanza, which then was converted into US dollars and categorized into: none, $150
or less, $151–299, or $300 or more. Frequency of consumption of alcoholic beverages during
the preceding 12 months was recorded as: none, daily, 5–6 days/week, 1–4 days/week, or 1–3
days/month. Area of residence (urban or rural) was classified as described for the Dande
HDSS area [17].
Assessment of tobacco use and nicotine dependence
Subjects were asked if they currently use or had ever used any type of tobacco (smoked or
smokeless), their age at initial use, current use, and average consumption. For analysis, indi-
viduals were classified as current, ex-, and never-users. Current users were asked about the
type of tobacco used: manufactured, hand-rolled, and/or smokeless. Smokers (manufactured
and/or hand-rolled cigarettes) were further grouped by frequency of consumption ( 1 and
<6, 6 and<20, or 20 cigarettes/day).
A validated version of the Fagerstro¨m Test for Nicotine Dependence, in Portuguese [20],
was also integrated into the interview. Per the test, nicotine dependence score was categorized
as 0–2: very low; 3–4: low; 5: medium; 6–7: high; or 8–10: very high.
Statistical analysis
Data were entered twice into a PostgreSQL (University of California, Berkeley, CA, USA)
database and imported into IBM SPSS Statistics for Macintosh, Version 23.0 (IBM Corp.,
Armonk, NY, USA) for statistical analysis. All analyses were conducted considering the sam-
pling weights [18]. Descriptive data are reported as absolute frequencies and percentages, and
mean and standard deviation (SD) when appropriate. Prevalence of tobacco use and its 95%
confidence interval (95% CI) were calculated according to the socio-demographic and beha-
vioural characteristics.
Ethics
All procedures performed in this study were in accordance with the standards of the 1964 Dec-
laration of Helsinki and its later amendments. The Ethics Committee of the Angolan Ministry
of Health approved the CardioBengo study protocol and all use of secondary data. Written
informed consent was obtained from each participant or from the parent or legal guardian of
those under 18 years old. A copy of the signed consent form, as well as contact information,
was subsequently delivered to each participant.
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Results
As shown in Table 1, the great majority of the participants reported never using any type of
tobacco (86.1% overall: 94.1% of females, 77.5% of males). The prevalence of current smoking
was 6.1%, and was higher among males (10.0%) than females (2.6%), and the prevalence of ex-
smokers was 7.5% (12.2% in males and 3.2% in females). Only five participants reported use of
smokeless (chewing) tobacco (0.2%, 95% CI: 0.1–0.5).
Around one-third of ever-smokers (current and ex-) began smoking before age 18
(Table 1). The average age at initiation was 20.1 (±6.9) years; 19.8 (±6.1) years for males and
21.4 (±9.3) for females. None of the current smokers reported intermittent use, with most
reporting five or fewer cigarettes per day (84.8% of females, 59.7% of males) (Table 1). The
average number of daily smoked cigarettes was 6.6 (±6.8), higher among males (7.5 ± 7.2) than
females (3.4 ± 3.3).
The nicotine dependence level was rated very low or low in 83.6% of the smoker popula-
tion. Only 9.1% of females presented a medium level and none were above, while 18.4% of
males had a medium or higher level (Table 1). Table 2 shows a breakdown of the mean values
of nicotine dependence by variable categories, revealing that males had consistently higher lev-
els of dependence than females. Among males, younger individuals presented a slightly higher
mean value, as with males from urban areas or who reported daily alcohol consumption.
Among females, the highest values of mean nicotine dependence were found in rural areas and
among women aged above 45 years (Table 2).
As shown in Table 2, the prevalence of smoking was highest in the 55–64 age group for
both sexes. The rural area had a higher smoking prevalence. Participants with 10 or more years
of education had the lowest prevalence in both sexes. The prevalence was similar among
income categories but slightly higher for those with lower levels of family income. Those who
consumed alcohol (especially daily users) presented a higher prevalence of smoking. Similar
trends were found for ex-smokers (Table 2).
Table 1. Prevalence, characteristics of tobacco use and nicotine dependence in smokers, by gender.
Total (n = 2,472) Female (n = 1,283) Male (n = 1,189)
n % (95% CI)* n % (95% CI)* n % (95% CI)*
Tobacco use
Never 2,129 86.1 (84.7–87.4) 1,207 94.1 (92.6–95.2) 922 77.5 (75.1–79.8)
Smokeless 5 0.2 (0.1–0.5) 2 0.2 (0.0–0.6) 3 0.3 (0.1–0.7)
Current smokers 152 6.1 (5.3–7.2) 33 2.6 (1.8–3.6) 119 10.0 (8.4–11.8)
Ex-smokers 186 7.5 (6.5–8.6) 41 3.2 (2.4–4.3) 145 12.2 (10.5–14.2)
Uptake below the age of 18 113 34.7 (29.7–40.0) 27 39.7 (28.9–51.6) 86 33.3 (27.9–39.3)
Daily smoked cigarettes (manufactured or hand-rolled)
 1 and <6 cigarettes/day 99 65.1 (57.3–72.3) 28 84.8 (69.1–93.3) 71 59.7 (50.7–68.0)
 6 and <20 cigarettes/day 36 23.7 (17.6–31.0) 4 12.1 (4.8–27.3) 32 26.9 (19.7–35.5)
 20 cigarettes/day 17 11.2 (7.1–17.2) 1 3.0 (0.5–15.3) 16 13.4 (8.4–20.7)
Nicotine Dependence (Fagerstro¨m Test)a
Very low dependence (0–2) 77 50.7 (42.8–58.5) 17 51.5 (35.2–67.5) 60 50.4 (41.6–59.2)
Low dependence (3–4) 50 32.9 (25.9–40.7) 13 39.4 (23.2–56.3) 37 31.1 (23.5–39.9)
Medium dependence (5) 16 10.5 (6.6–16.4) 3 9.1 (3.1–23.6) 13 10.9 (6.5–17.8)
High dependence (6–7) 8 5.3 (2.7–10.0) 0 - 8 6.7 (3.4–12.7)
Very high dependence (8–10) 1 0.7 (0.1–3.6) 0 - 1 0.8 (0.1–4.6)
* post-stratification weights used as described in the methods section.
a only determine for cigarette smokers.
https://doi.org/10.1371/journal.pone.0188586.t001
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Discussion
The analysis of the results from this survey contributes to the small body of tobacco-use-related
literature on Angola. Quite recently, the Global Burden of Disease Study (GBD) estimated a
smoking prevalence of 1.6% in females and 14.2% in males for Angola in 2015 [6].
Without a national prevalence survey, only a subnational survey from Huambo Province
was conducted under the auspices of the World Health Organization in 2010, and in a sample
aged 13–15 years found a 2.3% prevalence of smoking (3.2% in boys, 0.3% in girls) [21]. Three
other studies published since 2000 provided data on tobacco smoking: a survey of 667 adult
students of health sciences in Lubango estimated a prevalence of 4.0% [22]; a study conducted
on 615 active employees of the University Agostinho Neto, Luanda, found a value of 7.2%
(10.2% in males, 4.4% in females) [23]; and in 1,464 individuals aged 25–64 years, surveyed in
Table 2. Prevalence of smoking and ex-smoking by socio-demographic caracteristics and alcohol consumption frequency, by gender.
Sociodemographic
characteristics
Female Male
Current Smokers
(n = 33)
Ex-Smokers
(n = 41)
Nicotine
Dependence
(n = 33)
Current Smokers
(n = 119)
Ex-Smokers
(n = 145)
Nicotine
Dependence
(n = 119)
% (95% CI)* % (95% CI)* Mean ± SD % (95% CI)* % (95% CI)* Mean ± SD
Age
15–24 years -a 0.3 (0.0–1.4) -a 3.4 (2.1–5.3) 5.8 (4.0–8.1) 3.0 ± 2.3
25–34 years 0.9 (0.3–2.6) -a 2.3 ± 0.6 10.0 (7.2–13.9) 8.4 (5.8–12.0) 2.9 ± 1.9
35–44 years 2.5 (1.2–5.4) 3.8 (2.0–7.0) 1.6 ± 1.4 17.6 (12.5–24.3) 15.6 (10.8–22.0) 2.6 ± 1.9
45–54 years 6.8 (4.0–11.3) 7.9 (4.8–12.6) 2.7 ± 1.4 17.4 (11.6–25.1) 30.6 (23.1–39.3) 2.7 ± 1.8
55–64 years 9.9 (5.9–16.2) 13.0 (8.3–19.8) 2.4 ± 1.3 25.8 (18.1–35.3) 29.9 (21.7–39.6) 2.3 ± 1.9
Place of residence
Rural 5.3 (19.8–31.0) 2.4 (1.1–5.2) 3.0 ± 0.9 25.0 (19.8–31.0) 15.4 (11.2–20.6) 2.3 ± 1.9
Urban 2.1 (5.3–8.5) 3.4 (2.4–4.7) 2.0 ± 1.5 6.8 (5.3–8.5) 11.4 (9.6–13.6) 3.0 ± 2.2
Education
none 12.0 (8.2–17.1) 12.9 (9.0–18.1) 2.5 ± 1.4 29.4 (13.3–53.1) 18.8 (6.6–43.0) 2.0 ± 2.2
1–4 years 1.6 (0.8–3.2) 2.5 (1.4–4.4) 1.5 ± 2.6 33.1 (25.7–41.5) 21.2 (15.1–28.9) 3.2 ± 2.6
5–9 years 0.2 (0–1.2) 0.7 (0.2–1.9) 2.5 ± 2.1 11.3 (9.0–14.1) 13.7 (11.1–16.7) 2.4 ± 1.8
 10 years -a 0.6 (0.1–3.4) -a 1.5 (0.7–3.1) 7.5 (5.4–10.2) 2.5 ± 1.4
Montlhy Family Income
No income 5.0 (2.0–12.2) 5.0 (2.0–12.2) 1.6 ± 1.3 15.2 (6.7–30.9) 18.8 (8.9–35.3) 3.0 ± 2.0
150 USD 3.0 (1.7–5.1) 3.7 (2.3–6.0) 2.7 ± 1.6 14.9 (11.0–20.0) 18.6 (14.2–24.0) 2.1 ± 1.9
151–299 USD 1.9 (0.8–4.9) 2.9 (1.3–6.2) 1.4 ± 1.8 13.6 (9.4–19.3) 13.6 (9.4–19.3) 3.4 ± 2.3
 300 USD 2.1 (0.4–11.1) 2.1 (0.4–11.1) 2.0 ± 0.0 10.0 (6.2–15.8) 16.7 (11.6–23.4) 3.0 ± 1.5
Alcohol consumption
No 1.4 (0.8–2.4) 3.0 (2.1–4.4) 2.5 ± 1.3 5.2 (3.8–7.2) 10.4 (8.3–13.0) 2.7 ± 1.7
Yes 5.4 (3.5–8.1) 3.3 (2.0–5.6) 2.2 ± 1.3 17.2 (14.2–20.8) 15.0 (12.2–18.4) 2.6 ± 1.3
Alcohol consumption frequency
Daily 16.0 (6.4–34.7) 4.2 (0.7–20.2) 1.8 ± 0.9 25.9 (16.1–38.9) 18.5 (10.4–30.8) 3.5 ± 2.6
5–6 days per week 4.2 (1.2–14.0) 2.1 (0.4–11.1) 1.5 ± 2.6 12.7 (8.3–18.9) 16.6 (11.5–23.3) 2.7 ± 2.0
1–4 days per week 4.6 (2.6–7.8) 3.4 (1.8–6.4) 2.4 ± 1.4 19.4 (14.9–24.7) 14.1 (10.3–19.0) 2.3 ± 1.8
1–3 days per month 7.3 (2.9–17.3) 5.4 (1.8–14.6) 2.2 ± 1.3 9.8 (4.3–21.0) 11.5 (5.4–23.0) 2.9 ± 2.2
* post-stratification weights used as described in the methods section.
a No individuals in this category
https://doi.org/10.1371/journal.pone.0188586.t002
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2011 for hypertension in the same area as in the present study, the prevalence was 9.8% (18.3%
in males, 4.3% in females) [24].
To integrate our results with the GBD estimation and these four studies, it was necessary to
look at the age range of each. This survey included individuals aged 15–64 years, and none of
the above surveys had such a wide age range. The two with younger populations—Huambo
and Lubango [21,22]—had lower prevalence (2.3% and 4.0%, respectively), and the two with
older populations—Luanda and Bengo [23,24]—were higher (7.2% and 9.8%, respectively).
This situates the present findings in the middle, at 6.1%.
Smoking prevalence estimates present vast heterogeneity among countries in the sub-Saha-
ran Africa region [25,26]. National estimates for those countries, mainly after STEPS surveys,
ranged from 1.8% in Zambia to 37.7% in Sierra Leone [11,25,27]. In this way, the present
results evidently place Angola low in prevalence rankings for the region.
A commonality between the present study and the rest of the Angola-based studies regard-
ing tobacco is that the prevalence of current smoking has been consistently higher among
males than females. Smoking is the preferred type of tobacco consumption for males when
compared with females [26,28]. As in other populations, smoking among females was signifi-
cantly less prevalent, across all socio-demographic characteristics [26–29]. Culturally, female
smokers are not generally well accepted [29], and use of smokeless tobacco is more frequent
among females than males in Sub-Saharan Africa [28]. However, social changes and economic
growth in Angola may reflect females’ empowerment, including more equitable access to
income and educational opportunities and, therefore, accompanied by shifts in societal suit-
ability and acceptance of female smokers [29].
The rural areas have a higher proportion of smokers them the urban areas in this survey,
while it is more common to encounter greater prevalence of smokers in urban areas of sub-
Saharan African countries [27,30]. The region where the survey was conducted is only 60 km
from the capital. It serves as a commercial post between the capital and the northern cities, and
in this way may influence the publicity of tobacco in rural areas located near major roads to
other provinces.
The relation between smoking and education level, with a higher prevalence of smokers
among the less-educated, who may lack health literacy to critically evaluate their decisions
regarding tobacco use [7,31], is common in other African surveys. Low levels of family income
are usually associated with low levels of education, and indeed the prevalence of smokers was
also higher among low-income individuals in the present study. This reveals a higher level of
exposure among the population’s more disadvantaged groups, which further contributes to
inequalities in health promotion.
Together with the economic difficulties that youth show as a reason for not smoking in
Angola [14], the long period of colonial and civil war (1961–2002) may have strongly influ-
enced the higher prevalence among older groups and the initiation age of the majority of the
individuals. This evidence is reinforced by the prevalence of ex-smokers among older people
and the duration of smoking habits that correspond with normal years of active military duty.
This phenomenon of smoking, together with alcohol consumption and the use of other drugs
among populations from regions with armed conflict is described in other studies, and often
associated with rituals of manhood and integration in armed groups [32,33].
This connection associated with the higher prevalence of current and ex-smokers in the
groups of less-educated and less-wealthy males and females must be acknowledged and further
studied with qualitative approaches that enable understanding of the impact of war and post-
traumatic stress on tobacco and alcohol consumption patterns in Angola. This accumulation
of behavioural risk factors, which occurs in this population, must be a concern focused on in
future interventions addressing addiction and health education.
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With regard to addiction, the present results revealed that low nicotine dependence levels
were still predominant in this population, with low mean numbers of cigarettes smoked daily
(3.4 in females and 7.5 in males). The efficacy of individual smoking cessation strategies can be
improved by considering the target group’s nicotine dependence level [34].
The low rates of smoking prevalence and nicotine dependence among smokers, and the
substantial rate of ex-smokers, can be associated with individuals’ weighty economic difficul-
ties and the end of the war period. Angola has never had a legal framework for tobacco control;
this is now predicted in the national plan for health development for 2012–2025 [14]. There
are also absolutely no cessation programs or health promotion initiatives that specifically target
tobacco use. This owes to the inadequacy of health structures and lack of health professionals
trained in this subject, as identified by the Ministry of Health [14].
Strengths and limitations
The present study findings need to be interpreted cautiously, as the Dande HDSS was designed
as a district-level surveillance system. Even if it reflects the national demographic structure of
Angola in 2014 (young population with 50.3% aged 15–64 years, 51.5% females, and 68% con-
centrated in urban areas) [35], the goal herein was not to infer at a country level. This cross-
sectional survey only covered a relatively short time period and could not capture possible
cycles of temporary migration. Variables were also self-reported, which may have resulted in
self-report bias and reflected social desirability. Additionally, information on real household
constitution was not available, making the family income a possibly biased proxy of the partici-
pants’ economic power.
Migration and geographical isolation of some settlements within the Dande HDSS, together
with the fact that working individuals were unavailable during the daytime [17], were reflected
in the sampling definition, with a predictable 30% nonparticipation rate [18]. The distribution
of non-respondents was uneven, with a higher proportion among younger individuals and
males; this may have caused imbalance in the estimates in some strata.
However, this study is part of the largest community-based survey of NCD risk factors in
Angola, as the first to address nicotine dependence in smokers in the general population. It is
also expected to provide a baseline for further evaluating trends in tobacco use and under-
standing the dynamics in this population.
Conclusions
This population, such as others in sub-Saharan Africa, is in the early stages of a possible
tobacco epidemic, is characterized by low rates of smoking and increasing use of cigarettes
among males [26,27]. However, and differently from high-income countries, the more edu-
cated and wealthier males do not seem to be those initially affected by the epidemic; the poorer
and less-educated show higher smoking prevalence.
Tobacco use in Africa is on the rise as the tobacco industry shifts its marketing focus from
the West to areas in Africa and Asia seen as having strong market growth potential [10,11,36].
Increasing urbanization and globalization, together with non-existent policies for tobacco con-
trol in Angola, and low product prices, enhance the susceptibility to higher levels of tobacco
use in the near future.
Mass media campaigns and taxation of tobacco products, as proposed in the WHO Frame-
work Convention on Tobacco Control [12,13,36], together with the expected implementation
of tobacco control laws, may counteract the expected rising of smoking prevalence in Angola
while tobacco use is still relatively low.
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Abstract  
This cross-sectional survey with 2,357 subjects aged 15 to 64 years from a rural-urban 
community in Bengo Province, Angola, aimed to evaluate the gender differences in the 
prevalence of body mass index categories and how socio-demographic characteristics 
influence it. Women presented a significantly higher prevalence of obesity (10.5% versus 
2.8%) but the underweight frequency was similar to men (10.2% versus 12.4%). Overweight 
and obesity increased with age, with underweight being more prevalent in the age group 15 
to 24 years. Obesity was more prevalent among individuals living with a companion (in a 
marital relation), decreased with education (in women), but was higher in rural areas, and for 
those with a higher family monthly income, in both genders. The prevalence of obesity and 
underweight were similar in women, reflecting a nutrition transition state. Like in other African 
communities, women present a higher prevalence of overweight and obesity them men, but 
the values of underweight are similar between genders. This stresses the need of designed 
health interventions for women, to face the double burden and accumulation of risk factors in 
women. 
 
Keywords: Sub-Saharan Africa, Underweight, Obesity, Prevalence, Nutritional transition. 
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Introduction 
Overweight and obesity are major public health problems, consistently associated with 
increased risk of non-communicable diseases (NCD).1 Between 1980 and 2013 the 
proportion of adults with overweight and obesity increased worldwide, from 28.8% to 36.9% 
in men and from 29.8% to 38.0% in women,2 a phenomenon observed in all regions of the 
world.1-5 However, the other extreme of body mass index (BMI), underweight, remains an 
important social and health threat, associated with increased risk of morbidity and 
mortality,1,7 and it is only slowly decreasing in Africa.6 
 
Sub-Saharan Africa (SSA) faces a demographic and epidemiologic transition.8-11 
Urbanization, sedentary lifestyles and nutritional changes towards westernized diet, high in 
sugar and fats, led to an increased obesity and NCD prevalence that coexists with the 
burden of communicable diseases.8-13 This dual burden presented in national vital statistics 
also reflect potential inequalities at the level of households, with gender or generation 
differences in food allocation related to social norms.10 
 
Angola faces an increase in premature deaths caused by NCD and high rates of maternal 
and child mortality due to infectious diseases,14 as described by the early stage of the 
nutrition transition.9 One child in twelve does not survive to the age of five,15 with malnutrition 
as an underlying cause of most deaths, with 38.0% of children stunted and 15.6% 
underweight.16 However, data on gender, poverty, and health related issues is lacking in the 
country.17 
 
In this report, we present the prevalence of BMI categories in 15 to 64 years-old inhabitants 
of a well-defined community of Angola, evaluating its distribution according to gender and 
socio-demographic characteristics. 
 
Methods 
The results shown in this paper where extract from a community-based survey conducted in 
the catchment area of the Dande - Health Demographic Surveillance System (Dande-HDSS), 
located in the Dande Municipality, in Bengo Province, Angola.18  
 
A representative sex- and age-stratified random sample of the Dande-HDSS population 
(60,075 people) was drawn to constitute the baseline of a large prospective survey on 
cardiovascular risk factors, the CardioBengo.19 Participants were evaluated following the 
published protocol,19 based on the World Health Organization (WHO) STEPwise approach to 
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Surveillance (STEPS) to Chronic Disease Risk Factor manual (core and expanded version 
3.0).20  
 
A total of 2484 individuals (15 to 64 years old) were evaluated between September 2013 and 
March 2014. We excluded 116 pregnant women due to the fact that anthropometric 
parameters vary during pregnancy, and 11 individuals with missing data on anthropometric 
measurements, making the final sample of 2,357 individuals. 
 
Demographic and social characteristics 
Information on age, completed years of school education, marital status, monthly family 
income, were collected through a structure interview.19,20 For analysis, age was categorized 
into five 10-year age groups: 15 to 24; 25 to 34; 35 to 44; 45 to 54; and 55 to 64 years old. 
Education was categorized according to the number of completed schooling years as none; 1 
to 4 years; 5 to 9 years; 10 years or more. Marital status was classified into three categories: 
Single, divorced, widower (living alone); Single (living with parents); Married (living with a 
companion). Monthly family income in kwanzas was converted into United States Dollars 
(USD) at the currency valid in 2014, and categorized into groups of no income; under or 
equal to 150 USD; 151 to 299 USD; and greater or equal to 300 USD. The area of residence 
was classified as rural or urban as previously described.18  
 
Anthropometric measurements 
Trained interviewers and certified health professionals conducted all anthropometric 
measurements as described before.19 BMI was calculated as weight (kg) divided by squared 
height (m2), and further categorized according to WHO as underweight (<18.5 kg/m2), normal 
(18.5 to 24.99 kg/m2), overweight (25.0 to 29.99 kg/m2), and obese (≥30 kg/m2).3 
 
Statistical Analysis 
Data were double entered into a PostgreSQL® database and imported into SPSS® version 23 
(IBM, New York, USA) for statistical analysis. Post-stratification survey weights were 
calculated using the known sex and categorical age distribution of the Dande-HDSS 
population,19 and these were used in all further calculations. Descriptive data are reported as 
absolute frequencies and percentages, and means and standard deviations when 
appropriate. Pearson’s chi-square test or Fisher’s exact test were used to assess the 
independence of BMI categories and socio-demographic characteristics, with a significance 
level of p<0.05. Prevalence estimates with a 95% confidence interval (95% CI) were 
computed for BMI categories by socio-demographic characteristics. 
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Ethics 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki 
and all procedures involving human subjects/patients were approved by the Ethics 
Committee of the Angolan Ministry of Health. Written informed consent was obtained from all 
subjects/patients (in the case of under 18 years old, their parent or legal guardian). 
 
Results 
The study population had a mean age of 32.5 (±13.6) years, with women (34.4±13.7 years) 
older than men (30.5±13.2 years) with 9.2% being older than 54 years. Approximately one-
fifth of the population lived in rural areas and 16.6% of women and 1.4% of men had no 
formal education, with 51.1% of women having 4 or fewer years of formal education 
compared to 12.3% of men. The majority of the population (54.5%) reported living 
accompanied, women living alone (15.9%) more frequently them men (8.6%). Only 14.7% of 
the population had a monthly family income equal or superior to 300 USD, 56.4% presenting 
an income inferior to 150 USD, lower for women (Table 1). 
 
The mean BMI was 23.5 (±4.9) Kg/m2 in women and 21.8 (±3.4) Kg/m2 in men. The overall 
prevalence of obesity was 6.8%, significantly higher in women (10.5%) than in men (2.8%). 
The proportion of overweight and obesity was 31.1% (95% CI 28.6, 33.8) in females and 
13.5% (95% CI 11.6, 15.6) in males, with the gender prevalence of underweight being similar, 
10.2% for females and 12.4% for males (Table 1). 
 
The prevalence of overweight and obesity increased with age, obesity peaking in the age 
group 35 to 44 years, with 19.7% in females and 7.3% in males; underweight was more 
prevalent in the age group 15 to 24 years, 18.5% in females and 18.4% in males. Obesity 
prevalence has higher in urban areas, in both sexes (Table 2). 
 
The prevalence of overweight and obesity decreased with education in women but increased 
in men. The lowest frequency of overweight and obesity are found among the individuals 
living with parents, in both sexes. Prevalence of overweight and obesity tended to be highest 
among participants with a monthly income above 150 USD in both sexes, with underweight 
higher in females (11.7%) with no income (Table 2). 
 
Discussion 
Nationally representative studies of obesity in sub-Saharan Africa are scarce. The studies 
that are available, though, suggest that obesity rates vary widely from country to country, 
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lacking strong evidence to support further comparisons and an adequate picture of the region, 
and a first local approach is needed to better design future interventions.  
 
The 6.8% obesity prevalence encounter is lower than the 8.8% estimation made by NCD-
RisC for 2014,6 but similarly higher in females. This lower value that of the national estimates, 
possibly is due to the fact that the survey region is a tampon to Luanda, the capital of Angola, 
where people from the inner regions of the country, with less westernization of life patterns, 
tend to live and where the recent economic growth is not yet felt. 
 
However, the mean BMI found is similar to the mean BMI calculated for the Africa Region in 
2008 (23.9 Kg/m2 in women and 21.8 Kg/m2 in men),5 and the pooled prevalence of 
overweight and obesity in the SSA region of 22.2% estimated in 2010,4 being 22.7% (95% CI 
21.0, 24.4) in our study.  
 
In all reviews and WHO appraisals for African regional trends obesity is rising in the last 
decades according to the stages of nutrition transition.6,8,11,13 If this tendency confirms also 
for the Dande-HDSS population, in the next decade the prevalence of overweight and 
obesity will increase, raising the concern for action related with NCD and associated risk 
factors. 
 
The Dande-HDSS was developed as a district-level surveillance system in an urban and 
rural setting and is not representative of the demographic structure of Angola, but the 
findings, though not immediately generalizable, reveal the coexistence of similar levels of 
underweight and obesity, especially in urban areas and among females, common in the 
region,13,21 as shown in studies conducted in South Africa,22 Ghana,23 and Nigeria.24 
 
The prevalence of overweight and obesity is higher in women in all regions of the 
world.2,5,10,12 In SSA countries, like Angola, an increased level of body fat is associated with 
prosperity and health, and the ideals of feminine beauty includes chubbiness.25 Being slim, in 
contrast, is perceived to be a sign of illness or poverty and is something to be feared and 
avoided, particularly in recent years, when it has been associated with AIDS.12,26 This cultural 
factor that enhances the probability of obesity in SSA women and other known associations 
of obesity with the urbanization process, socioeconomic status, and education,5,9-14 puts the 
female gender more expose to this risk factor. 
 
Education and monthly income are essential socio-demographic determinants to 
consider.10,11,21-24,25 We found a higher prevalence of overweight and obesity among subjects 
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with higher income regardless of gender but only women with a lower level of education 
presented a higher prevalence of overweight and obesity. Higher incomes tend to be 
associated with differentiated professions, more sedentary, and to allow access to a more 
rich diet. If you associated the lower level of education of women (traditionally with domestic 
occupations) and the lack of knowledge to make the healthier choices (usually the family 
planner of meals), these factors can explain the results encountered. This is also compatible 
with other studies results, where living with a companion is associated with higher body 
weight.27 
 
BMI is an indicator of multifactorial exposures, mainly behavioral and environmental in nature, 
such as caloric intake and physical activity, with individual genetic profile also having a role.28 
A closer surveillance of populations is needed, to detect changes in the so-called cause of 
the causes or interactions between this factors. This study provides a much-needed baseline 
for the evaluation of trends and interventions in Angola, even if of a more local framework. 
The frequency of NCD is expected to increase but data is still lacking and there must be a 
specific effort to accommodate a new reality to a health system mainly prepared to deal with 
the burden of infectious diseases, even at the level of information processes.  
 
The training of human resources and the aim of the policies shall reflect this changes,13 and 
incorporate appropriate responses to approach therapeutic and preventive health care, 
taking advantage of infectious diseases programs already in place,29 and prioritizing the 
global obesity epidemic, one of seven risk factor targeted by the WHO “Global Action Plan 
for the Prevention and Control of NCDs, 2013/2020”.30 
 
Conclusion 
Obesity and underweight have a similar impact in this population describing an early stage of 
nutrition transition. Prevalence of overweight and obesity was higher in urban areas, among 
older individuals with a larger income, in both genders, and amongst more educated males. 
Female lower education and income compared with male, increases the need for dedicated 
health promotion programs that tackle the gender issue. Together with the double burden of 
communicable and NCD, this fight becomes more relevant in women if we consider that in 
the majority of the families they are the daily diet planners.   
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Abstract  
From a community-based survey conducted in Angola, 468 individuals aged 40 to 64 years 
and not using drug therapy, were evaluated according to the World Health Organisation 
STEPwise Approach to Chronic Disease Risk Factor Surveillance. Using data from tobacco 
use, blood pressure, blood glucose and total cholesterol levels, we estimated the 10-year risk 
of a fatal or nonfatal major cardiovascular event and computed the proportion of untreated 
participants eligible for pharmacological treatment according to clinical values alone and total 
cardiovascular risk. The large majority of participants were classified as having a low (<10%) 
10-year cardiovascular risk (87.6%), with only 4.5% having a high (≥ 20%) cardiovascular 
risk. If we consider the single criteria for hypertension, 48.7% of the population should be 
considered for treatment. This value decreases to 22.0% if we apply the risk prediction chart. 
The use of hypoglycaemic drugs does not present any differences (19.0% in both situations). 
The use of lipid-lowering drugs (3.8%) is only recommended by the risk prediction chart. This 
study reveals the need and urgency of pharmacological treatment for cardiovascular 
disorders in this population, integrated with non-pharmacological measures. Risk prediction 
charts can be used, which globally improves the efficacy of interventions and reduce costs. 
 
Keywords: Angola, hypertension, diabetes, hypercholesterolemia, risk assessment. 
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Introduction 
Cardiovascular diseases (CVD) caused 17.9 million deaths worldwide in 2015, a number that 
has increased globally by 12.5% since 2005, with almost 80% of these deaths occurring in 
low and middle-income countries [1]. Their common occurrence and associated mortality, 
loss of independence and productivity, impaired quality of life, and social and economic costs 
are compelling reasons for public health concern globally [2].  
 
The epidemiology of CVD is distinctly different in sub-Saharan Africa (SSA), compared to the 
rest of the world, where an unprecedented decline in mortality and a corresponding increase 
in the life expectancy at birth are shifting the epidemiological landscape of the region [3]. 
Countries in this region, where Angola is located, face a double burden as they struggle to 
cope with non-communicable and infectious diseases associated with lack of socio-economic 
development [3]. 
 
In 1990 the percentage of deaths by CVD in the region was 7.5% (the fourth cause of death), 
rising to 11.2% in 2015, being the third cause of mortality [4]. Myocardial infarctions, together 
with strokes, were responsible for 10.8% of deaths among females and 8.6% in males, in 
2015 in SSA [4]. This represents an increase in mortality of 38.0% for stroke and 52.1% for 
myocardial infarction in both sexes, since 1990 [4], revealing a rising trend of CVD in SSA. 
The estimates made for Angola follow the same pattern, with strokes being responsible for 
5.4% and myocardial infarction for 4.7% of all deaths, in 2015 - the fourth and sixth cause of 
mortality in Angola, respectively [4]. 
 
Risk factors for CVD are shared with the majority of non-communicable diseases and are 
due to exposure to behavioural risk factors: tobacco and alcohol consumption, unhealthy diet, 
and physical inactivity; individually modifiable. These unhealthy behaviours influence 
metabolic pathways and ultimately result in intermediate risk factors: obesity, hypertension, 
diabetes and dyslipidaemia [5-7].  
 
Common approaches that address behavioural and metabolic risk factors, which often 
coexist in the same person and act synergistically to increase an individual’s total risk, are 
proven effective for prevention [6,7], but in some settings, the risk factors are tackled one-by-
one, without a common strategy. To design the right strategy for an individual, it is important 
to realise his/her ‘global risk’ of developing CVD [7-9]. The World Health Organization (WHO) 
and the International Society of Hypertension (ISH) created a risk prediction chart [8], which 
can be applied in different populations.  
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In this short report, we aimed to quantify the proportion of individuals eligible for 
pharmacological treatment for hypertension, diabetes and hypercholesterolemia according to 
single risk factor and total cardiovascular risk approaches, according to the WHO-ISH risk 
prediction chart. 
 
Materials and Methods 
The present analysis results from CardioBengo, a community-based study conducted in the 
catchment area of the Dande - Health Demographic Surveillance System (Dande-HDSS), 
located in the Dande Municipality, in Bengo Province, Angola [10]. This survey, done 
between September 2013 and March 2014, constitutes a larger baseline on cardiovascular 
risk factors [11], being based on the WHO STEPwise approach to Surveillance (STEPS) to 
Chronic Disease Risk Factor manual (core and expanded version 3.0) [12]. 
 
Sample characterization 
A representative sex- and age-stratified random sample list was drawn from the Dande-
HDSS population database (15 to 64 years old) and a total of 2,484 individuals were included 
in the CardioBengo study [11,13]. 
 
Based on the WHO-ISH risk prediction chart criteria of application [8], only individuals aged 
40 or older were considered for analysis. From the initial 688 participants aged 40–64 years, 
123 were excluded because of missing information in any of the parameters, and another 97 
excluded because they were receiving pharmacological treatment for any of the three 
conditions. The final sample consists of 468 participants, not significantly different from the 
initial 688 participants considered for analysis regarding place of residence, sex, age, or 
education. 
 
Data collection 
Participants were evaluated by trained interviewers and certified health professionals. As 
previously described in the CardioBengo study protocol [11], information on age and tobacco 
consumption were collected through an interview, and blood pressure and all clinical 
measurements (measured only in participants with overnight fasting) were obtained with the 
use of point of care devices, namely: automatic sphygmomanometer OMRON M6 Comfort 
(OMRON Healthcare Europe BV, Hoofddorp, The Netherlands); blood glucose meter ACCU-
CHEK Aviva (Roche Diagnostic, Indianapolis, USA); and ACCUTREND Plus (Roche 
Diagnostic, Indianapolis, USA) with ACCUTREND CHOLESTEROL reactive strips (Roche 
Diagnostic, Indianapolis, USA) [11]. 
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Prediction methods and eligibility for pharmacological treatment 
The WHO-ISH prediction chart for the Africa D region was used to classify each participant 
regarding the individual absolute cardiovascular risk [8], based on sex (male or female), age 
(40–49, 50–59 and ≥ 60 years), current smoking status (non-smoker or smoker), systolic 
blood pressure (SBP) (120-139, 140–159, 160–179, and ≥ 180 mmHg), total blood 
cholesterol (4, 5, 6, 7 and 8 mmol/l) and diabetes (presence or absence, considering the 
WHO cut point of 6.9 mmol/l [14]).  
 
The WHO-ISH prediction charts estimate the 10-year risk of a fatal or nonfatal major 
cardiovascular event (myocardial infarction or stroke) expressed in five categories - ≤10% 
(low), 10–19% (moderate), 20–29% (high), and ≥30% (very high) - in people who do not 
have established cardiovascular diseases [8]. 
 
The eligibility for treatment with antihypertensive, hypoglycaemic or lipid-lowering drugs was 
defined according to the WHO guidelines for assessment and management of cardiovascular 
risk [8]. Also, eligibility for treatment according to the single risk factor approach was 
considered: for antihypertensive drug use SBP of ≥140 mmHg [15]; for hypoglycaemic drug 
use fasting blood glucose >6.9 mmol/l [14]; and for lipid-lowering drugs use a total blood 
cholesterol level ≥8 mmol/l [9]. 
 
Statistical Analysis 
Data were double entered into a PostgreSQL® database and imported into SPSS® version 
23 (IBM, New York, USA) for data analysis. Descriptive data are reported as absolute 
frequencies and percentages. We estimated the proportion of participants classified in 
different categories of total cardiovascular risk, as well as the proportion of subjects eligible 
for pharmacological treatment (according to the different criteria), by sex. We consider a 95% 
confidence interval (95% CI) for all proportions calculated. 
 
Ethical approval  
All procedures performed in this study were in accordance with the standards of the Ethics 
Committee of the Angolan Ministry of Health, and with the 1964 Helsinki declaration and its 
later amendments. Written informed consent was obtained from all participants. 
 
Results 
The majority of the population in this study was female (69.7%) following the structure of the 
Dande-HDSS [10], with 17.9% of the population aged above 60 years. Smoking was more 
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frequent among men (18.3% versus 7.4% in women) with almost half the population (48.7%) 
presenting a SBP ≥140 mmHg, with a higher occurrence in women (52.5% versus 40.1% in 
men). None of the individuals presented total blood cholesterol >8 mmol/l, with only women 
presenting values >7 mmol/l (6.1%). The prevalence of diabetes was similar among men and 
women (18.4% in women and 20.4% in men), with almost 10% of the population having both 
SBP ≥140 mmHg and diabetes (table 1). 
 
Table 1. Characteristics of the participants and prevalences by sex. 
  Total (n = 468) Female (n = 326) Male (n = 142) 
  % (95% CI) % (95% CI) % (95% CI) 
Age (years)    
40-49 36.3 (32.1-40.8) 35.0 (30.0-40.3) 39.4 (31.7-47.6) 
50-59 45.7 (41.2-50.2) 47.9 (42.5-53.3) 40.8 (33.1-49.0) 
≥ 60 17.9 (14.7-21.6) 17.2 (13.5-21.7) 19.7 (14.0-27.0) 
Current smoking status    
Non-smoker 89.3 (86.2-91.8) 92.6 (89.2-95.0) 81.7 (74.5-87.2) 
Smoker 10.7 (8.2-13.8) 7.4 (5.0-10.8) 18.3 (12.8-25.5) 
Systolic blood pressure (mmHg)    
120-139 51.3 (46.8-55.8) 47.5 (42.1-52.9) 59.9 (51.7-67.6) 
140-159 26.7 (22.9-30.9) 26.7 (22.2-31.8) 26.8 (20.2-34.6) 
160-179 14.3 (11.4-17.8) 16.6 (13.0-21.0) 9.2 (5.5-15.1) 
≥ 180 7.7 (5.6-10.4) 9.2 (6.5-12.8) 4.2 (1.9-8.9) 
Total blood cholesterol (mmol/l)    
4  55.6 (51.1-60.0) 52.1 (46.7-57.5) 63.4 (55.2-70.9) 
5  27.1 (23.3-31.3) 26.7 (22.2-31.8) 28.2 (21.4-36.1) 
6  13.0 (10.3-16.4) 15.0 (11.5-19.3) 8.5 (4.9-14.2) 
7  4.3 (2.8-2.8) 6.1 (4.0-9.2) 0 
8  0 0 0 
Diabetesa    
Absence 81.0 (77.2-84.3) 81.6 (77.0-85.4) 79.6 (72.2-85.4) 
Presence 19.0 (15.7-22.8) 18.4 (14.6-23.0) 20.4 (14.6-27.8) 
With SBP >140 mmHg and Diabetes 9.8 (7.4-12.8) 9.5 (6.8-13.2) 10.6 (6.5-16.7) 
a Fasting blood glucose ≥6.9 mmol/l 
 
Most of the participants (87.6%) were classified as having low (<10%) 10-year 
cardiovascular risk. The frequencies were 7.9%, 2.6% and 1.9% for the cardiovascular risk 
category 10–19 (moderate), 20–29 (high) and ≥30% (very high), respectively. Women 
presented higher frequencies than men in all cardiovascular risk categories above the 
moderate level and the total cardiovascular risk increased with age (table 2). 
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Table 2. Distribution of 10-year risk of a fatal or nonfatal major cardiovascular event, 
acording to sex and age. 
 Total, % (95% CI) 
  ≤10% 
Low 
10-19% 
Moderate  
20-29 % 
High 
≥30% 
Very High 
40-49 years 34.2 (30.0-38.6) 1.3 (0.6-2.8) 0.6 (0.2-1.9) 0.2 (0.0-1.2) 
50-59 years 40.6 (36.2-45.1) 3.6 (2.3-5.7) 0.6 (0.2-1.9) 0.9 (0.3-2.2) 
≥ 60 years 12.8 (10.1-16.2) 3.0 (1.8-5.0) 1.3 (0.6-2.8) 0.9 (0.3-2.2) 
Total 87.6 (84.3-90.3) 7.9 (5.8-10.7) 2.6 (1.5-4.4) 1.9 (1.0-3.6) 
 Female, % (95% CI) 
 ≤10% 
Low 
10-19% 
Moderate  
20-29 % 
High 
≥30% 
Very High 
40-49 years 32.5 (27.7-37.8) 1.5 (0.7-3.5) 0.6 (0.2-2.2) 0.3 (0.1-1.7) 
50-59 years 41.7 (36.5-47.1) 4.0 (2.3-6.7) 0.9 (0.3-2.7) 1.2 (0.5-3.1) 
≥ 60 years 11.7 (8.6-15.6) 3.1 (1.7-5.6) 1.8 (0.8-4.0) 0.6 (0.2-2.2) 
Total 85.9 (81.7-89.3) 8.6 (6.0-12.1) 3.4 (1.9-5.9) 2.1 (1.0-4.4) 
 Male, % (95% CI) 
 ≤10% 
Low 
10-19% 
Moderate  
20-29 % 
High 
≥30% 
Very High 
40-49 years 38.0 (30.5-46.2) 0.7 (0.1-3.9) 0.7 (0.1-3.9) -a 
50-59 years 38.0 (30.5-46.2) 2.8 (1.1-7.0) -a -a 
≥ 60 years 15.5 (10.5-22.3) 2.8 (1.1-7.0) -a 1.4 (0.4-5.0) 
Total 91.5 (85.8-95.1) 6.3 (3.4-11.6) 0.7 (0.1-3.9) 1.4 (0.4-5.0) 
a No individuals in this category 
 
Considering only the criteria of SBP ≥140 mmHg, 48.7% of the population should be 
considered for treatment with antihypertensive drugs, but if we apply the WHO/ISH criteria 
based on the prediction chart, this number will decrease by more them half to 22.0%. On the 
other hand, the use of lipid-lowering drugs is not considered for any individual by the singular 
criteria, but if we apply the prediction chart, this number rises to 3.8% (table 3). 
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Table 3. Frequencies of individuals who require pharmacological treatment by sex. 
 Single risk criteria Considering WHO/ISHa risk prediction 
  Total, % 
(95% CI) 
Female, %  
(95% CI) 
Male, %  
(95% CI) 
Total, %  
(95% CI) 
Female, %  
(95% CI) 
Male, %  
(95% CI) 
Antihypertensive drugs 
48.7  
(44.2-53.2) 
52.5  
(47.0-57.8) 
40.1  
(32.4-48.4) 
22.0  
(18.5-26.0) 
25.8  
(21.3-30.8) 
13.4  
(8.7-20.0) 
Lipid-lowering drugs -b -b -b 
3.8  
(2.4-6.0) 
4.9  
(3.0-7.8) 
1.4  
(0.4-5.0) 
Hypoglycaemic drugs 
19.0  
(15.7-22.8) 
18.4  
(14.6-23.0) 
20.4  
(14.6-27.8) 
19.0  
(15.7-22.8) 
18.4  
(14.6-23.0) 
20.4  
(14.6-27.8) 
a World Health Organization/International Society of Hypertension 
b No individuals in this category 
 
Discussion 
Only 4.5% of the population was classified as having at least a high (≥20%) cardiovascular 
risk. These results are in accordance with those described in other populations of the 
continental sub-Saharan Africa, namely 3.7% in Mozambique [16] and 5% in Nigeria [17], or 
in other low and middle-income countries in Asia (4.9% in rural India, 1.3% in Cambodia, 
2.3% in Malaysia and 6% in Mongolia) [18,19].  
 
In all these surveys, the accumulation of risk factors exists in different levels. In our 
population, almost one tenth accumulated at least two major risk factors (hypertension and 
diabetes). This raises additional concerns when we compare these results with the 
awareness levels for the conditions studied in our population - 48.5% among hypertensive 
individuals, 10.8% for diabetes and 4.2% for hypercholesterolemia (13).  
 
Even with the need to interpret cautiously the results - because they are based in a survey 
with only one time measure of blood pressure, blood glucose and lipids, and there is a 
chance that individuals enrolled did not report correctly the fasting period before the readings 
– this survey disclose an emerging public health issue and provides additional information on 
the impact of the use of risk prediction charts.   
 
According to the WHO guidelines for assessment and management of cardiovascular 
diseases [8], at least one quarter of the participants would be eligible for treatment with 
antihypertensive drugs, whereas if only the single criteria were applied for hypertension, 
almost half would be considered for pharmacological treatment.  
 
Results | 111 
The use of the WHO-ISH risk prediction chart has already been proven as more cost 
effective than other approaches that make treatment decisions based on individual risk-factor 
thresholds only, especially for hypertension management [7,20-22]. In a South-African study, 
different strategies for initiation of drug treatment were tested, and the conclusion points to 
the fact that hypertension treatment based on the total cardiovascular risk is more effective at 
saving lives and less costly than those based only on the BP level [23]. 
 
In this prediction chart, we included the total cholesterol measurement, however, the WHO-
ISH chart offers the possibility of not using this measurement [8]. The use of laboratory (or 
point of care) assessment in low-resource settings is dispensable, avoiding additional costs 
to the system without losing a significant predictive power or introducing an overconsumption 
of drugs, allowing for a better targeting of resources to those who are more likely to develop 
CVD [24,25]. 
 
The high percentage of individuals that requires pharmacological treatment for diabetes 
(19.0%, very similar between gender) is alarming, considering that diabetes alone is a very 
important health condition, but also an important risk factor for CVD - adults with diabetes 
have a two or three times higher rate of CVD than adults without diabetes [8,26].  
 
Health promotion initiatives such as smoking cessation, and individual advisement on 
specific lifestyle and diet control are also strategies necessary to align with the use of 
pharmacological treatments. Even if some of the proposed methodologies (statins for 
hypercholesterolemia, for example) cannot be easily applied due to the steady supply of 
drugs, changes to personal lifestyle should be encouraged, with good results in the decrease 
of the global cardiovascular risk [17,20,21]. 
 
The focus of targeting high-risk people through a total cardiovascular risk approach instead 
of a single risk factor approach reduces health care expenditure by reducing drug costs [17]. 
However, to diminish CVD burden in the entire population in a sustainable way, wider 
interventions are needed. The focus should be on the primary healthcare, where the majority 
of the individuals have access, allowing for the promotion of opportunistic screening of CVD 
risk factors and patient registration and tracking, with a better use of available resources [22]. 
 
Conclusion 
The use of the WHO-ISH guidelines for cardiovascular risk prediction reduces to half the 
population eligible for pharmacological treatment with antihypertensive drugs. Taking into 
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account the evidence on positive effects of different approaches to manage risk factors at a 
population level, the substantial differences in the number of individuals eligible for treatment 
according to the distinct criteria suggests that considering the total cardiovascular risk may 
allow a more wise use of resources available.   
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5. General discussion 
Angola is located in Central Africa (WHO region D) and classified by the World Bank as 
upper-middle-income country.111 However, this classification does not reflect the Human 
Development Index (HDI), which categorises Angola in the low human development group 
(rank 149 of a total 188 countries), and the inequality-adjusted HDI reduces this ranking by 
eight places.112 
 
After an aggregated period of 40 years of colonial (from 1961 to 1974) and civil war (from 
1975 to 2002), Angola started to develop its extracting industry (mainly crude oil), allowing 
the country to become one of the emerging economies of the 21st century that have suffered 
a significant blow in the recent global economic crisis.111  
 
Like many other transitional economies, Angola is undergoing a rapid demographic transition 
characterised by an increase in longevity that will alter the age-sex structure of the 
population.106 The life expectancy at birth is expected to rise from the actual 61 years to 69 
years between 2015 and 2050, together with a reduction in fertility from 5.5 new-borns per 
woman in 2015 to 3.2 in 2050.106 
 
With the economic growth and recent crisis, and considering the age-sex structural transition, 
a rising trend in the CVD burden is expected, putting the country in an epidemiological and 
nutritional transition period. During this time, CVDs and other NCDs will co-exist with 
infectious diseases and maternal and child deaths (one of the highest in the world),2,112 in a 
setting barely prepared to deal with the existing health problems. As already mentioned, data 
on gender-, poverty- and health-related issues lack in the country.112   
 
With this national social pattern as its background, this thesis elaborated on the epidemiology 
of CVD risks factors in an adult population from the Dande-HDSS. Without attempting to 
make general predictions at a national level, the similarities between the studied population 
and the national demographic structure were discussed in Section 3.1, allowing us to 
consider the results extracted from this survey as a good predictor of and strong evidence for 
future planning of health policies for CVDs in Angola. 
 
As a first result, we must point to the immediate effect on the health structures of the region. 
The implementation of an epidemiological survey with this magnitude (nearly 10% of all 
adults between the ages of 15 and 64 years were enrolled in the study) created a larger 
occurrence of hypertension and diabetes cases for the Bengo General Hospital. As a 
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response, and integrated into the extensive protocol CardioBengo, a new service dedicated 
to cardiovascular and metabolic disorders was created to respond to the nearly 10 new 
cases detected each day.  
 
CardioBengo, more than a single community-based survey, launched the foundation to 
further prospective studies, in particular among the younger age groups in this survey, to 
allow CVD research to become a reality in Angola. This thesis only analysed part of the data; 
other Angolan researchers are developing research work, especially in population genetics 
background and clinical outcomes. A large dataset is yet to be explored, and diet and 
physical activity variables need to be fine-tuned and related with other risk factors. Regarding 
the results shared in this thesis, an integrated discussion of the epidemiological observation 
is suggested in the next paragraphs. 
 
As expected, all risk factors were more frequent in older ages.2,22,23 However, the concept of 
older ages in this population must be reconsidered. Only 3.6% of this population was above 
65 years104,105 and were not represented in this study. The outcomes of CVD in developing 
countries (like Angola) occur 10 to 15 years earlier than in developed countries,25 and older 
ages with the higher prevalence of risk factors in the studied population were between 45 to 
54 years and 55 to 64 years, in both sexes. 
 
The differences between genders were clear in this survey, putting the female gender at the 
top of risk factor prevalence. In addition to the natural causes related to ageing (women live 
longer than men),27 and hormone regulation post-menopause,26 women accumulate other 
social disadvantages, like less education and income. Also, the cultural aspects of African 
societies that encourage overweight among females113 create additional pressure in this 
group. The only risk factor that was lower in females was smoking, which is culturally 
accepted among men but not for women. 
 
Urbanisation is taking its toll, with a higher prevalence of diabetes, hypercholesterolaemia 
and obesity in urban areas for this population. These risk factors are related to unhealthy 
diets and physical inactivity, common among urban dwellers.11,86,87 However, a better 
clarification of urban and rural areas for this region is needed. The concept of peri-urban 
areas (dispersive urban growth) possibly applies to the Dande-HDSS area due to the 
proximity to Luanda, the capital of Angola, and the migration patterns between these regions, 
making the influence of urbanisation in this population unclear.  
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Lower educational levels were associated with a higher prevalence of all behavioural risk 
factors for this population (except in men for obesity), following the pattern in high-income 
countries.82 The relationship between education and obesity in developing societies tends to 
follow the opposite direction, with more educated individuals presenting a higher prevalence 
of obesity84 due to a more sedentary life and “eating out”. 
 
Family income was also analysed in this population for the first time, and additional 
improvements are needed to access the population’s income levels. A higher income was 
associated with a lower prevalence of smoking and a higher prevalence of obesity. A better 
definition of this variable in this context is already in place, interconnecting other economic 
aspects of the individual and household incomes. 
 
Considering the standard of comparison among populations, which include only adults above 
the age of 25 years, almost a quarter of this population presents raised blood pressure, a 
high value, but aligned with the SSA region. Also, the cumulative incidence rate of 12.2% is 
higher than the majority of rates encountered in developed countries. Due to the novelty of 
this finding in SSA, comparing results to other regional studies is not possible.  
 
Hypertension is the CVD risk factor better studied in Angola and in SSA, affecting both sexes 
in similar values (but in a heavier weight in females), individuals with lower educational levels 
and associated with urban areas. However, in our study, it was higher in rural dwellers, 
possibly related to the migration patterns of the region with individuals exposed to the urban 
environment.  
 
The prevalence level of diabetes was aligned with the mean values encountered for SSA but 
was higher than the predictions and values from other studies conducted in Angola in the last 
15 years. The importance of this risk factor alone and association with all other risk factors 
justifies further follow-up of the diabetic population not only for the management of the 
disease, but also for a better understanding of the disease evolution and relation to possible 
metabolic syndrome. 
 
Hypercholesterolemia is the least studied metabolic risk factor in SSA, mainly due to the 
difficulties in implementing laboratory tests with confidence. We applied point of care 
technology with fair results limited to total blood cholesterol levels. The prevalence was 
relatively low, but association with other risk factors raises the total risk prediction for this 
population. Hypercholesterolemia is also a good predictor of the influence of unhealthy diets 
and sedentary life styles and should be further studied in this population. 
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The levels of awareness, treatment and control were low for hypertension. Because diabetes 
and hypercholesterolaemia were first studied in this population with the CardioBengo 
implementation, the levels of awareness, and consequently of treatment and control, were 
even lower. These values are aligned with the SSA region and highlight the increased 
urgency for intervention. This population was not previously targeted by any health program 
or initiative that promoted healthier lifestyles or provided diagnoses, but the few participants 
that were aware and under treatment for any of the conditions reported a health professional 
suggested non-pharmacological measures to prevent CVD.   
 
Obesity presented similar prevalence values as underweight, revealing the nutritional 
transition that this population is facing. Women were more obese than men, like other studies 
for SSA reveal.76,77 Obesity was associated with all the other risk factors, from hypertension 
to smoking, meaning that this risk factor is the primordial target for health promotion 
campaigns, but having in mind the limitation in food choices and cultural habits. 
 
Smoking prevalence was not high when compare with values worldwide, but it was 
associated with alcohol consumption and was a risk factor present in the majority of 
individuals with other risk factors, especially hypertension. This prevalence value, and 
general low level of nicotine dependence, implies an urgent implementation of restrictive 
policies for tobacco, before this value rises. 
 
Pharmacological treatment for some of these conditions can be a problem in terms of 
associated costs and availability of drugs. However, it must be consider, especially for 
individuals that already had clinical episodes of CVD or have long-term hypertension and/or 
diabetes. The use of guidelines for cardiovascular risk prediction is proven effective and 
efficient in the use of resources available in the region.21,22,93 If treatment is well-integrated in 
a “holistic” approach, with non-pharmacological measures in place, the results can improve, 
both in the individual and in the general population.21,93,94  
  
Having this knowledge for future local health policy planning is an advantage for public health 
practitioners; however, they should not plan alone. Politics, academia and international donor 
partners of the Angolan government must recognize that CVDs and associated risk factors 
already exist in the country, and if nothing is done, the costs of future interventions will rise 
and lose efficacy.114 
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The global health community is concern with CVDs and NCDs in general. The WHO, 
together with other multi-stakeholder organisations, is providing technical support and 
collecting evidence every day to find the “best buy” for NCD prevention, management and 
treatment. Most of this knowledge originates from high-income societies and is not adapted 
to the cultural and social pattern of a quick-shifting African society. 4,21,44,69,86,91,93,94,100 
 
Cardiovascular diseases and associated factors are becoming a public health problem, 
which carries economic implications created by premature mortality in an age group (40 to 60 
years) relevant to society due to the investment in its educational level and leadership 
skills.114,115 After the current phase of collecting this evidence, a new stage of implementation 
and interventional research is needed.116  
 
The strategy should include the strengthening of primary care, taking advantage of the 
structures and programs created to deal with infectious diseases. In a continent where health 
professional training and healthcare systems are designed to prevent and manage endemic 
communicable diseases (e.g., malaria, tuberculosis and HIV/AIDS), these resources should 
be maximised and adapted to deal also with NCDs.93,94,100 
 
Because of the limited resources and lack of infrastructure for the diagnosis and 
management of CVDs, possible strategies for strengthening health systems can focus on 
four major areas:64  
1) Development of human resources,  
2) Improvement in infrastructure for diagnosis and management of CVDs,  
3) Implementation of basic registries for mapping of CVDs and risk factors,  
4) Establishment of partnerships with stakeholders outside the health sector.  
 
Some of these solutions are already in place, and only time and continuous research of 
CVDs and associated risk factors can provide results.4,116 
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6. Conclusion 
We were able to create and implement a community-based study to research the 
epidemiology of CVD risk factors and associations between them in the adult population of 
the Bengo Province, in Angola. This survey can constitute the basis of a surveillance system 
for CVDs and NCDs in general for Angola, using a population that presents the same 
demographic structure of the country. 
 
The cultural and social pattern of the population should be considered in the implementation 
of health promotion strategies. The translation of solutions from other regions or countries is 
not possible without the evaluation of the previous environment and interaction among risk 
factors. 
 
The hypertension prevalence is high in this population, and we provide the first evidence that 
it is rising rapidly. Additionally, the current prevalence of diabetes is higher, with 
hypercholesterolaemia also existing. Diabetes and hypercholesterolaemia were higher 
among urban dwellers, where obesity was also higher. Urbanisation marks the rise of diet-
associated risk factors, especially among women. The observed low levels of awareness, 
treatment and control of these three conditions indicate a high burden of undiagnosed and 
uncontrolled conditions, putting additional stress on the need for primary care intervention. 
 
This Angolan population presents a low smoking prevalence, with a low number of daily 
smoked cigarettes and low levels of nicotine dependency, despite the low prices and easy 
access to manufactured cigarettes. The implementation of stronger interventions at the 
beginning of the expected rise in smoking prevalence may halt and reverse the tendency 
observed in the African region. 
 
The prevalence of obesity was similar to the prevalence of underweight, reflecting a nutrition 
transition state. As in other African communities, women present a higher prevalence of 
overweight and obesity than men, but both genders have similar values of underweight. This 
stresses the need for special health promotion and interventions, designed to deal with the 
accumulation of risk factors for different disease groups in the female gender. 
 
There is also an urgent need for pharmacological treatment of cardiovascular disorders, 
integrated with non-pharmacological measures, in this population. This can be created using 
risk prediction charts, which globally improve the efficacy of the interventions and reduce 
costs. 
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  ID: |___| |___| |___|-|___| |___|-|___| |___| |___| |___| - |___| |___| |___|    
                       Bairro                      Sector                             AF                                         ID                           
 
Nome Completo:     |___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___| 
|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|      Consentimento Informado Entregue ! !  
A. Dados sociodemográficos - com recurso a doc ID !(1) ou aproximação ! (2)                                         (Posto #1) 
                                                                      Dia                       Mês                                    Ano 
 
 
B. Análise de sangue (Posto #2)        ID do aparelho: |___|___|+|___|___|+|___|___|     ID do Técnico (abreviatura): |___|___|___| 
   
1. Há quanto tempo fez a sua última refeição?  |___|___| horas                                 NR ! (99) 
 
2. Glucose |___|___|___| mg/dL ! (1) Lo !(2)      Hi !(3) 
      
3. Colesterol total |___|___|___| mg/dL ! (1) Lo !(2)      Hi !(3) 
      
4. Triglicerídeos |___|___|___| mg/dL ! (1) Lo !(2)      Hi !(3) 
 
C. Urianálise (Posto #2)                                                                                                        ID do Técnico (abreviatura): |___|___|___| 
 
1. Tem Schistossomíase (também conhecida por Samba, Kussussa, Sangue na Urina)?          Sim ! (1)         Não ! (0)      NSNR ! (99) 
 
2. Albumina                           ! (1)         ! (2)        ! (3)          ! (4)          ! (5)        ! (6)         ! (7)    
     g/L | mg/L         0,01|10       0,03|30        0,08|80       0,15 |150       0,3|300        1|1000        5|5000  
3. Creatinina                               ! (1)          ! (2)           ! (3)          ! (4)             ! (5) 
 mmol/L | g/L               0,9|0,1          2,2|0,25           8,8|1            17,7|2             >26,5|>3 
 
 Data: |___|___|-|___|___|-|___|___|___|___|                                       Hora de início: |___|___| h |___|___| m 
                        Dia                Mês                         Ano  
1. Data nascimento: |___|___|-|___|___|-|___|___|___|___| 2. Sexo:         Feminino ! (1)                Masculino ! (2) 
3. Qual é a sua profissão:  |___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|               NR! (99)                                  
                                           Desempregado ! (1)                Reformado ! (2)                        Estudante ! (3)                      Inválido ! (4)  
4. É ex-combatente?          Sim, de |___|___|___|___| a |___|___|___|___| ! (1)                              Não ! (0)                                                     NR! (99)  
                                                                                                                                    Ano                                                      Ano 
5. Sabe ler e escrever?      Sim ! (1)                                                        Não ! (0)                                                                                       NR! (99) 
6. Frequentou a escola?    Não ! (0)                                                                                                                                         NR! (99) 
                                           Sim, até ao: |___|___|º ano de escolaridade! (1)                 Sim, |___|___| anos de Ensino Superior ! (2)      
7. Qual o seu estado civil atual:            Solteiro ! (1)            Viúvo ! (2)            Divorciado ! (3)            Casado ! (4)              NR! (99)     
8. E atualmente vive:                            Sozinho ! (1)           Maritalmente ! (2)                   Com os pais ! (3)                         NR! (99)     
9. Por mês, quanto dinheiro entrou em sua casa - considere todas as pessoas (em Kwanzas):                                        NSNR! (99)     
Nenhum! (0)  < 15.000! (1)  15.001 - 30.000! (2)   30.001 - 45.000! (3)   45.001 - 60.000! (4)   60.001 - 75.000! (5)   > 75.000! (6) 
10.  Que línguas sabe falar? (Registe os códigos das 3 principais)   |___|___|            |___|___|           |___|___|                  
11. Qual é a língua em que aprendeu a falar? (Registe o código)   |___|___|                                                                       
12. Qual é a sua religião?    Nenhuma! (0)        Católica ! (1)      Protestante ! (2)      Islamista! (3)         Animista ! (4)         Judaica ! (5) 
Outra! (6)   Especifique: |___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|         NR! (99) 
Encaminhar participante para posto #2 (Análise de sangue e urina) 
Encaminhar participante para posto #3 (Dados Antropométricos) 
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D. Dados antropométricos (Posto #3)                                 ID da balança: |___|___|       ID do Técnico (abreviatura): |___|___|___|  
 
1. Peso |___|___|___|,|___| Kg 3. Altura sentado |___|___|___|,|___| cm 
2. Altura |___|___|___|,|___| cm 4. Perímetro de braço |___|___|___|,|___| cm 
 
E. Consumo de tabaco - perguntar depois de recolher dados antropométricos                                                                       (Posto #3) 
 
1. Fuma ou alguma vez fumou tabaco?              Sim ! (1)                                                                       Não ! (0) NSNR ! (99) !  Passa para F  
2. Se sim, começou a fumar aos |___|___| anos de idade                                                   NSNR ! (99) 
3. Se sim:  
! (1) É ex-fumador ! parou há |___|___|___| anos, fumava |___|___| cigarros/dia ! Passa p/ F 
! (2) Fuma menos de 1 vez/dia  
! (3) Fuma pelo menos: |___|___| cigarros/dia     |___|___| charutos/cigarrilha/dia     Outro: |___|___|___|___|___|___|___|___|___|  
! (99) NSNR 
4. Quanto tempo depois de acordar fuma o primeiro cigarro? 
Após 1 hora ! (0)         Entre ½ hora e 1 hora ! (1)        6 a 30 minutos ! (2)        até 5 minutos ! (3)        NR ! (99) 
5. Acha difícil não fumar em locais onde é proibido (exemplo: igreja, hospital)?                  Sim ! (1)          Não ! (0)                   NR ! (99) 
6. Qual o cigarro do dia que mais gosta de fumar?           O primeiro da manhã ! (1)          Qualquer outro ! (0)                          NR ! (99) 
7. Quantos cigarros fuma por dia? < de 10 cigarros! (0)   entre 11 e 20! (1)  entre 21 e 30! (2)  mais de 30 cigarros! (3)      NR ! (99) 
8. Fuma mais frequentemente nas 1as horas após acordar do que no resto do dia?              Sim ! (1)         Não ! (0)              NR ! (99) 
9. Fuma mesmo quando está tão doente que tem de ficar na cama a maior parte do dia?    Sim ! (1)         Não ! (0)              NR ! (99) 
 
F. Consumo de álcool                                                                        (Posto #3) 
 
1. Bebe ou alguma vez bebeu bebidas alcoólicas (Vinho, cerveja, maruvo, aguardente)? Sim! (1)    Não! (0)   NR! (99) ! Passa p/ G 
2. Se sim, começou a beber aos |___|___| anos de idade                                                                                                  NSNR ! (99) 
3. Se sim:  
! (1) É ex-bebedor ! parou há |___|___| anos e bebia habitualmente |___|___| bebidas por dia !  Passa para G  
! (2) Ainda bebe ! avança para próxima questão. 
4. No último ano quantas vezes bebeu pelo menos 1 bebida (p.e. lata de cerveja, taça de vinho, copo de whisky)?            NR ! (99) 
                              Diariamente ! (1)                     5 a 6 vezes/semana ! (2)                      3 a 4 vezes/semana! (3)  
                              1 a 2 vezes/semana! (4)         1 a 3 vezes/mês! (5)                             menos de 1 vez/mês ! (6) 
5. No último mês, quantas vezes bebeu 6 bebidas ou mais numa só ocasião? |___|___| dias                                               NR ! (99) 
 
Encaminhar participante para posto #4 (Electrocardiograma) 
 
G. Electrocardiograma (Posto #4)                                      ID do aparelho: |___|___|       ID do Técnico (abreviatura): |___|___|___| 
 
D5. Perímetro de anca |___|___|___|,|___| cm                                                             D6. Perímetro da cintura |___|___|___|,|___| cm 
1. Alguma vez realizou um electrocardiograma?     Sim ! (1)  Não ! (0)        NSNR ! (99) 
2. Alguma vez realizou um ecocardiograma?     Sim ! (1)  Não ! (0)        NSNR ! (99) 
Indicar à supervisora se existe necessidade de encaminhamento !  Sim !  Não !  
Observações: ______________________________________________________________________________________________ 
___________________________________________________________________________________________________________ 
Encaminhar participante para posto #5 (medição de TA) 
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H. Hábitos alimentares                ID do aparelho: |___|___|        ID do Técnico (abreviatura): |___|___|___|                     (Posto #5) 
                       Pressão Arterial      Frequência Cardíaca 
1ª medição |___|___|___| /     / |___|___|___| mm Hg  |___|___|___| bpm 
 
Numa semana normal, em quantos dias: Quantas porções come/bebe nesses dias:            
1. Come fruta |___| dias 2. fruta  |___|___|  peça de fruta 
3. Come verduras (por exemplo kisaka, couve, erva) |___| dias 4. verduras (por exemplo kisaka, couve, erva) |___|___|  porções 
5. Bebe café/chá preto |___| dias 6. café/chá preto |___|___|  chávena 
7. Quantas vezes coloca sal no prato, antes de comer?  
Sempre ! (5)    Muitas vezes ! (4)    Algumas vezes ! (3)    Raramente ! (2)    Nunca ! (1)    NR! (99)    
8. Quantas vezes coloca sal na panela quando prepara a comida em sua casa? 
Sempre ! (5)    Muitas vezes ! (4)    Algumas vezes ! (3)    Raramente ! (2)    Nunca ! (1)    NSNR! (99)    
9. Quantas vezes come comida conservada com sal (carne salgada, peixe seco)? 
Sempre ! (5)    Muitas vezes ! (4)    Algumas vezes ! (3)    Raramente ! (2)    Nunca ! (1)    NR! (99)    
10. Que quantidade de sal é que acha que come? 
Exagerado ! (5)    Muito ! (4)    Suficiente ! (3)    Pouco ! (2)    Muito Pouco ! (1)    NR ! (99)    
11. Considera importante reduzir a quantidade de sal na comida? 
Muito importante ! (3)    Mais ou menos importante ! (2)    Pouco Importante ! (1)    Não Sabe ! (0)    NR ! (99)    
12. Acha que comer demasiado sal pode ser perigoso para a saúde?                 Sim ! (1)         Não ! (0)          Não sei ! (2)          NR ! (99)    
13. Que tipo de gordura usa quando prepara comida em sua casa? Outra (7) |___|___|___|___|___|___|___|___|___|     NSNR ! (99)    
Óleo de Palma ! (1)    Azeite ! (2)     Óleo comercial (soja, amendoim) ! (3)       Banha ! (4)       Manteiga ! (5)       Margarina vegetal ! (6)     
14. Quantas vezes coloca açúcar na comida/bebida ou come doces e bolos ou bebe gasosas?  
Sempre ! (5)    Muitas vezes ! (4)    Algumas vezes ! (3)    Raramente ! (2)    Nunca ! (1)    NR ! (99) 
 
I. Atividade física                   (Posto #5) 
 
A sua atividade profissional (mesmo estudante) obriga a: Não se aplica (Desempregado, reformado, etc) ! (99) !  Passa para 8 
1. Esforços físicos pesados como levantar cargas pesadas, cavar, outros.                            Sim ! (1)              Não ! (0)                   NR! (99) 
                  2. Se sim, durante |___|___| dia por semana, por |___|___| horas por dia ou menos de 1 hora por dia ! (1) 
3. Esforços físicos moderados como levar cargas leves.                                                        Sim ! (1)              Não ! (0)                   NR! (99) 
                  4. Se sim, durante |___|___| dia por semana, por |___|___| horas por dia ou menos de 1 hora por dia ! (1) 
5. Esforços físicos leves como trabalhar à secretária.                                                             Sim ! (1)              Não ! (0)                   NR! (99) 
                  6. Se sim, durante |___|___| dia por semana, por |___|___| horas por dia ou menos de 1 hora por dia ! (1) 
7. Como se desloca para o emprego ou escola e quanto tempo demora (ida e volta)?   
A pé ou bicicleta |___|___|___|min/dia!(1) Carro ou transporte público |___|___|___|min/dia!(2)  Outro!(88) |___|___|___|___|___|   
8. Quanto tempo passa por dia sentado(a) a descansar?    |___|___| horas por dia ou menos de 1 hora por dia ! (1)           NR! (99)   
9. No último ano praticou desporto ou exercício físico regular? 
Sim, durante |___|___| dia/semana, por |___|___| horas por dia ou menos de 1 hora por dia ! (1)                 Não!(0)            NSNR! (99) 
10. A que horas vai dormir numa noite normal de semana de trabalho? |___|___| horas                                                    NSNR! (99) 
      11. Se sabe, perguntar a que horas acorda?      |___|___| horas  
      12. Se NSNR, perguntar quantas horas dorme por noite numa semana normal de trabalho?   |___|___| horas 
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13. A que horas vai dormir durante o fim de semana e feriados? |___|___| horas                                                               NSNR! (99)  
      14. Se sabe, perguntar a que horas acorda?       |___|___| horas  
      15. Se NSNR, perguntar quantas horas dorme durante uma noite de fim de semana ou feriado?  |___|___| horas 
 
                       Pressão Arterial      Frequência Cardíaca 
2ª medição |___|___|___| /     / |___|___|___| mm Hg  |___|___|___| bpm 
 
 
J. História Obstétrica (só mulheres)                 (Posto #5) 
 
1. Quando foi a última menstruação? Há |___|___| semanas! (1)                                                                                                                                        NSNR! (99) 
Não tem menstruação, há |___|___| meses ! (2)                                                      Já não tem menstruação, há |___|___| anos! (3)       
2. Quantos anos tinha quando teve a primeira menstruação? |___|___| anos de idade.                                                                                   NSNR! (99) 
3. Quantas vezes esteve grávida?   |___||___|  gravidezes                                         Se nenhuma ou NSNR! (99) !  passa para 10 
4. Quantos bebés nasceram vivos? |___|___| bebés.                                        5. Quantos abortos teve? |___|___| abortos. 
6. Quantos anos tinha quando teve a primeira gravidez? |___|___| anos de idade.                                                                                              NSNR! (99) 
7. Quantos anos tinha quando teve a última gravidez? |___|___| anos de idade.                                                                                                   NSNR! (99) 
8. Sabe se alguma vez teve Tensão Alta durante a gravidez?    Sim, teve ! (1)     Não teve ! (0)        Não sabe ! (2)            NR! (99) 
9. Se sim, tomou algum medicamento?       Sim ! (1)                 Não ! (0)                 NSNR! (99) 
Usa ou usou alguma medida contraceptiva medicamentosa (medicamento para não engravidar como a “pílula”, implante)?  
10. ! (1) Sim, |___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___|___| há |___|___| anos           
11. ! (1) Já usou |___|___|___|___|___|___|___|___|___|___|___|___|___| durante |___|___| anos    Nunca usei ! (2)    NSNR! (99) 
12*. Está grávida?                       Sim ! (1)                          Não ! (0)                    Não Sabe ! (2)                            NR ! (99) 
* Não perguntar se já não tiver menstruação. 
 
 
K. História clinica pessoal                                                                                                                                                        (Posto #5)  
 
 
1. No último ano quantas vezes foi visto por um profissional de saúde: |___|___|                                                                   NR ! (99) 
2. Alguma vez, esteve internado? Sim! (1), porque: |___|___|___|___|___|___|___|___|___|___|___|___|      Não! (0)          NSNR! (99) 
3. No último mês, esteve internado? Sim! (1), porque: |___|___|___|___|___|___|___|___|___|___|___|___|      Não! (0)   NSNR! (99) 
 
 
 
 Tensão Arterial Diabetes (açúcar no sangue) 
Colesterol 
(gordura no sangue) 
4. Alguma vez um profissional de saúde lhe mediu a/o:   Sim        Não     NSNR       ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
      ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
      ! (1)         ! (0)      ! (99) 
5. Alguma vez um profissional de saúde lhe disse que tinha 
valores elevados de: 
  Sim        Não     NSNR 
      ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
      ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
  ! (1)         ! (0)      ! (99) 
6.* Disseram-lhe isso nos últimos 12 meses:   Sim        Não     NSNR    ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
7.* Nas últimas 2 semanas tomou medicamento prescrito para:   Sim        Não     NSNR    ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
8.* Tomava algum medicamento que já abandonou para a:    Sim        Não     NSNR    ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
9.* Foi a um curandeiro para tratar da:   Sim        Não     NSNR    ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
10.* Está tomar alguma planta, chá ou remédio tradicional para:   Sim        Não     NSNR    ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
  Sim        Não     NSNR 
   ! (1)         ! (0)      ! (99) 
11. Se sim à questão 10, indique qual a planta: |__|__|__|__|__|__|__|__| |__|__|__|__|__|__|__|__| |__|__|__|__|__|__|__|__| 
   * Só perguntar se responder sim à situação respetiva na questão 5. 
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Alguma vez, algum profissional de saúde lhe recomendou:                                             12. não fumar: Sim! (1)   Não! (0)  NSNR! (99) 
         13. reduzir o consumo de sal: Sim! (1)   Não! (0)  NSNR! (99) 
14. comer cinco peças de frutas e/ou porções de vegetais por dia: Sim! (1)   Não! (0)  NSNR! (99) 
15. reduzir o consumo de gorduras: Sim! (1)   Não! (0)  NSNR! (99) 
16. fazer exercício físico: Sim! (1)   Não! (0)  NSNR! (99) 
17. manter um peso saudável ou perder peso: Sim! (1)   Não! (0)  NSNR! (99) 
18. reduzir a quantidade de bebidas alcoólicas consumidas:  Sim! (1)   Não! (0)  NSNR! (99) 
 
19. Em geral, diria que a sua saúde é: 
Óptima ! (5)    Muito boa ! (4)  Boa ! (3)     Razoável ! (2)    Fraca ! (1)            NR ! (99) 
 
L. Terapêutica medicamentosa                                                                                                                             (Posto #5) 
 
1. Esta a tomar medicamentos neste momento (registar apenas os que toma todos os dias): Sim ! (1)     Nenhum ! (0)       NSNR! (99) 
  |___|___|___|___|___|___|___|___|___|___|___|___|___| (nome, dosagem),  |___|___| por dia, há |___|___| semanas / meses / anos 
  |___|___|___|___|___|___|___|___|___|___|___|___|___| (nome, dosagem),  |___|___| por dia, há |___|___| semanas / meses / anos  
  |___|___|___|___|___|___|___|___|___|___|___|___|___| (nome, dosagem),  |___|___| por dia, há |___|___| semanas / meses / anos 
  |___|___|___|___|___|___|___|___|___|___|___|___|___| (nome, dosagem),  |___|___| por dia, há |___|___| semanas / meses / anos  
  |___|___|___|___|___|___|___|___|___|___|___|___|___| (nome, dosagem),  |___|___| por dia, há |___|___| semanas / meses / anos 
                       Pressão Arterial      Frequência Cardíaca 
3ª medição |___|___|___| /     / |___|___|___| mm Hg  |___|___|___| bpm 
 
Referenciação para consulta no HGB  / consulta pré-natal                                                      Confirmar pelo Supervisor 
 
Indivíduo com (Preencher pelos postos, confirmado pelo Supervisor): 
" pressão arterial sistólica (PAS) ≥ 140 mmHg e/ou pressão arterial diastólica (PAD) ≥ 90 mmHg  
" PAS ≥ 140 mmHg e/ou PAD ≥ 90 mmHg  com uso de terapia medicamentosa anti-hipertensiva  
" valor de glicemia ≥ 126 mg/dL em jejum ou ≥ 180 mg/dL se não estiver em jejum 
" valor de colesterol total ≥ 200 mg/dL ou triglicerídeos ≥ 150 mg/dL 
" alterações no seu ECG (anexar relatório técnico) 
" outro: ________________________________________________________________________ 
 
Encaminhamento para consulta (Preencher pelo Supervisor): 
" Sim. Data da Consulta: ____ / ____ / _____  (certificar que cartão preenchido entregue ao indivíduo ! ! ) 
" Não. Porque? ___________________________________________________________________________ 
" Indicação para inscrever-se nas consultas pré-natais. 
 
Hora de fim: |___|___| h |___|___| m 
 
Observações: 
 ECG encaminhado para análise por cardiologista, sem marcação de consulta. 
 Outra: _____________________________________________________________________________________________ 
______________________________________________________________________________________________________ 
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Visita às casas 
escolhidas do bairro e 
conversa com as 
pessoas escolhidas à 
sorte 
1 a 2 dias depois, visita de 
toda a equipa – deve 
apresentar-se em jejum e 
trazer consigo as caixas dos 
medicamentos que toma 
Inscrição das pessoas escolhidas, 
Entrega de frascos de urina 
Inconvenientes Possíveis/ 
Contra-indicações 
 
•  Dor ou desconforto com a recolha de 
sangue (pequena picada). 
•   Incómodo pela situação de estar em 
jejum – será dada refeição ligeira no fim. 
•  Se estiver grávida ou souber que tem 
alguma doença do coração, deve avisar a 
equipa. 
Estudo dos fatores de risco cardiovasculares numa população adulta do Bengo 
Informações para as pessoas que vão entrar no estudo 
 Picada no dedo para  tirar 
sangue (4 a 5 gotas) 
e teste à urina 
Realização de 
Questionário 
Medição da Altura  
e Peso 
Realização de Electrocardiograma 
Medição da  
Tensão Arterial 
Estudo dos fatores de risco cardiovasculares numa população adulta do Bengo 
Informações para as pessoas que vão entrar no estudo 
 
Somos uma equipa do Projecto CISA (Centro de Investigação em Saúde em Angola) e 
gostaríamos de alguns minutos da sua atenção – gostaríamos de falar com o Sr(a) 
________________________________________________________________________. 
 
Estamos a fazer um estudo sobre algumas doenças na comunidade (doenças do coração e dos 
vasos sanguíneos). Este trabalho vai permitir conhecer a dimensão destes problemas e os 
resultados serão partilhados com o Ministério da Saúde de Angola, e com a Direção Provincial 
de Saúde que autorizou este estudo. 
 
O Sr(a) foi escolhido(a) pelo que precisamos que apareça às ______ horas na ______ª feira, 
dia _____________de _______________, no local combinado (ver abaixo) para participar.  
 
Precisamos que venha em jejum e traga consigo as caixas vazias dos medicamentos que 
costuma tomar. 
 
Pedimos a sua colaboração para o seguinte: 
•  Doação de amostra de urina e sangue. Com estas amostras serão feitos testes no dia da 
visita, e outros no laboratório do CISA, e se tiver algum problema será posteriormente 
seguido no Hospital Provincial do Bengo. A urina serve para saber se o seu rim funciona 
bem; e o sangue para saber se tem gordura ou açúcar.  
•  Medir a sua tensão arterial e fazer um electrocardiograma. 
•  Queremos ainda conversar consigo e fazer algumas perguntas relacionadas com estes 
problemas de saúde. 
 
A sua colaboração é voluntária pelo que tem o direito de recusar, contudo se aceitar estará a 
ajudar a saúde da comunidade. Toda a informação que nos der nunca será usada associada ao 
seu nome.  
 
Hora e data da visita ao bairro para os exames: _______________________________________ 
 
Local da visita: ___________________________________________________________________ 
 
Nota: Por favor, traga consigo o seu bilhete de identidade, cartão de saúde. 
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Consentimento Informado 
Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo 
 
Eu, _______________________________________________________________________, aceito participar de forma 
voluntária, no “Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo”. Foi-me 
explicado que este trabalho pretende conhecer o número de pessoas que possam ter doenças cardiovasculares (doenças do 
coração e dos vasos sanguíneos) na área de estudo do CISA, quais os meus hábitos alimentares e de consumo de álcool e 
tabaco, atividade física, o meu conhecimento sobre estas doenças e quais os tratamentos e diagnósticos que já fiz.  
Depois de explicados os objectivos deste estudo (conforme panfleto que fica em minha posse) fui informado/a que a minha 
participação, após um jejum de 8h, consiste na: 
• medição da pressão arterial, frequência cardíaca, peso, altura, perímetro abdominal, e da anca e do braço; 
• realização de electrocardiograma; 
• recolha de uma amostra de sengue para medição de colesterol, triglicerídeos (gordura), glucose (açúcar) e análises 
genéticas posteriores no laboratório CISA. 
• recolha de uma amostra de urina para medição de creatinina/albumina; 
• resposta a um questionário. 
Fui ainda informado/a que: 
• só terão acesso aos dados os trabalhadores do CISA envolvidos neste estudo; 
• a publicação dos resultados deste estudo nunca permitirá a minha identificação; 
• Se houver necessidade de tratamento serei encaminhado para a unidade sanitária mais próxima de casa. 
 
________________________________________  Se menor de 18 anos: Concordo com a participação do meu encarregando de educação 
     (Assinatura ou impressão digital do participante)        
______________________________________________________________ 
            (Assinatura ou impressão digital do encarregado de educação)      
 
______________________________________________        ________________ 
                   (Assinatura do profissional do CISA )                                                                                         (Data)      
 
----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ----- 
 
Consentimento Informado 
Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo 
 
Eu, _______________________________________________________________________, aceito participar de forma 
voluntária, no “Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo”. Foi-me 
explicado que este trabalho pretende conhecer o número de pessoas que possam ter doenças cardiovasculares (doenças do 
coração e dos vasos sanguíneos) na área de estudo do CISA, quais os meus hábitos alimentares e de consumo de álcool e 
tabaco, atividade física, o meu conhecimento sobre estas doenças e quais os tratamentos e diagnósticos que já fiz.  
Depois de explicados os objectivos deste estudo (conforme panfleto que fica em minha posse) fui informado/a que a minha 
participação, após um jejum de 8h, consiste na: 
• medição da pressão arterial, frequência cardíaca, peso, altura, perímetro abdominal, e da anca e do braço; 
• realização de electrocardiograma; 
• recolha de uma amostra de sengue para medição de colesterol, triglicerídeos (gordura), glucose (açúcar) e análises 
genéticas posteriores no laboratório CISA. 
• recolha de uma amostra de urina para medição de creatinina/albumina; 
• resposta a um questionário. 
Fui ainda informado/a que: 
• só terão acesso aos dados os trabalhadores do CISA envolvidos neste estudo; 
• a publicação dos resultados deste estudo nunca permitirá a minha identificação; 
• Se houver necessidade de tratamento serei encaminhado para a unidade sanitária mais próxima de casa. 
 
________________________________________  Se menor de 18 anos: Concordo com a participação do meu encarregando de educação 
     (Assinatura ou impressão digital do participante)        
______________________________________________________________ 
            (Assinatura ou impressão digital do encarregado de educação)      
 
______________________________________________        ________________ 
                   (Assinatura do profissional do CISA )                                                                                         (Data)      
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Information card 
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Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
 Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL  Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL 
Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL  Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL 
Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL  Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL 
Tensão Arterial           /           /           / mmHg  Tensão Arterial           /           /           / mmHg 
Data:       /      /       /      /       /      /   Data:       /      /       /      /       /      /  
           
Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
 Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL  Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL 
Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL  Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL 
Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL  Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL 
Tensão Arterial           /           /           / mmHg  Tensão Arterial           /           /           / mmHg 
Data:       /      /       /      /       /      /   Data:       /      /       /      /       /      /  
           
Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
 Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL  Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL 
Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL  Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL 
Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL  Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL 
Tensão Arterial           /           /           / mmHg  Tensão Arterial           /           /           / mmHg 
Data:       /      /       /      /       /      /   Data:       /      /       /      /       /      /  
           
Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
 Nome: __________________________________________________ 
Data Nascimento:             |___||___| - |___||___| - |___||___||___||___| 
Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL  Glicemia |__||__||__| |__||__||__| |__||__||__| mg/dL 
Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL  Colesterol Total |__||__||__| |__||__||__| |__||__||__| mg/dL 
Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL  Triglicéridos |__||__||__| |__||__||__| |__||__||__| mg/dL 
Tensão Arterial           /           /           / mmHg  Tensão Arterial           /           /           / mmHg 
Data:       /      /       /      /       /      /   Data:       /      /       /      /       /      /  
Cartão de monitorização de valores clínicos 
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Reference for medical follow-up  
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Folha de encaminhamento para seguimento clínico 
Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo 
 
__________________________________________________________________, com _______ anos de idade, participou no 
“Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo”. Neste sentido, realizou 
um conjunto de exames de diagnóstico no dia ____/____ , apresentando os seguintes resultados:  
 
Pressão Arterial de: |___|___|___| / |___|___|___| mm Hg  Frequência Cardíaca de |___|___|___| bpm 
Glucose de |___|___|___|mg/dL  em ________________ Colesterol total|___|___|___|mg/dL  Triglicerídeos|___|___|___|mg/dL 
Peso: |___|___|___|,|___| Kg; Altura: |___|___|___|,|___| cm; Anca: |___|___|___|,|___| cm; Cintura: |___|___|___|,|___| cm 
 
Consideramos que necessita de avaliação médica para eventual tratamento adequado, uma vez que: 
 pressão arterial sistólica (PAS) ≥ 140 mmHg e/ou pressão arterial diastólica (PAD) ≥ 90 mmHg  
 PAS ≥ 140 mmHg e/ou PAD ≥ 90 mmHg com uso de terapia medicamentosa anti-hipertensiva 
 valor de glicemia ≥ 126 mg/dL em jejum ou ≥ 180 mg/dL se não estiver em jejum 
 valor de colesterol total ≥ 200 mg/dL ou triglicerídeos ≥ 150 mg/dL 
 alterações no seu ECG (relatório técnico em anexo) 
 Outra: _______________________________________________________________________________________ 
 
Observações: __________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
 
Data:_______________________              Assinatura do profissional de saúde:_______________________ 
 
Contacto para mais informações: 945731743 (Enf.ª Ana Maria Oliveira) 
 
----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ------ ----- ----- ----- ----- ----- ----- ----- ----- 
 Folha de encaminhamento para seguimento clínico 
Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo 
 
__________________________________________________________________, com _______ anos de idade, participou no 
“Estudo dos fatores de risco cardiovasculares numa população adulta da Província do Bengo”. Neste sentido, realizou 
um conjunto de exames de diagnóstico no dia ____/____ , apresentando os seguintes resultados:  
 
Pressão Arterial de: |___|___|___| / |___|___|___| mm Hg  Frequência Cardíaca de |___|___|___| bpm 
Glucose de |___|___|___|mg/dL  em ________________ Colesterol total|___|___|___|mg/dL  Triglicerídeos|___|___|___|mg/dL 
Peso: |___|___|___|,|___| Kg; Altura: |___|___|___|,|___| cm; Anca: |___|___|___|,|___| cm; Cintura: |___|___|___|,|___| cm 
 
Consideramos que necessita de avaliação médica para eventual tratamento adequado, uma vez que: 
 pressão arterial sistólica (PAS) ≥ 140 mmHg e/ou pressão arterial diastólica (PAD) ≥ 90 mmHg  
 PAS ≥ 140 mmHg e/ou PAD ≥ 90 mmHg com uso de terapia medicamentosa anti-hipertensiva 
 valor de glicemia ≥ 126 mg/dL em jejum ou ≥ 180 mg/dL se não estiver em jejum 
 valor de colesterol total ≥ 200 mg/dL ou triglicerídeos ≥ 150 mg/dL 
 alterações no seu ECG (relatório técnico em anexo) 
 Outra: _______________________________________________________________________________________ 
 
Observações: __________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
_____________________________________________________________________________________________________ 
 
Data:_______________________              Assinatura do profissional de saúde:_______________________ 
 
Contacto para mais informações: 945731743 (Enf.ª Ana Maria Oliveira) 
